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ABSTRACT 
 
microRNA (miRNA) are short, non-coding RNAs that can significantly affect gene 
expression. In Multiple Sclerosis (MS), an autoimmune disease targeting the central 
nervous system, much is understood about how the immune system promotes 
neurodegeneration in early stages of disease. However, studies on secondary 
progressive MS (SPMS) demonstrate that the continued role of the immune system 
in disease progression is not well characterised. As key regulators of gene 
expression, identifying changes of miRNA expression patterns in SPMS tissues will 
provide insight into disease mechanisms at this stage. 
Using next-generation sequencing, a comprehensive miRNA expression profile of 
CD4+ T-cells was attained, and the NanoString nCounter miRNA array was used to 
the same effect in normal appearing white matter (NAWM) of SPMS individuals. RT-
qPCR confirmed results from these methods, and further explored associated gene 
expression changes, such as common targets of dysregulated miRNAs, and genes 
essential to miRNA biogenesis and DNA methylation. The role of DNA methylation on 
miRNA dysregulation was also explored using Illumina 450k arrays. 
A convergence of several factors, led by changes in miRNA expression, was found to 
reduce activity of CD4+ T-cells in SPMS. Broad down-regulation of miRNAs was 
identified, a novel observation in MS miRNA studies, caused by a reduction of miRNA 
biogenesis molecules. This resulted in: up-regulation of SOCS6, negatively 
regulating T-cell activation; and de novo hypermethylation driven by miR-29b-
associated up-regulation of DNMT3b. These findings point towards CD4+ T-cells 
having a diminished role in SPMS. Additionally, analysis of miRNA expression in 
NAWM also identified miR-29b down-regulation, amongst other miRNAs, that may 
act to prevent oligodendrocyte maturation and thus hinder remyelination. This 
suggests that neurodegenerative mechanisms are fully operational in NAWM during 
SPMS.  
In conclusion, the mechanisms of disease progression in SPMS are now better 
understood. miRNA down-regulation prompts CD4+ T-cells to take a backseat, and 
neurodegeneration assisted by miRNA dysregulation, is primed to occur in NAWM.  
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CHAPTER ONE - INTRODUCTION 
 
Multiple Sclerosis (MS) is a complex autoimmune disease affecting the central 
nervous system, and risk of developing MS is determined by genetics, environment 
and epigenetic factors. A key epigenetic factor of interest is microRNAs (miRNAs), 
which regulate gene expression by binding to messenger RNA (mRNA) thus 
repressing translation to proteins or triggering mRNA degradation. Each miRNA can 
regulate multiple mRNAs and an mRNA can be targeted by multiple miRNAs. 
Dysregulation of miRNA levels plays an important role in disease by causing altered 
cell growth, apoptosis and tissue differentiation.  
 
MiRNA species are short (~22nt), non-coding RNAs that are remarkably stable and 
there is great potential for them to be used as biomarkers to diagnose and predict 
disease outcome in MS. Analysis of miRNA expression has been conducted in 
peripheral blood mononuclear cells (PBMCs), whole blood, T regulatory cells (T-
regs), plasma, serum and white matter. However, miRNA studies in heterogeneous 
cell populations fall short of identifying the effect miRNA dysregulation has on 
particular cell types. Furthermore, MS pathology initiates in the normal appearing 
white matter (NAWM) before development of symptomatic lesions, yet studies in 
white matter have looked at a limited panel of microRNAs and/or in small sample 
cohorts, and potentially missed significant dysregulation in the MS brain. 
 
The significance of this research lays in identifying microRNA changes in CD4+ T-
cells and the NAWM of secondary progressive MS (SPMS) patients, how these 
changes are correlated, and understanding how this dysregulation plays a role in 
disease progression. 
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Multiple sclerosis 
MS is an autoimmune disease caused by multifocal inflammatory attacks on the 
central nervous system (CNS) resulting in demyelination and axonal damage. 
Propagation of action potentials along the axon is hindered when the insulating 
myelin sheath is damaged. This results in physical symptoms including muscle 
weakness, vision impairment and lack of coordination. MS typically affects young 
Caucasian individuals with disease onset between 20 to 50 years of age. Females 
account for more cases of MS than males with a ratio ranging from 2:1 to 3:1 (1) and 
are predisposed to higher relapse activity than males (2). MS has moderate 
heritability; the concordance rate for developing MS is only 25% in monozygotic 
twins, whom share 100% of their genes (3, 4), indicating that factors other than 
genetics significantly contribute to the development of MS, such as environment and 
epigenetics. 
Several forms of MS define varying degrees of symptomatic debilitation over time: 
relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary 
progressive MS (PPMS). The most common form of MS is RRMS, accounting for 
~85% of initial diagnoses. RRMS is characterised by relapses followed by periods of 
remission.  New symptoms appear spontaneously while existing symptoms become 
more severe. Relapses can occur over days, weeks or months and recovery can be 
slow, gradual or instantaneous. The remission phase of RRMS is highly variable in 
duration, ranging from months to years. Age of disease onset and the use of disease 
modifying therapies (DMT) influence the risk of RRMS patients converting to a SPMS 
disease course; risk decreases with DMT treatment (5), whereas higher age of 
disease onset increases the likelihood of transition to SPMS (5, 6). Onset of 
progression is more dependent on age rather than the duration of pre-progression 
symptomatic disease course (7). Over half of RRMS patients will transition to SPMS 
within 33 years of disease onset; SPMS has no remitting phase and is characterised 
by demonstrated disability accumulation in the absence of relapses (8). At this stage, 
the disease is considered to be more neurodegenerative than inflammatory (9) 
(figure 1.1). Once diagnosed with SPMS, treatment with a DMT is usually halted, as 
disease progression is less sensitive to current treatment options (10). 
PPMS is progressive from disease onset. Disease course is relentlessly progressive 
without interspersed relapses or significant recovery, and symptoms gradually 
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worsen. This type of MS is the most severe form and accounts for 15% of MS cases 
(11). The age of onset of PPMS is typically later than in RRMS, presenting itself in 
the late thirties or early forties (12). PPMS onset is slow and followed by gradually 
worsening symptoms and almost no remissions (13). 
A single episode of neurological symptoms is defined as Clinically Isolated Syndrome 
(CIS) (14). On further laboratory or imaging investigation, the clinician may find 
evidence of a second attack that defines RRMS. Repeat investigations after an 
interval or a second attack may be necessary to diagnose MS in very early cases. 
 
Figure 1.1:  Schematic detailing the relationship between disability, 
neurodegeneration, inflammatory events, brain volume, and disease course. 
 
Diagnosis 
MS is diagnosed according to the McDonald criteria that combines neurological 
history and examination, disseminating lesions in space and time, paraclinical 
laboratory examinations and magnetic resonance imaging (MRI) (15, 16). Disease 
severity is measured using the Expanded Disability Status Scale (EDSS), which 
ranges from 0 to 10 and is based on measures of impairment in seven functional 
systems as well as walking ability. A score of 0 to 5.5 indicates the MS patient can 
walk unaided, though walking distance is reduced between EDSS 4.0 to 5.5. A score 
of 6.0 to 9.5 indicates impairment to walking through to confinement to bed and other 
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functional deficiencies (17). Following RRMS, EDSS increase in the absence of 
relapse, over the course of at least three months, indicates the patient has 
transitioned to SPMS disease course (8). 
 
Pathogenesis and progression 
MS is an autoimmune disease that attacks the CNS, however the initial mechanism 
of pathogenesis is not fully established. Does the immune system attack the CNS 
unprompted, or is there a starting point in the CNS that cascades down to activation 
of the immune system?  
Homeostasis of the CNS is largely controlled by the blood-brain barrier (BBB) that 
actively limits movement of mediators and lymphocytes from the periphery to the 
CNS. The BBB is a highly specialised component of the neurovascular system and is 
disrupted in MS allowing immune activity within the CNS. In RRMS, CD4+ T-cells are 
amongst the primary infiltrators moving from the periphery, through the BBB into the 
CNS (18). These cells then initiate an immune response that results in localised 
demyelination and corresponding symptoms.  
Several neurodegenerative disorders have BBB dysfunction as a component of their 
pathogenesis including Alzheimer’s (AD) and Parkinson’s diseases and Amyotrophic 
Lateral Sclerosis (ALS) (19). Studies have thus far defined a number of pathways for 
lymphocyte entry from blood to the CNS (20-22) and results of a study in 
experimental autoimmune encephalopathy (EAE) in mice (animal model of MS) 
suggest that infiltration of the BBB occurs in parenchymal capillaries and post-
capillary venules (21). Recently, a lymphatic system within the CNS was discovered 
(23), presenting a further potential path for lymphocyte infiltration into the CNS. 
Endothelial cells in the BBB express tight junction and adherens junction proteins 
which act to reduce paracellular permeability (24). Astrocytes play an important role 
in maintaining the integrity of the BBB through contact-dependant mechanisms and 
secretion of essential factors, however in neuroinflammatory disorders such as MS, 
astrocytes can also release inflammatory cytokines causing endothelial cell activation 
and BBB dysregulation (24, 25). In MS, activated T-cells produce cytokines, reactive 
oxygen species and matrix metalloproteinases that either disrupt BBB components or 
act on receptors expressed by endothelial cells of the BBB (for in-depth review see 
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(26)). In contrast, resting T-cells have limited capability to cross the BBB (27). 
Advancement of brain endothelial cells towards an inflammation phenotype is 
considered to be mediated by proinflammatory cytokines such as TNFα and IFN-γ, 
secreted from lymphocytes and CNS-resident cells. These induce the expression of 
chemoattractant cytokines (e.g. CXCL10, CX3CL1 and CCL3) on the brain 
endothelium, promoting adhesion of lymphocytes to the BBB and increased 
permeability (26, 28, 29). Furthermore, it should be noted that lymphocyte infiltration 
of the BBB increases the barrier’s permeability, facilitating subsequent crossings 
(30). Consequently, a permissive environment is created for the trafficking of 
inflammatory molecules and circulating lymphocytes into the CNS, causing 
demyelination and axonal loss. 
Many studies have focused on the activity of lymphocytes, particularly CD4+ T-cells 
(31), in RRMS, and their pathway into the CNS. However, the interplay between the 
immune system and CNS in SPMS is an incomplete puzzle. While it is recognised 
that neurodegeneration is a significant driving force in accumulation of disability 
(increased EDSS) in SPMS, the continued role of CD4+ T-cells and the immune 
system in disease progression is poorly established (32). 
Myelin is synthesised by mature oligodendrocytes and forms the extended 
membrane of oligodendrocyte cells; it is composed of a lipid bilayer and proteins. The 
function of myelin is to insulate neurons providing rapid conduction of action 
potentials along the axon. Damage to axons occurs very early on in disease (33) and 
repeated demyelination events eventually destroy the axon (34). Over the course of 
MS, a series of remyelination events occur whereby oligodendrocyte precursor cells 
(OPC) migrate to surround active lesions in response to semaphorin 3A and 3F (35), 
temporally coinciding with the phagocytic removal of myelin. These OPCs then 
differentiate to mature oligodendrocytes and remyelinate the naked axons. Cycles of 
demyelination and remyelination eventually exhaust the capacity for tissue repair and 
the degree of recovery associated with remyelination decreases after each event 
(36). 
Histologically, MS presents as lesions throughout the CNS (figure 1.2). Demyelinated 
lesions form most commonly in the white matter but can also form in grey matter and 
across white and grey matter (leukocortical) (37). The diameter of lesions can vary 
greatly, from one millimetre to several centimetres and occur throughout the CNS but 
  
 6 
most predominantly in the periventricular white matter and optic nerve (38). 
Formation of lesions is associated with degeneration of myelin and resulting impaired 
neuronal function causing physical symptoms of MS. There are three main types of 
lesions: active, chronic active and chronic. Active lesions are filled with macrophages 
containing myelin debris, demonstrate infiltration by lymphocytes, and BBB disruption 
(39). Unlike active lesions, chronic active lesions exhibit well demarcated margins 
and myelin-containing macrophages are commonly found here. The centre of a 
chronic active lesion may be either absent of myelin or contain remyelinated fibres 
originating from the lesion edge. Chronic lesions have no inflammatory component 
and a fibrous centre, as with chronic active lesions, remyelination can also occur 
throughout the whole lesion; this is known as a shadow plaque (40). 
Normal appearing white matter (NAWM) is defined as a region that appears 
unaltered upon light microscopic analysis. However, in-depth molecular analyses of 
NAWM indicate that MS pathology initiates within this tissue before development of 
symptomatic lesions. A study focused on microglia analysed the phenotype ex vivo 
and the immune responsiveness in vitro of microglia from MS NAWM. This study 
found elevated levels of the immunoregulatory molecule CD45, however contrasting 
low levels of additional markers such as CD206 were also observed. These findings, 
combined with increased mRNA levels of the inhibitory CD32b isoform, demonstrate 
that microglia within MS brain NAWM are in an alerted state but displaying features 
of immunosuppression (further characterised by unresponsiveness to bacterial 
lipopolysaccharide) (41), likely preventing full activation of the inflammatory response 
responsible for lesion formation. In murine EAE models, severe nerve fibre pathology 
was detected in the NAWM, comparable to that found in white matter lesions (42).  
MRI techniques have also been used to observe NAWM and monitor its influence on 
MS pathology. Diffusion tensor imaging (DTI) can assess the micro-structural integrity 
of white matter in MS. The degree of axonal degradation and white matter pathology 
is resolved by observing the extent to which water diffuses preferentially along axons 
and is constrained by cell walls (43). DTI is sensitive to myelin content and axon 
count (44), and to the evolution of tissue damage within lesions (45). DTI of NAWM 
also correlates with processing speed in MS individuals (46).  
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Figure 1.2: Brain sections stained with Luxol Fast Blue – Periodic acid Schiff (LFB-
PAS) depicting MS pathology. (A) Whole section showing white matter (WM), grey 
matter (GM) and a chronic lesion. (B) Chronic lesion (x400) astrocytes (arrows) 
present. (C) Active lesion (x400) LFB+ macrophages (arrows). (D) Normal appearing 
WM (NAWM) (x200) with consistent myelin coverage and normal oligodendrocyte 
morphology. GM adjacent. (E) Remyelinated region (x400) patchy areas of myelin 
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and oligodendrocytes difficult to locate. (F) Recently active region (x400), 
macrophages (arrows) containing PAS positive material. These images were 
produced by Katherine Sanders from samples and methods described in Chapter 
Five. 
 
Environmental risk factors 
Many studies have shown that environmental influences can cause significant 
changes to epigenetic traits (47-49), which in turn may impact of risk of developing 
MS, disease course and progression. Factors such as vitamin D deficiency, smoking 
and Epstein-Barr virus (EBV) infection show strong and consistent association with 
development of MS (in-depth review (50)).  
The prevalence of MS is significantly lower in countries in close proximity to the 
equator (51); this observed latitudinal effect complements the finding that MS risk 
decreases with increasing vitamin D levels in serum (52). Vitamin D is produced in 
the skin as a result of exposure to ultraviolet-B (UV) radiation and it has been shown 
that vitamin D regulates expression of histone modifying enzymes (53), 
demonstrating a probable link between vitamin D and epigenetic regulation in MS. 
Disease course in MS also appears to be influenced by levels of vitamin D; degree of 
disability (54) and frequency of relapses are augmented by lower levels of vitamin D 
(54, 55). However, it should be noted that serum vitamin D levels are often used as a 
proxy for patient’s UV exposure. UV has immunomodulatory mechanisms that can be 
vitamin D independent (56). Therefore, caution must be exercised when describing 
effects of UV and vitamin D as the same factor, as they can operate independently. 
Cigarette smoke is a very heterogeneous substance containing many toxins and 
carcinogens; this makes it difficult to associate any specific substance with a 
particular mechanism of action.  However, analysis of the large scale Nurses’ Health 
Study clearly demonstrated significantly increased risk of getting MS in smokers 
compared to those who never smoked (57).	Cigarette	smoke	also	has	a	significant	 impact	
on	epigenetic	mechanisms	 including	DNA methylation (49), microRNA	(miRNA)	expression	
(58-60)	and	histone	modification	(61-63).	
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EBV infection is very common and persists latently in memory B cells after infection. 
Seropositivity for EBV in adults is approximately 95% in the normal population 
complicating studies into the effect of EBV on MS risk. Seronegativity is associated 
with very low risk of MS development (64), whereas a symptomatic response to EBV 
(infectious mononucleosis) nearly doubles the risk of getting MS (65). Changes in 
DNA methylation occur in response to EBV infection via the up-regulation of several 
DNA methyltransferase genes (66), and miRNA expression in B cells is dysregulated 
(67). EBV was the first virus in which miRNAs were found (68) and the Sanger 
database presently lists EBV as encoding 44 mature miRNAs. Several EBV-encoded 
miRNAs have been found to be dysregulated in the B cells of RRMS individuals (69). 
Other potential environmental risk factors for MS have been identified, including 
sodium intake (70, 71), alcohol consumption (72) and childhood obesity (73, 74). 
However, further studies are necessary to corroborate their effect on MS risk. 
 
Genetic risk factors 
MS is a complex disease and incidence is influenced by many factors including 
genetics, though polymorphisms alone cannot fully determine MS risk. As 
demonstrated above, environmental factors are strongly associated with MS risk and 
some have also been associated with epigenetic modifications. There are a number 
of genetic loci that predetermine an individual’s MS risk baseline before 
environmental risk factors are accounted for. The human leukocyte antigen (HLA) 
gene cluster located at chromosome 6p21.3 in the major histocompatibility region 
(MHC), has strong association to MS susceptibility with the primary signal located at 
the HLA-DRB1 gene (75); some HLA-DRB1 alleles are associated with an up to 
three-fold increased risk of developing MS (76). The gene products of the MHC locus 
are involved in antigen presentation which ties-in with the autoimmune status of MS. 
HLA-DRB1*15 has been identified as a risk allele for MS; its frequency is higher in 
females than males and transmission is more common from mother to daughter 
compared with father to daughter inheritance (77). Also, the HLA-DRB1*15 allele is 
related with lower age of onset (78). In contrast, the HLA-DRB1*08 allele is prevalent 
in RRMS and associated with lower relapse rate and degree of disability (79). 
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New genetic susceptibility variants for MS continue to be discovered; in 2013 the 
International Multiple Sclerosis Genetics Consortium identified 48 new susceptibility 
single nucleotide polymorphisms (SNPs) (80) bringing the total number of variants 
outside the MHC locus to 110 (80-84). Variants were identified in a number of loci 
including nuclear factor-kB that plays a role in controlling gene expression relevant to 
autoimmune disease (85). Furthermore, two SNP variants in the MHC produce a two-
fold increase in the likelihood of positive oligoclonal bands in the cerebrospinal fluid 
(CSF); a key diagnostic marker of MS (86). Other genomic regions containing 
susceptibility variants are related to functions including antigen presentation and 
processing, the MHC, oxidative phosphorylation, synaptic transmission, cellular 
transport and translational initiation (for a detailed review see (87)).  A large 
proportion of these variants were in regions not previously associated with known 
function, though they are predominantly found in close proximity to immunologically 
relevant genes (83). Many of these variants have no known function and may not 
have any consequence for the gene in which they are located. However, it is now 
becoming apparent that some of these variants are associated with control of gene 
expression (88). Perturbation of gene expression control would have wide 
consequences and could be significantly contributing to MS. Interestingly, these 
genetic studies have identified susceptibility factors strongly concentrated on the 
immune system. Though why the immune system specifically targets the CNS in MS 
is still not clear. 
 
Epigenetics 
Epigenetics causes modification of the expression of genes without altering the 
genetic code itself. Epigenetic factors are capable of creating or influencing chemical 
modifications on the genome, affecting the way genes are expressed. There are 
numerous epigenetic mechanisms including DNA methylation, histone modifications 
(methylation and adenylation), post-transcriptional alterations (polyadenylation) and 
RNA interfering molecules such as miRNAs.  
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DNA methylation 
DNA methylation is the addition of a methyl group to cytosine at 5’-C-phospate-G-3’ 
(CpG) dinucleotides, often concentrated in hundreds of dinucleotide repeats (CpG 
islands) near gene promoter regions. Hypermethylation in promoter regions 
suppresses gene expression (89). DNA methylation is mediated by DNA 
methyltransferases (DNMTs). Maintenance of DNA methylation patterns is performed 
by DNMT1 during cell replication, whereas de novo methylation of unmethylated sites 
is carried out by DNMT3a and DNMT3b (90). Methylation patterns are dynamic and 
can change with age (91), environmental pressures (92), and disease, including MS 
(93). 
A study of discordant monozygotic twins identified no significant differential DNA 
methylation (94) suggesting other epigenetic mechanisms play a crucial role in MS 
risk, however it should be noted that the study only looked at three pairs of twins and 
did not perform MRI on the unaffected twin to show discordance. In fact, other DNA 
methylation studies have identified differentially methylated regions (DMRs) in 
numerous MS tissues compared to healthy controls (HC) (95-101). Genome-wide 
DNA methylation analyses have been conducted in CD4+ and CD8+ T-cells of 
RRMS patients (98, 99, 101), and a hypomethylated DMR in the MHC region, 
specifically HLA-DRB1,  was identified in CD4+ T-cells (98). Furthermore, hypo- and 
hypermethylated DMRs in NAWM of MS patients have a demonstrated effect on 
associated gene transcription (100). 
However, while DNA methylation changes clearly play a role in MS pathology, it does 
not account for all remaining risk, and other epigenetic factors such as miRNAs must 
also be considered. Interestingly, epigenetic mechanisms can regulate or influence 
one another. DNA methylation can control expression of miRNAs (102), and vice 
versa (103), though there are currently no studies in MS cross-referencing DNA 
methylation and miRNA expression patterns. 
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MicroRNA 
miRNAs are endogenous short (~22nt), non-coding RNAs that play a role as post-
transcriptional regulators. Gene silencing occurs when they bind to the 3’ 
untranslated region (UTR) of target mRNAs, suppressing translation or marking the 
mRNA for degradation. According to miRBase v21, over 1800 miRNAs have been 
identified in the human genome (104) and it is estimated that miRNAs regulate at 
least half of human genes. Dysregulation of one or many miRNAs will affect cellular 
gene expression, resulting in abnormal phenotype that may contribute to disease 
onset, progression and exacerbation. 
One miRNA can target many mRNA; likewise, a mRNA may have binding sites for 
multiple miRNAs. The target sites on mRNAs are only partially complementary to the 
miRNA itself and this makes predicting the target genes of miRNAs difficult. However, 
nucleotides 2-7 of the miRNA (known as the seed region) are critical for target 
recognition (105). Software packages are available that utilise prediction algorithms 
to identify potential targets and are often used in combination to select target mRNAs 
for experimental validation. For example, miRSystem, a freely accessible online tool, 
incorporates seven miRNA gene target prediction programs to robustly predict gene 
targets (106). 
 
MicroRNA biogenesis and mechanism of action 
MiRNA-coding sequences are commonly found within or overlapping with mRNA or 
other RNA genes; these are referred to as the host genes for miRNAs. In most 
cases, miRNA genes are transcribed by RNA polymerase II producing the primary 
miRNA transcript (pri-miRNA) (107). There are two pathways that lead to the 
processing of mature miRNAs, canonical and non-canonical. The majority of miRNAs 
are processed in the canonical pathway and shall be described (Figure 1.2). 
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Figure 1.3: The canonical pathway of microRNA biogenesis. See text below for 
explanation.  
 
Within the nucleus the pri-miRNA is cleaved by Drosha, bound by its regulatory 
subunit DGCR8 (DiGeorge critical region 8), to an isolated hairpin-structured 
precursor (pre-miRNA) approximately 60-70nt long. A two-nucleotide overhang is 
produced by Drosha’s ribonuclease (RNase) III activity and marks the pre-miRNA for 
export to the cytoplasm performed by Exportin 5 associated with Ran cofactor 
coupled to guanosine triphosphate (GTP). Once in the cytoplasm, Exportin 5 
releases the pre-miRNA when GTP is replaced by guanosine diphosphate (GDP). 
Dicer (another RNase), assisted by its cofactor TAR RNA binding protein (TRBP), 
then cleaves the pre-miRNA to produce a miRNA duplex approximately 22nt (108). 
The duplex then associates with Argonaute (Ago) protein where it is unwound; one 
strain is retained as the mature miRNA and forms an RNA-induced silencing complex 
(RISC) and is then capable of mRNA regulation. The two strands of the mature 
miRNA follow established nomenclature, -5p or -3p, dependant on whether they 
originate from the 5’ or 3’ end of the pri-miRNA loop. Often, one strand is dominant 
and is not annotated as -5p or -3p in the literature. However, both strands are 
functional in many miRNAs, and will associate with different Ago protein complexes 
to become active (109). 
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The RISC complex utilises the mature miRNA for direct target recognition using base 
pairing interactions with the 3’UTR of mRNA transcripts (110). As previously 
mentioned, miRNA-mRNA complementarity is partial and downstream regulatory 
mechanisms are influenced by the extent of this complementarity. A perfect match 
triggers degradation of the mRNA catalysed by Ago2 protein (111) whereas 
translational repression is the result of mismatches. In animals, the most prevalent 
mechanism of miRNA action is translational repression though the exact process of 
repression is not fully understood. A review by Tang et al. (112) outlined proposals of 
RISC-directed repression including: relocation or sequestration of target mRNA to 
processing bodies or stress granules, translational repression at initiation or post-
initiation stages, mRNA decay through rapid deadenylation and protein degradation 
immediately following translation. 
Dysregulation of miRNA levels plays a key role in disease by causing altered cell 
growth, apoptosis and irregular tissue differentiation. In MS, it is not clear whether 
miRNA dysregulation contributes to disease onset/progression or if it is a reflection of 
the affected cell’s response to disease; it is likely both. The mechanisms that cause 
this dysregulation are varied (113) and include genomic sequence mutations, DNA 
methylation, transcription factor dysregulation, and changes in the expression of 
miRNA biogenesis molecules, Drosha, DGCR8 and Dicer. Expression changes in 
miRNA biogenesis molecules have been investigated in MS (114, 115), though their 
correlation with overall miRNA expression has not been fully ascertained. Magner et 
al. have observed that changes in Dicer expression were not correlated with miRNA 
expression (115), though no miRNA expression correlation analyses have been 
performed for Drosha or DGCR8. 
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MicroRNAs and Multiple Sclerosis 
Analysis of miRNA expression has been conducted in many tissues in MS (Tables 
1.1 and 1.2), predominantly in RRMS. As an autoimmune disease targeting the CNS, 
miRNA profiles in the immune system and CNS are of particular interest, and studies 
have been conducted on cellular tissues, including PBMCs, whole blood, T cells, B 
cells, and white matter (116).  
Samples that are routinely acquired and processed, such as whole blood and non-
cellular circulating fluids (plasma, serum and CSF), are excellent for establishing 
biomarkers. miRNA species are remarkably stable molecules due to their short length 
and minimal recognition sites for nucleases (117), and their aberrant expression may 
be used for diagnosis, predicting treatment response, and differentiating MS 
subtypes.  
However, identifying the effect of dysregulation on cell activity is impossible in 
heterogeneous cell samples. Insight into the functional consequences of miRNA 
dysregulation in MS can only be resolved from analyses of individual cell subtypes, 
such as T and B-cells, microglia and oligodendrocytes. miRNA targets have only 
been experimentally validated in a few studies. Identifying the effect of dysregulated 
miRNAs in specific cells will provide key insight into the mechanisms of disease and 
guidance for the design of future MS therapies.  
  
 
Table 1.1: MicroRNA observed as dysregulated in more than one MS study or with experimentally validated functional 
consequences. See Table 1.2 for details on sample size, miRNAs analysed and methodologies. MiRNAs dysregulated in CD4+ T-
cells and NAWM have been highlighted using f and q respectively. 
MicroRNA Tissue Direction of change in MS Disease stage Validated Target Functional result 
miR-15af CD4+CD25+
high T-cells 
(118) 
Up RRMS   
 CD4+ T-cells (119) Down RRMS BCL2 Decreased apoptosis. 
miR-15b Serum (120-122) Down RR & PPMS (120) 
RR, SP & PPMS 
(121) 
  
  Up after 6-months FIN-therapy RRMS (122)   
 Whole blood (123) Down compared to NMOSD RRMS/CIS   
miR-16f CD4+ T-cells (119) Down RRMS BCL2 Decreased apoptosis. 
 CD4+ and CD8+ T-cells 
(124) 
Up & normalised after AHSCT RR, SP & PPMS   
miR-17-5pf CD4+ T-cells (125) Up RRMS PTEN & PI3KR1  
 CD4+ T-cells (126) Down after NTZ-therapy & up 
during relapse 
RRMS PTEN, BIM & 
TGFBR2 
Reduced miR-17 
decreases cell 
proliferation.  
 Whole blood (127) Down RR, SP & PPMS   
miR-19bf CD4+CD25+
high T-cells 
(118) 
Up RRMS   
 B-cells (69) Down & normalised in NTZ-
treated 
RRMS   
miR-20a-5p Whole blood (127, 128) Down RR, SP & PPMS 
(127) RRMS & CIS 
(128) 
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MicroRNA Tissue Direction of change in MS Disease stage Val. Target Functional result 
miR-21-5p Whole blood (123) Down compared to NMOSD RRMS/CIS   
 PBMCs (129) Up RRMS   
miR-22-3pf CD4+CD25+
high T-cells (118) Up RRMS   
 Plasma (130) Up MS (unspecified)   
miR-26a-5p PBMCs (131) Up in relapse compared to 
remitting 
RRMS – relapse 
and remitting states 
  
 PBMCs (132) Up after 3 months IFN-β 
therapy in responders 
RRMS - IFN-β 
responders and 
non-responders 
DLG4  
 PBMCs (133) Down after 6 months NTZ-
therapy 
RRMS   
miR-27af CD4+ T-cells (134) Up in relapse vs. remitting & 
HC 
RRMS – relapse 
and remitting states 
  
 Serum (135) Up in RRMS vs. SPMS RR & SPMS   
miR-27bf Naïve CD4+ T-cells (136, 
137) 
Up RR, SP & PPMS BMI1 (136) 
TGFb 
signalling 
components 
(137) 
Inhibits Th2 differentiation. 
Inhibits differentiation of naïve 
CD4+ T-cells into T-reg. 
miR-29a-3pf CD4+CD25+
high T-cells (118) Up RRMS   
 PBMCs (138) Down after 1 month IFN-β 
therapy 
RRMS & CIS   
miR-29b-3pf CD4+CD45RO+ T-cells (139) Up  RR, SP & PPMS IFN-g Feedback loop – IFN-g induces 
miR-29b-3p expression. 
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MicroRNA Tissue Direction of change in MS Disease stage Validated Target Functional result 
miR-29c-3pfq CD4+CD25+high T-cells 
(118) 
Up RRMS   
 PBMCs (138) Down after 1month IFN-β 
therapy 
RRMS & CIS   
 NAWM (140) Down MS (unspecified)   
miR-34a Active & inactive WM lesion 
(141) 
Up in active lesions MS (unspecified) CD47 Promotes phagocytosis 
of myelin by 
macrophages. 
miR-93f CD4+CD25+
high T-cells 
(118) 
Up RRMS   
 PBMCs (142) Up RRMS   
miR-106bf CD4+CD25+
high T-cells 
(118) 
Up RRMS   
 B-cells (69) Down & normalised in NTZ-
treated 
RRMS   
 CD4+ T-cells (126) Up in NTZ-treated RRMS TGFBR2  
miR-124 Hippocampus (143) Up in demyelinated  MS (unspecified) AMPA receptor Reduced memory 
performance. 
miR-125a-5p BEC (144) Down MS (unspecified) ICAM-1 Increased monocyte 
migration through BBB. 
 PBMCs (145) Up RRMS   
 Whole blood (146) Down after NTZ-therapy RRMS & PML   
miR-125a-3p  CSF (147) Up & active-MS vs. RRMS RR & SPMS MBP, FYN, NRG1, 
MAP1B 
Blocks maturation in 
OPCs impairing 
remyelination. 
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MicroRNA Tissue Direction of change in MS Disease stage Validated Target Functional result 
miR-126f CD4+ T-cells (125) Up RRMS   
 CD4+ T-cells (148) Down in NTZ-treated RRMS POU2AFI  Regulates expression of 
transcription factor Spi-B. 
 PBMCs (149) Down in NTZ-treated, up in PML RRMS   
miR-128f Naïve CD4+ T-cells 
(136, 137) 
Up RR, SP & PPMS BMI1 (136) 
TGFb signalling 
components (137) 
Inhibits Th2 differentiation. 
Inhibits differentiation of naïve 
CD4+ T-cells into T-reg. 
miR-132 B-cells (150) Up RRMS SIRT1 Increases expression of 
proinflammatory cytokines 
(TNFα and LT). 
 PBMCs (133) Up RRMS   
miR-140-5pf CD4+ T-cells (151) Down RRMS STAT1 Increased encephalitogenic 
Th1 differentiation. 
miR-142-3pf CD4+ and CD8+ T-
cells (124) 
Up & normalised after AHSCT RR, SP & PPMS   
 PBMCs (152) Up & normalised in GA-treated RRMS   
miR-145 Whole blood (153) Up RRMS   
 PBMCs (142) Up  RRMS   
 Plasma (142, 154) Up & RRMS vs. SPMS RR & SPMS   
 Serum (142) Up RRMS   
miR-146a PBMCs (129) Up RR, SP & PPMS   
 PBMCs (152) Up & normalised in GA-treated RRMS   
 BEC (155) Up MS (unspecified) IRAK1, TRAF6, 
NFAT5, RhoA 
Inhibits NF-kB to negatively 
modulate leukocyte adhesion. 
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MicroRNA Tissue Direction of change in MS Disease stage Validated Target Functional result 
miR-150 CSF (156) Up in CIS-converters CIS & MS   
miR-155fq  Active & inactive WM 
lesion (141) 
Up in active lesions MS (unspecified) CD47 Promotes phagocytosis of 
myelin by macrophages.  
 BEC (active lesions 
and NAWM) (157) 
Up in active lesions RR, SP & PPMS CLDN-2, 
ANXA-2, 
DOCK-1, 
SDCBP 
Cell-cell complex molecules and 
focal adhesion molecules 
targeted resulting in BBB 
permeability. 
 CD4+ and CD8+ T-
cells (124) 
Up & normalised after AHSCT RR, SP & PPMS   
 NAWM (158) Up RR, SP & PPMS AKR1C1 & 
AKR1C2 
Reduced neurosteroid synthesis 
(including allopregnanolone). 
 PBMCs (133, 152, 159) Up & down after NTZ-therapy RRMS   
miR-181a Hippocampus (143) Down in demyelinated MS (unspecified)   
 B-cells (69) Down  RRMS   
miR-181c Hippocampus (143) Down in demyelinated MS (unspecified)   
 CSF (160) Up RR, SP & PPMS   
miR-191q NAWM (140) Down MS (unspecified) SOX4, FZD5, 
BDNF, WSB1 
SOX4 over-expression in 
oligodendrocytes prevents 
myelination. 
 B-cells (69) Down & normalised after 6-
months NTZ-therapy 
RRMS   
miR-221f CD4+CD25+
high T-cells 
(118) 
Up RRMS   
 Plasma (154) Up in RRMS vs. ALS RRMS & SPMS   
  
20 
  
 
MicroRNA Tissue Direction of change in MS Disease stage Validated Target Functional result 
miR-223fq Whole blood (153) Up RRMS   
 CD4+CD25+high T-
cells (118) 
Up RRMS  
 CD4+ T-cells (161) Up in relapse, down in 
remission vs. HC 
RRMS  
 PBMCs (120) Up  RRMS  
 Serum (120-122) Down RR & PPMS (120), RR, SP  
& PPMS (121), RRMS (122) 
miR-223  NAWM (140) Up MS (unspecified)   
miR-326f  Active & inactive 
WM lesion (141) 
Up in active lesions MS (unspecified) CD47 Promotes phagocytosis of 
myelin by macrophages. 
 CD4+ T-cells (162) Up RRMS Ets-1 Promotes Th-17 differentiation. 
 PBMCs (152) Up RRMS   
 PBMCs (131) Up in relapse compared to 
remitting 
RRMS – relapse and 
remitting states 
  
miR-338-
5pfq 
NAWM (158) Up RR, SP & PPMS AKR1C1 & 
AKR1C2 
Reduced neurosteroid synthesis 
(including allopregnanolone). 
 CD4+CD25+high T-
cells (118) 
Down RRMS   
miR-340f Resting memory 
CD4+ CD45RO+ T-
cells (136) 
Up RR, SP & PPMS BMI1 & IL-4 Inhibits Th2 differentiation and 
contributes to proinflammatory 
Th1 response. 
miR-422a Whole blood (153) Up RRMS   
 Plasma (130) Up MS (unspecified)   
 B-cells (125) Down RRMS   
21 
  
 
MicroRNA Tissue Direction of change in MS Disease stage Validated Target Functional result 
miR-497f CD4 + T-cells (125) Up RRMS   
 CD8+ T-cells (125) Down RRMS   
 B cells (125) Up RRMS   
miR-629-5p CD8+ T-cells (125) Up RRMS   
 Whole blood (128) Up RRMS & CIS   
 Whole blood (146) Down in PML onset (NTZ-
therapy) 
RRMS & PML   
let-7c Plasma (154) Up in RRMS vs. SPMS RR & SPMS   
 Whole blood (146) Down after NTZ- therapy RRMS & PML   
 Serum (135) Up RR, SP & PPMS   
let-7d Plasma (154) Up in RRMS vs. HC & RRMS 
vs. ALS 
RR & SPMS   
 PBMCs (142) Up RRMS   
let-7g Hippocampus (143) Up in demyelinated MS (unspecified)   
 PBMCs (163) Down RR, SP & PPMS   
 
Abbreviations: AHSCT = autologous haematopoietic stem cell transplant; BEC = brain endothelial cells; CSF = cerebrospinal fluid; 
FIN = fingolimod; GA = glatiramer acetate; HC = healthy controls; IFN-β = interferon-beta; IFN-g = interferon-gamma; NMOSD = 
neuromyelitis optica spectrum disorder; NTZ = natalizumab; OPC = oligodendrocyte precursor cell; PBMC = peripheral blood 
mononuclear cell; PML = progressive multifocal leukoencephalopathy; PPMS = primary progressive MS; RRMS = relapsing-remitting 
multiple sclerosis; SPMS = secondary progressive MS; Th = T-helper cells; T-reg = T regulatory cells; WM = white matter.  
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Table 1.2: Experimental details of studies recorded in Table 1.1.  
Paper Sample size and type Methodology 
Number of 
miRNA 
analysed 
De Santis (118) DC: 12 RRMS, 14 HC. VC: 10 RRMS, 10 HC Microarray 723 
Lorenzi (119) DC: 15 RRMS, 15 HC. VC: 5 RRMS, 5 HC qPCR 2 
Ridolfi (120) 15 MS (11 remitting RRMS, 4 PPMS), 12 HC qPCR 3 
Fenoglio (121) Italian pop – DC: 3 RRMS, 4 PPMS, 3 HC. VC: 8 RRMS, 
5 PPMS, 11 HC 
USA pop – 15 RRMS, 13 PPMS, 30 HC 
qPCR 88 
Lindberg (125) DC: 8 RRMS, 10 HC. VC: 15 RRMS, 10 HC qPCR (TLDA) 365 
Meira (126) 14 NTZ-treated RRMS, 14 untreated RRMS, 14 HC qPCR 2 
Cox (127) 59 MS (24 RRMS, 17 SPMS, 18 PPMS), 37 HC Microarray 733 
Sievers (69) DC: 10 untreated RRMS, 10 NTZ-treated RRMS, 10 HC. 
VC: 30 RRMS, 7 HC 
Microarray & qPCR 1059 
Keller (128) 25 RRMS, 25 CIS, 25 HC NGS, microarray & qPCR All 
Siegel (130) 4 MS, 4 HC Microarray >900 
Honardoost (131) 20 relapsing RRMS (treatment naïve), 20 remitting 
RRMS (IFN-β treated), 20 HC 
qPCR 2 
De Felice (132) DC: 20 IFN-β treated RRMS, 10 non-responder RRMS 3 
time points (0,3,6 months). VC: 20 IFN-β treated RRMS. 
3 time points (0,3,6 months) 
Cloning based sequencing & qPCR All 
Guerau-de-Arellano 
(136) 
22 MS (12 RRMS, 5 SPMS, 5 PPMS), 16 HC qPCR (TLDA) 667 
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Paper Sample size and type Methodology 
Number of 
miRNA 
analysed 
Hecker (138) DC: 4 RRMS, 2 CIS. VC: 8 RRMS, 4 CIS. 4 time points 
(before 1st, 2nd & 3rd IFN-β injection & 1 month after 
treatment) 
qPCR (TLDA) & microarray 651 
Junker (141) 20 MS, 10 HC qPCR 365 
Søndergaard (142) PBMC – DC: 20 RRMS, 21 HC. VC: 12 RRMS, 20 HC 
Plasma – 22 RRMS, 15 HC 
Serum – 40 RRMS, 40 HC 
Microarray (PBMCs only) & qPCR 847 
Dutta (143) 18 MS (9 myelinated, 9 demyelinated hippocampus), 9 HC qPCR Unknown 
Reijerkerk (144) 8 MS, 4 HC Microarray & qPCR 939 
Yang (145) DC: 10 RRMS, 10 HC. VC: 40 RRMS, 40 HC. (Chinese 
pop) 
Microarray & qPCR 754 
Munoz-Culla (146) 19 RRMS (NTZ-treated) 3 time points (0,6,12 months) qPCR (TLDA) 754 
Meira (148) 12 untreated RRMS, 24 NTZ-treated RRMS, 12 HC qPCR 1 
Miyazaki (150) 19 RRMS, 19 HC qPCR 102 
Keller (153) 20 RRMS, 19 HC Microarray 866 
Gandhi (154) DC: 10 RRMS, 9 SPMS, 9 HC. VC: 50 RRMS, 51 SPMS, 
32 HC 
qPCR 368 
Fenoglio (129) 29 MS (16 remitting MS, 6 SPMS, 7 PPMS), 19 HC qPCR 5 
Waschbisch (152) 36 RRMS, 20 GA-treated RRMA, 18 IFN-β treated RRMS, 
32HC 
qPCR 5 
Lopez-Ramirez (157) 6 MS (4 SPMS, 1 PPMS, 1 SP/RRMS), 6 HC qPCR 1 
Noorbakhsh (158) 16 MS (3 RRMS, 10 SPMS, 3 PPMS), 10 HC Microarray & qPCR 847 
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Paper Sample size and type Methodology 
Number of 
miRNA 
analysed 
Paraboschi (159) 10 RRMS, 10 HC Microbead-based technology 22 
Haghikia (160) 53 MS (17 RRMS, 30 SPMS, 6 PPMS), 39 OND qPCR 760 
Du (162) 43 RRMS, 42 HC, 11 NMOSD qPCR 8 
Martinelli-Boneschi (163) DC: 19 MS (7 RRMS, 6 SPMS, 6 PPMS), 14 HC  
VC: 10 MS (5 RRMS, 2 SPMS, 3 PPMS), 10 HC 
Microarray 1145 
Guerau-de-Arellano 
(140) 
15 MS, 5 HC, mRNA qPCR on 10 samples NanoString nCounter 800 
Guan (151) 22 RRMS (4 relapse, 18 remitting), 22 HC Affymetrix miRNA array v4 & qPCR 2578 
Lecca (147) 30 MS (28 RRMS, 2 SPMS), 13 HC qPCR 1 
Fenoglio (122) 30 RRMS (FIN treated) 5 time points (0,3,6,9,12 months), 
11 HC  
qPCR 3 
Regev (135) DC: 26 MS (7 RRMS, 9 SPMS, 10 PPMS), 20 HC 
VC: 58 MS (29 RRMS, 19 SPMS, 10 PPMS), 30 HC, 74 
other diseases 
qPCR 652 
Ahmadian-Elmi (134) 40 RRMS (20 relapse, 20 remitting) qPCR 2 
Mameli (133) 24 RRMS (NTZ treated) 2 time points (0 & 6 months), 24 
HC 
qPCR 4 
Meira (149) 65 RRMS (21 untreated, 21 NTZ treated <24 months, 23 
NTZ treated >24 months), 20 NTZ treated who 
developed PML 
qPCR (TLDA) 377 
Munoz-Culla (164) 24 RRMS (2 samples/patient – relapse vs remission), 24 
HC 
Affymetrix miRNA array v1.0 & qPCR 847 
25 
  
 
Abbreviations: AHSCT = autologous haematopoietic stem cell transplant; CIS = clinically isolated system; DC = discovery cohort; 
FIN = fingolimod; GA = glatiramer acetate; HC = healthy controls; IFN-β = interferon-beta; NGS = next generation sequencing; 
NMOSD = neuromyelitis optica spectrum disorder; NTZ = natalizumab; OND = other neurological diseases; PML = progressive 
multifocal leukoencephalopathy; pop = population; PPMS = primary progressive MS; qPCR = quantitative polymerase chain 
reaction; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive MS; TLDA = TaqMan Low Density Array; 
VC = validation cohort.  
Paper Sample size and type Methodology 
Number of 
miRNA 
analysed 
Hosseini (161) 40 RRMS (20 relapse, 20 remitting), 12 HC qPCR 1 
Keller (123) DC: 60 CIS/RRMS, 11 NMOSD, 43 HC 
VC: 19 CIS/RRMS, 18 NMOSD 
NGS & qPCR All 
Arruda (124) 24 MS (5 RRMS, 18 SPMS, 1 PPMS) 3 time points 
(0,6, 12,24 months after AHSCT treatment), 9 HC 
qPCR 3 
Smith (139) 19 MS (11 RRMS, 4 SPMS, 4 PPMS), 17 HC NanoString nCounter 1 
Wu (155) 6 MS, 6 HC qPCR 1 
Bergman (156) DC: 15 CIS, 15 MS, 27 OND 
VC1: 34 CIS, 43 MS, 65 OND 
VC2: 96 CIS, 120 MS, 214 OND 
qPCR (TLDA) 754 
26 
  
 27 
Here, miRNA dysregulation across published tissue types will be discussed, including 
effects on cellular function, the regulatory role of DMTs on miRNA expression, and 
potential biomarker candidates for diagnosing MS, predicting treatment responses, 
and differentiating disease subtypes.  
 
MicroRNA in Central Nervous System 
Limited research has been conducted on miRNA expression in tissues of the CNS, 
primarily because of difficulties obtaining post-mortem brain tissue samples. A study 
by Junker et al. (141) reported the analysis of the expression of 365 mature miRNAs 
in both MS lesions and control white matter. A total of 167 miRNAs were detected in 
all groups with data demonstrating that active and inactive MS lesions have distinct 
miRNA profiles. miR-155, miR-34a and miR-326 were particularly found to be up-
regulated in active lesions, and CD47 was a common target for these three miRNAs. 
CD47 is a cell-surface protein responsible for inhibiting phagocytosis by 
macrophages. The consequence of the miRNAs up-regulation is reduced production 
of CD47, providing a permissible environment for macrophage activation and the 
phagocytosis of myelin. The scope of this study was limited as it looked at only a 
fraction of the >1800 miRNAs in the genome, and a broader analysis could highlight 
further candidate miRNAs involved in MS pathology. However, the identification of 
miR-155-5p as up-regulated in MS CNS tissue has been seen repeatedly in many 
studies since Junker’s.   
The expression of miR-155-5p appears to be highest in active lesions and reduces 
through chronic lesions and NAWM to a baseline low in control white matter (141, 
157, 158). Furthermore, silencing of miR-155 ameliorates EAE in mice (165). miR-
155 has been shown to affect the BBB to an extent that immune cells may then 
infiltrate the CNS. Up-regulation of miR-155 in brain endothelial cells (BEC) mediates 
reduced expression of cell-cell complex and focal adhesion molecules (144), making 
the BBB more permeable. Also, the observed up-regulation of miR-155 in the CNS of 
MS patients can be inducted by proinflammatory cytokines, IFN-g and TNFa (144), 
further underscoring the link in MS between the central nervous and immune 
systems.  
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Other miRNAs have also been shown to exacerbate BBB breakdown. Down-
regulation of miR-125a-5p in BEC results in increased expression of intercellular 
adhesion molecule 1 (ICAM-1), necessary for leukocyte adhesion, and permits their 
migration through the BBB (144). ICAM-1 expression is further enhanced by the 
targeting of its negative regulators by miR-155, along with VCAM-1, a similar cell 
adhesion molecule (166). In contrast, miR-146a over-expression in BEC negatively 
modulates T cell adhesion to the BBB by indirectly inhibiting VCAM1- and CCL2 
(155). Interestingly, while miR-146a and miR-155 have opposite actions, anti-
inflammatory and proinflammatory respectively, the expression of both is induced by 
proinflammatory cytokines (144, 155). In terms of exacerbating disease activity, 
induction of miR-155 is logical. In contrast, cytokine-mediated over-expression of 
miR-146a in BEC may signal a self-mediated decline in inflammation in the BBB at 
the conclusion of relapse. 
A recent study of miRNA expression in NAWM identified a number of dysregulated 
miRNAs, demonstrating underlying dysregulation in the CNS of MS individuals (140). 
Unfortunately, details on the subtype of MS from which the samples were derived are 
not available, and a mix of MS subtypes make exposing stage-specific dysregulation 
of NAWM problematic. Nonetheless, their finding of miR-191 down-regulation and 
subsequent over-expression of SOX4 and BDNF (table 1.1) is very interesting. SOX4 
negatively regulates myelination by oligodendrocytes (167), whereas BDNF and 
other genes targeted by miR-191 have known neuroprotective effects (168). Guerau-
de-Arellano et al. thus came to the intriguing conclusion that NAWM is enriched in 
neuroprotective mechanisms, though is prone to inflammation and has reduced 
repair mechanisms (140). This complements the observation previously stated by 
Melief et al., that NAWM is alert but in an immunosuppressed state (41).  
miR-125-3p is a miRNA that is enriched in the human CNS, specifically neurons and 
oligodendrocytes. However, its over-expression in vitro impairs myelination by 
blockading oligodendrocyte maturation (147). In the CSF of MS patients with 
radiologically active disease, miR-125a-3p is up-regulated, and the cellular origin of 
this is likely to be either neurons or oligodendrocytes undergoing damage in active 
MS (147). This miRNA is of particular interest as it is the opposing arm (-3p vs. -5p) 
of the mature miRNA duplex, miR-125a, that is down-regulated in BEC (144). Both 
arms of the miRNA duplex are dysregulated in MS, however in different directions. 
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Nonetheless, the dysregulation of both contributes to disease exacerbation; miR-125-
3p by inhibiting oligodendrocyte maturation, and miR-125-5p by increasing leukocyte 
adhesion to the BBB (144, 147). 
Dutta et al. (143) analysed post-mortem MS brains to investigate if the loss of myelin 
in the hippocampus has an effect on neural miRNA expression. Hippocampal 
demyelination reduces neural gene expression and is likely linked to memory loss in 
MS patients. Most significantly, the neuronal miRNA, miR-124, was found to be up-
regulated in the neurons of demyelinated samples. miR-124 has target binding sites 
on 3’UTRs of 26 neural mRNAs. The study also analysed a mouse model of 
demyelinated hippocampus and found that an increase in miR-124 resulted in 
reduced expression of AMPA receptors and decreased memory performance; 
remyelination of the hippocampus reversed this effect on memory (143). 
Contrastingly, increased levels of miR-124 in microglia have been associated with 
microglial quiescence and suppression of EAE in mice (169). This highlights the 
diverse effects miRNAs can have on cell populations. It would appear that miR-124 
expression is beneficial for MS prognosis in microglia, but detrimental when 
expressed more broadly in the hippocampus. It is essential therefore, that individual 
cell types be studied to understand the impact miRNA dysregulation has on disease 
aetiology and pathology. 
 
MicroRNA in the immune system 
The majority of studies on miRNAs in MS have been performed on blood derived 
samples as these are much more easily acquired than CNS tissue, and may be 
collected longitudinally. A recent study of the TGF-β-signalling pathway and miRNA 
expression in naïve CD4+ T-cells suggests that miRNA dysregulation is not a result 
of inflammation, but an inherent susceptibility factor of MS (137). However, miRNA 
profiles in RRMS and SPMS individuals are distinct (135, 154), indicating that while 
miRNA dysregulation may be a risk factor for MS, it also dynamic and shifts with 
changes in disease. miRNA dysregulation should therefore be considered as both 
contributing to disease onset and progression, and a reflection of affected tissue’s 
response to disease.  
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In 2016, Munoz-Culla et al. described the “mirror pattern” of miRNA expression in 
relapse vs. remission of RRMS patient PBMCs (164). When observing expression of 
short non-coding RNAs (sncRNA including miRNA and small nucleolar RNA 
(snoRNA)), they found 10 sncRNAs that were dysregulated in both relapse and 
remission compared to HC, but in opposite directions. Of further interest, the miRNA 
expression profiles of each disease state were enriched for mRNA targets in different 
gene pathways. Relapse-miRNAs strongly target genes involved in general leukocyte 
metabolism, whereas miRNAs dysregulated during MS remission regulate genes 
involved in innate immunity (164). The aforementioned mirror effect in relapsing vs. 
remitting has also been observed in CD4+ T-cells. miR-233 is significantly up-
regulated during relapse compared to HC, whereas it is down-regulated (not 
significant, p=0.07) in remission (161). miR-223 is up-regulated in many tissues: 
whole blood, CD4+ T-cells (relapse), PBMCs and NAWM (118, 120, 140, 153, 161); 
and down-regulated in serum (120-122). Furthermore, the frequency of a T/T 
genotype at rs1044165, a SNP in miR-223’s genomic sequence, is significantly 
reduced in MS patients, suggesting the polymorphism acts as a protective factor 
(120). 
In 2009, Otaegui et al. reported differential miRNA expression in PBMCs for MS 
patients in relapse status, remitting status and HC. Up-regulation of miR-18b and 
miR-599 was indicative of relapse status, whereas up-regulation of miR-96 
significantly indicated the MS patients were in remission (35). RRMS may also be 
distinguished from HC via miRNA expression patterns of T-regs. Specifically, miR-
106b and miR-25 were down-regulated in RRMS compared to HC, and target 
prediction indicates genes in the TGF-β-signalling pathway may be affected by these 
miRNA, ultimately having an effect on T-reg differentiation and maturation (118). This 
is supported by the findings of Severin et al. (137). 
Another study comparing relapse and remission miRNA profiles identified miR-27a 
(up-regulated) and miR-214 (down-regulated) as miRNAs able to distinguish relapse 
from remission in CD4+ T-cells (134). Up-regulation of miR-27a in serum has also 
been shown to differentiate RRMS from SPMS (135).  
Also, miR-140 expression changes in relapsing and remitting stages of disease, 
negatively correlating with disease severity in PBMCs. This occurs specifically in 
CD4+ T-cells and non-T cells, whereas its expression remained stable in CD8+ T-
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cells (151). mRNA and protein expression analyses confirmed STAT1 as a target of 
miR-140, and demonstrated that miRNA-associated over-expression of this gene 
caused increased levels of T-helper (Th)-1 differentiation (151), leading to disease 
exacerbation. The excessive presence of Th-1 cells is characteristic of active MS 
disease, and miR-29b is a key part of a feedback loop that controls the balance of 
Th-1 cells. miR-29b is up-regulated in CD4+ T-cells of MS patients, which represses 
T-bet and IFN-γ, dysregulating Th-1 bias. However, its initial up-regulation is the 
result of high IFN-γ (139). Persistent up-regulation of both miR-29b and IFN-γ in MS 
is indicative chronic inflammation. 
miRNA dysregulation also has effects on other Th cells. As in Junker et al.’s study on 
lesions in the CNS (141), miR-326 has also been identified as being up-regulated in 
PBMCs of MS patients in relapse (162). Here, it targets Ets-1, a negative regulator of 
Th-17 cells, thus the up-regulation of miR-326 (predominantly in CD4+ T-cells) 
promotes differentiation of Th-17 cells. This finding was followed up with a functional 
study in the EAE murine model and found inhibition of miR-326 coincided with milder 
pathology (162). 
In a study on peripheral whole blood, miR-17 and miR-20a were consistently under-
expressed in RRMS, SPMS and PPMS individuals. Knock-in and knock-down 
experiments on these miRNAs in Jurkat cells (partially differentiated T-cell line 
derived from a T-cell lymphoma patient) revealed that these miRNAs targeted genes 
involved in translation regulation, immune response, activin A signalling regulation 
and vitamin B7 metabolism pathways (127). miR-17 was also identified as being 
dysregulated in CD4+ T-cells of RRMS patients by Lindberg et al. (125) though it was 
found to be up-regulated in this case. This could be due to a number of reasons: (1) 
small sample number, (2) analysis of different disease courses (RRMS vs. all MS 
subtypes) or (3) dysregulation in CD4+ T-cells may be masked in PBMCs by the 
expression profiles of other cell types. It is likely a combination of these three factors 
that resulted in contradictory findings between the studies. However, it should be 
noted that Lindberg et al. reported miR-497 to be over-expressed in CD4+ T-cells 
and B-cells whilst under-expressed in CD8+ T-cells of the same individuals 
compared to healthy controls (HC) (125), highlighting the critical need to focus on 
single cell subsets.  
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This is further emphasised by Søndergaard et al. (142), who analysed miRNAs in 
blood, plasma and serum for the purpose of identifying diagnostic biomarkers for MS. 
miRNA expression in PBMCs was compared between treatment naïve MS patients in 
clinical remission and HC. Analysis of isolated PBMC subpopulations identified 
antigen presenting cells and natural killer cells as the primary source of miRNA 
dysregulation in MS patients, though this varied between miRNAs. miR-145 was up-
regulated (three-fold) in MS patients and the highest expression was seen in CD8+ 
T-cells, monocytes and natural killer cells. Furthermore, miR-145 expression in 
plasma is negatively correlated with EDSS (154). Of the 16 miRNAs analysed in 
plasma, only miR-145 and miR-939 were similarly dysregulated as in PBMCs (142). 
This suggested either that: (1) cells other than PBMCs are also releasing miRNAs, 
(2) PBMC cell subsets have contrasting miRNA dysregulation which is masked when 
looking at PBMCs as a whole, or (3) specific miRNAs are more prone to release from 
cells than others. 
Using miRNAs as biomarkers for diagnoses of any disease is only effective if similar 
diseases do not exhibit dysregulation in the same miRNAs; in the case of MS, 
miRNAs will need to be excluded from other neurological diseases (OND) to be 
effective. A study compared miRNAs differentially expressed in MS whole blood to 
dysregulated miRNAs reported in other diseases. Of 165 miRNAs that were identified 
to be dysregulated by Keller et al. (153), 43 had been associated with a variety of 
other diseases; thus 122 are thought to be exclusively linked with MS and warrant 
further exploration as potential diagnostic biomarkers. 
In 2014, Keller et al. (128) produced the first study in MS using next generation 
sequencing (NGS) for miRNA profiling in whole blood. The study employed a 
stringent experimental design whereby miRNAs had to be identified as dysregulated 
by both NGS and microarray before being further assessed with quantitative 
polymerase chain reaction (qPCR). Eight miRNAs were identified and three were 
confirmed significantly dysregulated by qPCR (miR-16-2-3p, miR-7-1-3p and miR-
20a-5p). Using various methods and patient cohorts, the down-regulation of miR-
20a-5p in whole blood of MS patients has been confirmed (127, 128, 153). Prediction 
algorithms suggest that miR-20a-5p regulates approximately 500 genes, 19 of which 
have been experimentally validated and many are involved in T cell regulation. This 
study was followed up a year later using NGS in serum and whole blood to identify 
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miRNAs that may be used as biomarkers to distinguish CIS/RRMS from 
neuromyelitis optica spectrum disorder (NMOSD). No miRNAs were significantly 
different between the disease groups or HC in serum, however 178 miRNAs in whole 
blood showed differential expression in pairwise comparisons of CIS/RRMS, NMOSD 
and HC (123), and should be researched further to validate them as biomarkers for 
differential diagnosis of NMOSD. 
	
Non-cellular circulating miRNAs 
The acquisition of samples peripheral to the CNS is much more common and less 
distressing for patients, and thus a more realistic approach for biomarker profiling. 
Identification of dysregulated miRNAs in PBMC subsets is critical to determine the 
mechanisms occurring in the immune system during MS pathogenesis. The impact of 
non-cellular circulating miRNAs on system processes is difficult to infer, as their 
action on specific cell types cannot be established. However, they are excellent 
sources for biomarker analyses. Plasma, serum and CSF samples are more easily 
handled in the laboratory than cell subsets, and are therefore more likely to be used 
in clinical practice for identifying and utilising disease biomarkers. It should be noted 
that longitudinal studies would exclude CSF as it is not feasible to repeatedly perform 
lumbar puncture to longitudinally monitor miRNA changes. 
In 2013, Gandhi et al. (154) measured and compared the expression of 368 miRNAs 
in plasma of RRMS, SPMS and HC samples with the goal of identifying diagnostic 
biomarkers. A number of miRNAs were identified that distinguished RRMS vs. HC, 
SPMS vs. HC and RRMS vs. SPMS (Table 1). The differential expression of two 
miRNAs (miR-92 and let-7) distinguished RRMS from SPMS and also RRMS from 
ALS patients, but not SPMS from ALS; suggesting similar pathology in the 
neurodegenerative stage of MS (SPMS) and ALS. Differential expression of miR-92 
was found in the largest number of comparisons (RRMS vs. SPMS, RRMS vs. HC 
and RRMS vs. ALS) and was also shown to be associated with EDSS score and 
disease duration. miR-92 targets CD40 pathways involved in cell cycle regulation and 
cell signalling and the cluster to which it belongs (miR-17-92) is involved in regulating 
proliferation and activation of CD4+ T-cells. Another differentially expressed miRNA is 
miR-145 involved in down-regulation of CTLA-4 in CD4+ T-cells; a receptor that 
inhibits T cell response and when mutated has been associated with autoimmune 
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disease. This finding is corroborated by Keller et al.’s 2014 study in whole blood 
(153) and by Søndergaard et al. in PBMCs (142).  
A more recent study from Gandhi’s group focused on identifying biomarker miRNAs 
in serum to differentiate between MS, HC, OND (AD and ALS) and inflammatory 
diseases (rheumatoid arthritis and asthma) (135). Four miRNAs distinguished 
between MS and OND, and a further two between MS and inflammatory diseases. 
An interesting outcome of this paper was the establishment of a clear definition 
between plasma and serum miRNA expression profiles. In plasma, miR-145 
correlated strongly with EDSS (154), whereas it showed no correlation in serum 
where miR-199a-5p had the strongest correlation (135).  
Circulating miRNAs in plasma have been analysed in a few studies. In one, authors 
identified 6 up-regulated and 1 down-regulated miRNAs in MS individuals (130). 
Microarray analysis of over 900 miRNA transcripts demonstrates a good proportion of 
known miRNAs however, the sample size of 4 MS patients and 4 HC was a small 
power study and no variation in disease stage was investigated. Two of the identified 
miRNAs had been identified in previous studies; miR-22 expression is increased in T-
reg cells of MS patients (118) and miR-422a was found to be differential to RRMS 
patients compared to HC in whole blood (153). Notably miR-648 was over-expressed 
in MS patient plasma; as this miRNA targets the myelin-associated oligodendrocyte 
basic protein mRNA, reduction of protein level reduces the stability of the CNS 
myelin sheath (130).  
To establish potential diagnostic biomarkers in CSF, Haghikia et al. (160) compared 
the expression profiles of miRNAs in the CSF of patients with MS, and patients with 
ONDs. Of the 760 miRNAs included in the panel, 50 were detectable in CSF and 3 of 
those (miR-922, miR-181c and miR-633) have diagnostic potential. The combined 
dysregulation of miR-181c and miR-633 feasibly differentiated between patients with 
RRMS and SPMS. All three of the miRNAs were dysregulated in MS compared to 
OND. Some of the ONDs were neuroinflammatory diseases that may have similar 
presentations to MS, supporting the potential of these miRNAs to be used as 
diagnostic biomarkers for MS (160). However, the sample size for OND patients was 
low (n=39) and diverse. A study by Bergman et al. (156) used a much larger cohort, 
though the OND cohorts were still not well-defined. However, 88 miRNAs were 
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detected in the CSF; a marked improvement on Haghikia’s earlier study. miR-150 in 
particular stands out as its expression was able to discriminate between CIS 
converters and non-converters, as well as showing positive correlation with 
oligoclonal bands in the CSF (156). 
How miRNAs end up in non-cellular fluids may be due to a number of reasons, such 
as apoptotic release from cells. However, extracellular vesicles, particularly 
exosomes, should be analysed. Exosomes are non-toxic, naturally occurring 
nanovesicles that are produced by a number of MS-related tissues actively produce 
exosomes including T- and B-cells, oligodendrocytes and astrocytes (in-depth review 
by Jagot and Davoust (170)). Interestingly, miRNA are often actively incorporated into 
exosomes by these cells, and are sufficiently small enough that they can easily cross 
the BBB. Future therapies may utilise exosomes for miRNA delivery to the CNS to 
treat MS. One study has started to explore such an option; IFN-γ-stimulated 
exosomes produced by dendritic cells are enriched with miR-219 and in vivo 
application of these exosomes in brain slide culture was sufficient to stimulate 
oligodendrocyte differentiation into myelinating cells (171).  
 
MicroRNA and MS treatments 
Aberrant expression of miRNAs contributes to MS pathology and thus the effect of 
DMTs on miRNA expression has been the key focus of numerous studies. DMTs 
utilise various pathways to ameliorate the progression of disease. Glatiramer acetate 
(GA) is a random polymer of glutamic acid, lysine, alanine, and tyrosine; it has a 
similar structure to myelin basic protein and is thought to act as a decoy for the 
immune system. Waschbisch and colleagues (152) compared the expression levels 
of 5 miRNAs identified in previous studies as being dysregulated in MS. The 
expression of the miRNAs was analysed in the PBMCs of treatment naïve RRMS 
subjects, GA treated RRMS, IFN-β treated RRMS, and HC. miR-142-3p and miR-
146a were significantly up-regulated in the treatment naïve and IFN-β treated RRMS 
subjects. However, in the GA treatment group, expression of these two miRNAs was 
reduced to a level resembling the HC group. These miRNAs were previously 
identified by as being dysregulated in active white matter lesions (141) and the 
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reduced expression of these miRNAs in GA treated RRMS subjects warrants further 
research. 
Interferon-beta’s (IFN-β) mechanisms of action are vast and not fully understood, 
though it appears to inhibit trafficking of immune cells across the BBB, decreases 
production of proinflammatory cytokines (IL-17 and osteopontin) and increases the 
production of anti-inflammatory agents (IL-10) (172). A recent longitudinal study on 
the impact of IFN-β treatment on miRNA expression in PBMCs found that miRNA-
mediated regulation plays an important role in the mechanisms of action of IFN-β in 
RRMS and CIS cases (138). During time-points ranging from two days to one month, 
Hecker et al. observed the simultaneous up-regulation of IFN-β-responsive genes 
and the down-regulation of miRNAs associated with apoptosis and IFN feedback 
loops. The miRNAs identified as being dysregulated were observed in a small 
discovery cohort (n=6) and validated in a moderately larger cohort (n=12). MiRNA 
expression screening of a larger number of cases could possibly have yielded other 
miRNAs also affected by IFN-β’s mechanism of action. The expression of a number 
of miRNAs was affected by IFN-β. Interestingly, miR-193a was down-regulated 
following treatment, a previous study found this miRNA to be up-regulated in RRMS 
versus healthy HC (125) and it has also been implicated with the remission phase of 
RRMS (173); this supports evidence that IFN-β therapy reduces relapse rates (174). 
This study also supports the findings by Waschbisch et al., who found several 
miRNAs normalised following GA treatment (152) but were not affected by IFN-β 
treatment in both studies. 
Natalizumab (NTZ) is an anti-α4β1	 integrin	 antibody	 that	 restricts	 lymphocyte	migration 
into the CNS, decreasing formation of lesions (175). A cross-sectional investigation 
into miRNA expression dynamics compared a broad panel of miRNAs in the B-cells 
of untreated and NTZ treated RRMS patients and HC (69). 49 miRNAs were 
identified as down-regulated in untreated RRMS compared to HC however, no 
miRNAs were found to be significantly up-regulated. When compared to untreated 
RRMS, 10 miRNAs were up-regulated in NTZ-treated cases six months after 
initiation of treatment. Of these 10, five miRNAs overlapped the miRNAs found to be 
dysregulated in untreated RRMS vs. HC, indicating that NTZ has a normalising effect 
on some miRNA expression. This effect has also been observed in CD4+ T-cells 
(176). MiRNA-mRNA interaction analysis identified key affected pathways as B cell 
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receptor, phosphatidyl-inositol-3-kinase (PI3K) and phosphatase and tensin 
homology (PTEN) signalling; PI3K and PTEN were also found to be targets of miR-
17 by Lindberg et al. (125). Interestingly, 3 viral miRNAs from EBV were found to be 
down-regulated in RRMS compared to HC and two were up-regulated in NTZ treated 
vs. untreated RRMS (69). The implications of this finding on pathogenesis is not 
understood, though the high incidence of EBV-seropositivity in MS indicates that 
EBV-miRNAs likely play a significant role in the disease pathophysiology. 
A potential side effect of NTZ treatment is the development of progressive multifocal 
leukoencephalopathy (PML), a virus mediated inflammation of the brain that is fatal in 
some cases (177). miR-10b is very lowly expressed in patients being treated with 
NTZ, however those that develop PML have undetectable levels of miR-10b in their 
PBMCs (149). This absence of expression may be used as a biomarker for 
monitoring patients on NTZ. Likewise, 3 miRNAs have been shown to be differentially 
expressed in whole blood of PML patients after 12 months on NTZ, compared to 
those unaffected (146). They are also candidates for monitoring PML development in 
patients treated with NTZ. 
Fingolimod (FIN) is a modulator of sphingosine 1 phosphate (S1P) receptor (178). 
FIN induces down-regulation of S1P1 which is highly expressed on T- and B-cells, 
causing these cells to be sequestered in the lymph nodes, thus preventing migration 
into the CNS (179). After six months of treatment, the expression of three miRNAs in 
serum (miR-15b, miR-23a and miR-223) increased to levels similar to HC, and 
remained stable up the 12 months (the length of the study) (122). Expression of miR-
150 in plasma decreases after 12 months fingolimod treatment, though it is not clear 
if this normalisation as a HC comparison was not performed (156). As with the 
aforementioned DMTs, fingolimod has a normalising effect (miR-150 not confirmed), 
though it would more informative to observe its effect in immune cells rather than 
serum and plasma. 
An alternative to traditional immunosuppressive DMTs utilises a patient’s own stem 
cells to reduce relapse and improve disability in patients with active disease (180). 
Autologous haematopoietic stem cell transplantation (AHSCT) is a risky procedure 
involving chemotherapy to eradicate the patient’s white blood cells, and the re-
introduction of haematopoietic stem cells to reset the immune system. A recent study 
analysed the effect of AHSCT on the expression of three miRNAs. miR-16, miR-142 
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and miR-155 were all initially up-regulated in MS CD4+ and CD8+ T-cells. Their 
expression normalised in both cell types 6 months after AHSCT and remained stable 
throughout the study’s 24-month duration (124). While this finding is exciting and 
promising for the future of AHSCT, it should be noted that the sample cohort was a 
mixture of RRMS and SPMS, with active and inactive disease, and this may have 
skewed their baseline miRNA expression readings. An earlier study on untreated 
RRMS CD4+ T-cells identified miR-16 down-regulation compared to HC (119), a 
direct contradiction to the AHSCT study baseline.  
It has been clearly demonstrated that DMTs have an effect on miRNA expression 
patterns. Because of this, it is important that studies aimed at elucidating the role of 
miRNAs in disease pathology use only samples from patients who are treatment 
naïve or have been free from treatment for over six months. 
 
MicroRNA biogenesis and MS 
While miRNA dysregulation is important in understanding MS and developing reliable 
biomarkers for diagnosis and disease activity, the mechanism of miRNA 
dysregulation should not be overlooked. As mentioned earlier, miRNA expression can 
be affected by DNA methylation. Furthermore, the molecules in the biogenesis 
pathway (figure 1.3) may also exhibit aberrant expression, with a knock-on effect to 
general miRNA expression. In RRMS Dicer is down-regulated in B-cells (181), 
whereas in PBMCs, Drosha, DGCR8 and Dicer are all up-regulated (114). A 
contradicting study in PBMCs found Dicer mRNA to be stable in RRMS, though 
protein was down-regulated. However, Dicer was observed to increase expression in 
IFN-β responders (115). As with most miRNA studies in MS, these were all carried 
out in RRMS patients or mixed MS subtypes, with no specific focus on SPMS.  
  
  
 39 
Summary 
Multiple sclerosis is a complex autoimmune disease caused by multifocal 
inflammatory attacks on the CNS resulting in lesional demyelination and axonal 
damage. Symptoms vary between patients and as disease progresses disability 
accumulates. Whilst there are genetic loci that confer risk of developing MS, 
environment also plays a crucial role. Epigenetic factors are partially heritable but 
also highly sensitive to environment and many studies have highlighted these factors 
as contributory to MS pathology.  
MicroRNAs are of key interest and have the potential to play many roles in MS and 
its treatment. There are over 1800 miRNAs in the human genome and they are highly 
stable molecules, which makes them great candidates as biomarkers for diagnosing 
and monitoring disease progression. More importantly, they are regulators of gene 
expression and changes in their expression pattern have great impact on cellular 
pathways crucial to the pathophysiology of MS. The expression of miRNAs 
themselves may be affected or affecting other epigenetic mechanisms such as DNA 
methylation, which also has demonstrated differential presentation in MS patients. 
The vast majority of studies on miRNAs in the immune system have focused on 
heterogeneous cell populations; analyses of miRNA expression in specific cell types 
(particularly CD4+ T-cells which are highly involved in disease), are essential to 
understand the effect of miRNA dysregulation in MS. Furthermore, SPMS has largely 
been ignored and either left out of studies, or analysed in conjunction with RRMS and 
PPMS samples. To better understand the role of the immune system in SPMS, 
miRNA studies need to be performed. Additionally, as SPMS patients are not treated 
with DMTs, expression changes key to understanding cell pathology will not be 
hidden by the normalising effect of most DMTs. 
As with SPMS, normal appearing white matter has not been exhaustively 
investigated in miRNA studies, but has been shown to display pathology linked to 
symptomatic lesions. MiRNAs could be playing a pivotal pathological role in the 
NAWM and the identification, location and functional analysis of dysregulated 
miRNAs could yield information on MS pathology and new therapeutic strategies. 
Correlating these miRNAs in the NAWM to circulating body fluids will identify 
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potential biomarkers for monitoring disease course, as well as informing the interplay 
of CNS and immune system in SPMS. 
 
Research Question and Aims 
The studies included in this thesis were designed to provide answers for the following 
research questions: 
1. Which microRNAs are dysregulated in the CD4+ T-cells of SPMS patients, 
and how does this affect the role of CD4+ T-cells in SPMS? 
2. Are DNA methylation profiles of CD4+ T-cells different between in RRMS and 
SPMS, and are changes in microRNA expression caused by DNA 
methylation? 
3. Are microRNA biogenesis molecules differentially expressed in SPMS CD4+ 
T-cells, and does this have an effect on microRNA expression? 
4. Is DNA methylation affected by changes in microRNA expression, specifically 
miRNA-29b?  
5. Is there differential microRNA expression in SPMS normal appearing white 
matter compared to controls, and how does this compare to microRNA 
expression patterns seen in CD4+ T-cells? 
The study aims of this project are to: 
1. Identify miRNAs dysregulated in SPMS CD4+ T-cells using next generation 
sequencing; these will be confirmed using RT-qPCR. And determine if 
common gene targets demonstrate associated expression changes. 
2. Determine DNA methylation signature of CD4+ T-cells in SPMS and associate 
these with miRNA dysregulation. 
3. Determine whether changes in expression of miRNA biogenesis molecules 
correlate with miRNA expression trends in SPMS, and compare this to a 
RRMS cohort. 
4. Determine if levels of DNA methyltransferase enzymes correlate with miRNA-
29b levels, and how this affects DNA methylation levels in CD4+ T-cells. 
5. Investigate the dysregulation of microRNAs in SPMS NAWM on a series of 
post-mortem brain samples from control and SPMS subjects.  
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CHAPTER TWO – microRNA expression profile of SPMS CD4+ T-cells 
 
Next-generation sequencing reveals broad down-regulation of microRNAs in 
secondary progressive multiple sclerosis CD4+ T-cells 
 
Published in Clinical Epigenetics (IF 4.327) 27 August 2016. See appendix 1. 
 
This chapter addresses my first research question – Is there dysregulation of miRNA 
expression in the CD4+ T-cells of secondary progressive MS patients? 
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Abstract 
Background: The immune system has a diminished role in secondary progressive 
MS (SPMS) compared to the relapsing-remitting disease stage. MicroRNA (miRNA) 
can regulate gene expression; determining their impact on immune-related cell 
functions, especially CD4+ T-cells, during disease progression will advance our 
understanding of MS pathophysiology. This study aimed to compare miRNA profiles 
of CD4+ T-cells from SPMS patients to healthy controls (HC) using whole miRNA 
transcriptome next generation sequencing (NGS).  
Methods: Total RNA was extracted from CD4+ T-cells of 24 SPMS and 22 HC. 
miRNA expression patterns were analysed using Illumina-based small-RNA NGS in 
12 SPMS and 12 HC and confirmed in all samples by qPCR.   
Results: The ten most dysregulated miRNAs identified by NGS were selected for 
qPCR confirmation; five (miR-21-5p, miR-26b-5p, miR-29b-3p, miR-142-3p and miR-
155-5p) were confirmed to be down-regulated in SPMS (p<0.05). SOCS6 is targeted 
by eight of these ten miRNAs. Consistent with this, SOCS6 expression is up-
regulated in SPMS CD4+ T-cells (p<0.05). Previously, SOCS6 has been shown to act 
as a negative regulator of T-cell activation.  
Conclusions: 97% of miRNA candidates identified by NGS were down-regulated in 
SPMS. The down-regulation of miRNAs, and increased expression of SOCS6 in 
SPMS CD4+ T-cells may contribute to reduced immune system activity in 
progressive MS.  
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Introduction 
Multiple Sclerosis (MS) is an autoimmune disease characterized by multifocal 
inflammatory attacks in the central nervous system (CNS) (36). In the relapsing-
remitting (RRMS) stage of the disease, CD4+ T-cells are amongst the primary 
infiltrators moving from the periphery, through the blood-brain barrier, and into the 
CNS (18). These cells then initiate an immune response that results in localized 
demyelination and corresponding symptoms. The later stage of MS, secondary 
progressive (SPMS), is characterized by compounding neurodegeneration and 
sustained disability; however the relevance of inflammation is unclear (32). As key 
regulators of gene expression, microRNA may be affecting the immune-related 
functions of CD4+ T-cells in SPMS and may help to elucidate their actions in SPMS. 
MicroRNAs (miRNAs) are short, non-coding RNA molecules (~22bp) that regulate 
gene expression at the post-transcriptional stage by targeting the 3’ untranslated 
region of target genes. Their small size and stable structure make them ideal 
biomarkers. miRNA expression patterns in MS have been the focus of numerous 
studies in recent years, many of which have concentrated on using miRNAs as 
biomarkers for diagnosis and prognosis (182). These studies predominantly use 
easily acquired (and often highly heterogeneous) samples such as whole blood, 
peripheral blood mononuclear cells (PBMCs), serum and plasma. Numerous 
dysregulated miRNAs have been identified, however which cell types are actually 
responsible for differing miRNA profiles and the consequences of altered miRNA 
expression is not clear in many studies. Furthermore, it is likely that these 
heterogeneous samples are masking the signal of differentially expressed miRNA in 
specific cell subtypes. To overcome this, we have focused on CD4+ T-cells in this 
study. 
Next generation sequencing (NGS) allows for stringent examination of cell specific 
miRNA expression profiles as well as discovery of previously uncharacterized 
miRNAs. Here, we have used small-RNA NGS of CD4+ T-cells from SPMS patients 
and healthy controls (HC). The total coverage approach of NGS generates 
expression information on all small RNA species including all known and novel 
miRNAs, as well as other small RNA species (isomiRs, and snoRNAs); a clear 
advantage over microarray and candidate approach assays. Three previous studies 
in MS have used NGS to effectively identify miRNA expression profiles in the whole 
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blood (123, 128), serum (123) and peripheral blood mononuclear cells (PBMCs) 
(132) of RRMS patients. However, NGS techniques have not been used for specific 
cell types or in SPMS samples.  
The miRNA expression profile of CD4+ T-cells, either as instigating molecules or by-
products of erroneous molecular mechanisms, will provide insight into the function of 
these cells in SPMS. Here, we used NGS to provide a comprehensive analysis of the 
miRNA expression profiles of CD4+ T-cells from SPMS patients and healthy controls 
(HC), and confirmed these results using targeted assays. 
 
Patients and Methods 
Sample collection 
Whole blood was collected at a single study centre from an initial cohort of 12 SPMS 
patients and 12 HC, and a replication cohort of 12 SPMS and 10 HC. All patients 
were diagnosed with SPMS according to the McDonald criteria (183) and 
demonstrated EDSS progression without evidence of relapse (8).  Controls were age 
(±5 years) and gender matched (Table 2.1). The SPMS patient group was free of MS 
specific treatments for a minimum period of 6 months prior to collection. 
 
Ethics Statement 
Samples were collected at the John Hunter Hospital, and laboratory work conducted 
at the University of Newcastle. The Hunter New England Health Research Ethics 
Committee and University of Newcastle Ethics committee approved this study 
(05/04/13.09 and H-505-0607 respectively), and methods were carried out in 
accordance with institutional guidelines on human subject experiments. Written and 
informed consent was obtained from all patient and control subjects. 
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Table 2.1: Details of SPMS and healthy control individuals. 
 Next-generation 
sequencing 
Replication cohort 
SPMS HC SPMS HC 
Number 12 12 12 10 
Female 9  9  8  5  
Age in yrs  
(mean ±SD) 
60.2 ±8.3 61.3 ±9.5 61.4.0 ±6.5 60.1 ±5.9 
EDSS (mean 
±SD) 
6.9 ±0.9 NA 5.9 ±1.0 NA 
Active SPMS 3 NA 4 NA 
Disease duration 
in yrs (mean 
±SD) 
25.6 ±11.1 NA 18.3 ±6.5 NA 
Progression 
duration (mean 
±SD) 
10.8 ±8.1 NA 8.9 ±6.2 NA 
EDSS = expanded disability status scale, SD = standard deviation, NA = not applicable. 
 
Blood sample processing  
PBMCs were isolated from 45mL of heparinised whole blood by density gradient 
centrifugation on lymphoprep (Axis-Shield PoC AS, Norway). CD4+ T-cells were 
enriched from the PBMCs using EasySep magnetic negative selection according to 
manufacturer’s protocol (StemCell Technologies, Canada). The purity of the CD4+ 
selection was assessed by flow cytometry using a FITC conjugated anti-CD4 
antibody (anti-human CD4 antibody, clone OTK4, FITC, catalogue# 60016FI, 
StemCell Technologies, Canada) on a BD FACSCanto II flow cytometer, then 
analysed using FACSDiva software (BD Biosciences, USA) at the Analytical 
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Biomolecular Research Facility of the University of Newcastle. All samples met a 
minimum purity threshold of >90%.  
 
RNA isolation 
Total RNA was isolated from the CD4+ T-cells using the miRNeasy Mini kit (Qiagen, 
USA) following the manufacturer’s instructions. The quality of the RNA was assessed 
using the RNA 6000 Nano kit on a 2100 Bioanalyzer (Agilent Technologies, USA); a 
RNA integrity number (RIN) greater than 8 was deemed suitable for sequencing and 
RT-qPCR. Purity was measured on an Epoch spectrophotometer (BioTek, USA) and 
concentration was measured using the high sensitivity RNA kit on Qubit 2.0 
Fluorometer (Life Technologies, Thermo Fisher Scientific, USA).  
 
miRNA sequencing and analysis 
A cohort of 12 SPMS and 12 HC samples was run through NGS at the Diamantina 
Institute, University of Queensland, Brisbane, Australia. Samples were individually 
barcoded and then sequenced in two multiplexed pools each containing 12 samples. 
The sequencing libraries were prepared from 1μg total RNA, using the TruSeq Small 
RNA preparation kit (Illumina, USA), and sequenced using the 50bp fragment 
protocol on the HiSeq 2500 platform. The sequencing generated 4-9 million reads 
per sample, more than sufficient for expression and discovery applications. The 
sample sequencing reads were demultiplexed using the CASAVA 1.8 software 
package (Illumina, USA). The Illumina adapter sequences were trimmed from the 
fastq files using Trimmomatic (184). All reads were aligned and counted against 
miRBase 21 (104).  
 
RT-qPCR 
Mature miRNA TaqMan assays (Applied Biosystems, Thermo Fisher Scientific, USA) 
were used for reverse transcription qPCR (RT-qPCR) to determine expression of the 
ten most differentially expressed miRNAs in the initial NGS cohort as well as a 
replication cohort of 12 SPMS and 10 HC (assay IDs in miRNA numerical order: 
000397, 000399, 000407, 000408, 000409, 000413, 002223, 000464, 002623, 
  
 47 
000524). The small RNA RNU44 (ref: 001094) was used as an endogenous control. 
RNU44 has previously been demonstrated to be a stable control in CD4+ T –cells 
(125) and its stability has been shown in our 47 samples (mean ±standard deviation 
Ct value of 23.58 ±0.63). RNU44 was used for normalization using the ΔCt method. 
The relative expression (2-ΔCt) of all samples (24 SPMS and 22 HC) was calculated. 
 
Statistical analysis 
The two-sample Kolmogorov-Smirnov test (K-S test) was used to test whether 
differences in expression level was statistically significant between the case and 
control group as implemented in R. The K-S test was chosen (over the F test 
comparison of means) because of the non-normality of the expression level 
distributions among miRNAs. Our statistical significance threshold allowing for 
multiple testing correction was determined using the False Discovery Rate (FDR) 
procedure of Benjamini-Hochberg (185).  Based on the number of miRNA elements, 
this threshold was set at 1.2´10-4. We also considered a relaxed (or nominal) 
significance threshold of 0.05.  In addition to using statistical significance thresholds 
for miRNA selection we also included a count threshold of >800 to exclude miRNAs 
that were very lowly expressed and unlikely to be replicated with the less-sensitive 
RT-qPCR (see appendix 2). The K-S test was also used to determine significant 
differential miRNA and SOCS6 expression from the RT-qPCR relative expression 
data. 
 
Correlation to patient characteristics 
The Pearson correlation coefficient was calculated using RT-qPCR data for MS 
samples (n=24) and patient characteristics: EDSS, age, disease duration and 
progression duration. A correlation coefficient (r value) >±0.5 was considered strong, 
±-0.3-0.49 moderate, and <±0.29 weak. 
 
Gene target prediction 
miRSystem integrates seven different target gene prediction algorithms and contains 
experimentally validated data on miRNA:mRNA interactions (106). This integration 
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system was used to identify genes that may be targeted by more than one of our 
identified dysregulated miRNAs. 
 
Analysis of SOCS6 expression 
500ng of total RNA was reverse transcribed using high-capacity cDNA reverse 
transcription kits (Applied Biosystems, Thermo Fisher Scientific, USA) in 21 SPMS 
and 21 HC samples. qPCR was performed using an exon-spanning TaqMan probe 
for SOCS6 (ref: Hs00377781_m1). Expression of SOCS6 was determined as relative 
expression to the housekeeping genes GAPDH (ref: 4326317E) and β-actin (ref: 
4326215E) using a ViiA 7 (Applied Biosystems, Thermo Fisher Scientific, USA).  
 
Results 
We used NGS to establish miRNA expression profiles in CD4+ T-cells from a cohort 
of 12 SPMS and 12 HC samples. RT-qPCR was then employed to validate 
differences in miRNA expression in the NGS cohort as well as a second cohort of 12 
SPMS and 10 HC samples (total 24 SPMS and 22 HC).  
 
NGS 
Whilst we did not observe any statistically significant miRNAs at the FDR correct 
threshold, which probably reflects the modest sample size, we did observe 42 
miRNAs at the nominal significance threshold (97% of these were down-regulated).  
Of these 42 miRNAs, only 10 met our secondary criteria of having a read count >800: 
miR-21-5p (p=0.031), miR-23a-3p (p=0.007), miR-26b-5p (p=0.031), miR-27a-3p 
(p=0.031), miR-27b-3p (p=0.031), miR-29b-3p (p=0.007), miR-30e-5p (p=0.031), 
miR-142-3p (p=0.031), miR-155-5p (p=0.031) and miR-221-3p (p=0.031). Each of 
these miRNAs were found to be down-regulated in SPMS as summarized in Figure 
2.1, and were forwarded for replication testing in an independent cohort.  
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Figure 2.1: Tukey boxplot demonstrating the ten most significantly dysregulated 
microRNA identified using NGS. Data is presented as log10 of the read count and 
clearly exhibits the down-regulation of miRNAs in SPMS (purple) compared to HC 
(grey). Whiskers represent data within 1.5 interquartile range (IQR) of the upper and 
lower quartile. Data points outside of the 1.5 IQR are represented by black dots. * 
p<0.05, ** p<0.01. 
 
RT-qPCR  
To confirm our NGS findings, the top ten most dysregulated miRNAs were selected 
for further analysis in 24 SPMS and 22 HC samples using RT-qPCR (including the 12 
SPMS and 12 HC samples that underwent NGS analysis). Of these ten miRNAs, RT-
qPCR confirmed significant down-regulation of miR-21-5p (p=0.0048), miR-26b-5p 
(p=0.007) miR-29b-3p (p=0.00001), miR-142-3p (p=0.05) and miR-155-5p (p=0.001) 
in SPMS CD4+ T-cells (figure 2.2). These five miRNAs were confirmed in the original 
NGS cohort, the replication cohort, and the combined cohort. This provides 
statistically significant evidence of replication indicating these five miRNAs are very 
unlikely to be false positives. A trend of down-regulation of miRNA in SPMS samples 
was still observed across all ten miRNAs. 
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Figure 2.2: Tukey boxplot of top ten miRNAs expression (relative to RNU44) using 
RT-qPCR. Significant down-regulation of miR-21-5p, miR-29b-3p, miR-142-3p and 
miR-155-5p in SPMS was confirmed. Whiskers represent data within 1.5 interquartile 
range (IQR) of the upper and lower quartile. Data points outside of the 1.5 IQR are 
represented by black dots.  * p<0.05, ** p<0.01, *** p<0.001.  
 
Comparison of methods 
Concordance of differential expression can vary between quantitation methods (186). 
To determine the magnitude of fold-change in SPMS vs. HC we compared qPCR and 
NGS results and found no change in the degree of decreased expression between 
NGS and RT-qPCR methods in the miRNAs confirmed by RT-qPCR (figure 2.3).   
 
Correlation to patient characteristics 
No strong correlations between miRNA expression and patient characteristics were 
identified (table 2.2). However, moderate positive correlation between EDSS, and 
miR-21-5p, miR-26b-5p and miR-29b-3p was seen. Further positive correlation was 
also found between disease duration and miR-21-5p and miR-155-5p. All miRNAs 
demonstrated weak correlation to patient age and progression duration.  
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Figure 2.3: Comparison of miRNA fold-change between NGS and RT-qPCR. 
Magnitude of change is consistent between NGS and RT-qPCR methods. 
 
Table 2.2: Correlation coefficients calculated from RT-qPCR data against patient 
characteristics.  
 miR-21-5p miR-26b-5p miR-29b-3p miR-142-3p miR-155-5p 
EDSS 0.34 0.42 0.41 0.28 0.26 
Age (HC) 0.22 0.17 0.31 0.21 -0.08 
Age (SPMS) -0.07 -0.17 -0.17 -0.30 -0.01 
Disease duration 0.49 0.15 0.23 -0.08 0.49 
Progression 
duration 
0.12 0.12 0.11 -0.07 0.17 
Correlation of miRNA expression and age of HC has also been calculated as a reference 
point for age of patients. Moderate correlations are in bold text. 
 
Target prediction 
miRNA fold change was <2 in all miRNAs. It is therefore unlikely that any one 
particular miRNA is causing a great effect on gene expression. It is more likely to be 
a combination of multiple miRNAs targeting a few specific genes. Furthermore, as 
RT-qPCR is a less sensitive methodology than NGS, and the trend of down-
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regulation is still seen (though not significant) in the other miRNAs, all ten miRNAs 
were cross-analysed potential gene targets.  miRSystem was used to identify genes 
that have multiple target genes in common, both in the five confirmed miRNAs and all 
ten miRNAs identified by NGS.  One gene, bromodomain and WD repeat domain 
containing 1 (BRWD1), is targeted by all five confirmed miRNAs. No genes are 
targeted by all ten miRNAs however; eight genes are targeted by eight of the 
miRNAs (table 2.3).  
 
Table 2.3: Genes identified by miRSystem targeted by eight of the ten microRNAs. 
Verified targeting miRNAs are identified with a “V”. 
 miR-
21-5p 
miR-
23a-3p 
miR-
26b-
5p 
miR-
27a-
3p 
miR-
27b-3p 
miR-
29b-3p 
miR-
30e-
5p 
miR-
142-
3p 
miR-
155-
5p 
miR-
221-3p 
ACVR2B V V V V V V   V V 
ZBTB41 V V  V V V V V V  
BRWD1 V V V   V V V V V 
CAMTA1 V V  V V V V  V V 
CFL2 V V  V V V V V V  
SOCS6 V V V V V  V V V  
MIER3  V V V V V V  V V 
KLF12 V V V V V V V   V 
 
These genes are involved in transmembrane ligand binding, regulation of actin 
filaments, or are transcription factors.  However, only one gene is specifically linked 
to immune cell functioning, SOCS6 (suppressor of cytokine signalling 6). This gene 
has previously been reported to negatively regulate T-cell activation by promoting 
ubiquitin-dependent proteolysis (187) and was thus selected for further investigated. 
 
SOCS6 expression 
Gene expression analysis using RT-qPCR was conducted to determine whether 
SOCS6 is up-regulated in SPMS CD4+ T-cells in direct negative correlation to the 
miRNA expression (Figure 2.4). Both the preliminary and validation cohorts were 
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analysed and SOCS6 expression is increased in SPMS compared to HC. 
Normalisation against GAPDH and β-actin generated the same results (data for β-
actin not shown). 
 
Figure 2.4: Expression of SOCS6 relative to GAPDH. Up-regulation of SOCS6 in 
SPMS is significant though widely distributed (* p=0.042). 
 
Discussion 
This is the first study in MS to utilize NGS for miRNA expression profiling in the CD4+ 
T-cells of SPMS patients. We found 42 miRNAs that are dysregulated in the CD4+ T-
cells of SPMS patients as compared to controls; 97% of which were down-regulated. 
TaqMan assays confirmed five of these miRNAs (miR-21-5p, miR-26b-5p, miR-29b-
3p, miR-142-3p and miR-155-5p) to be down-regulated in SPMS. Each of these 
miRNAs (excluding miR-26b) has been reported on previously in MS though not 
necessarily in SPMS or CD4+ T-cells. Lindberg et al. (125) identified seven miRNAs 
dysregulated in the CD4+ T-cells from RRMS patients, but did not identify 
dysregulation in any of the five miRNA in this study.  Thus, down-regulation of these 
miRNAs may be exclusive to SPMS.  
Here, we report a decrease in miR-155-5p expression in MS; this is the first study to 
identify this. miR-155-5p has a major proinflammatory role in MS and has been 
shown to be up-regulated in a number of tissues. Studies of post-mortem brain tissue 
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find a gradient of miR-155-5p expression that peaks in active lesions (141) and 
associated neurovascular units (157), and decreases through chronic lesions and 
normal appearing white matter to a low baseline in healthy control white matter (157, 
158). This increased expression of miR-155 has been associated with suppression 
of: CD47 in active lesions that creates a permissive environment for myelin 
phagocytosis (141); focal adhesion and cell-cell complex molecules in the blood brain 
barrier, thus increasing permeability (157) and; AKR1C1 and AKR1C2, essential for 
biosynthesis of allopregnanolone (a neuroprotective steroid) (158).  
Interestingly, a study of miR-155 in the EAE mouse model found that miR-155 
expression in CD4+ T-cells increases during EAE and that miR-155-/- mice had an 
attenuation of EAE (165). Specifically, Th17 cells lacking miR-155-5p are unable to 
cause EAE (188). miR-155-5p is required for normal immune function (189) and 
together, these studies confirm the significant role that miR-155-5p over-expression 
plays in the inflammatory process of MS. In contrast, our finding of miR-155-5p 
down-regulation may be exclusive to SPMS patients and/or CD4+ T-cells, and is 
consistent with SPMS as a non-inflammatory mediated disease.   
In PBMCs, miR-155-5p is up-regulated in RRMS (152, 159). Waschbisch et al. 
compared miR-155 expression in PBMCs of 74 RRMS patients against 32 controls 
and identified at baseline up-regulation of miR-155-5p and miR-142-3p. Glatiramer 
acetate (GA) treatment resulted in normalized expression of miR-142-3p. However, in 
our study, all patients had been treatment free for >6 months prior to collection and 
thus GA cannot be attributed as the cause of miR-142-3p down-regulation in our 
patient cohort.  
A recent study on autologous haematopoietic stem cell transplant (AHSCT) also 
found co-dysregulation of miR-155-5p and miR-142-3p (124). Contrary to our results, 
Arruda et al. found these miRNAs to be up-regulated in MS patient CD4+ T-cells 
before treatment (cohort was 75% SPMS). However, we reason that there are 
differences in the immune activity of the patient cohorts. AHSCT is most effective in 
active MS disease and the European Bone Marrow Transplant Register 
recommended that only SPMS patients with some inflammatory activity and 
gadolinium-enhancing (Gd+) lesions be considered for AHSCT (190). Six of the 19 
SPMS patients enrolled in the Arruda et al. study presented with gadolinium-
enhancing lesions in the year approaching the treatment indicating inflammatory 
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activity. Further, the average disease duration in the Arruda et al. study was 8.1 
years, as opposed to 25.6 (primary cohort) or 18.6 (replication cohort) years in our 
study.  While the AHSCT study also utilized TaqMan microRNA assays, our data is 
corroborated further by NGS expression analysis, which is a more sensitive measure 
of expression changes. 
In a study of potential biomarkers in Alzheimer’s disease (AD), miR-26b-5p was 
shown to be down-regulated in the serum and CSF of AD patients when compared to 
patients with inflammatory neurological diseases (191) supporting the predominantly 
neurodegenerative pathology of SPMS. 
Previously, miR-29b-3p is reported as being up-regulated in memory CD4+ T-cells in 
all MS subtypes however, the SPMS sample group was very small (n=4) (139) 
compared to our cohort (n=24). This study also identified a feedback loop where miR-
29b-3p targets IFN-γ which induces miR-29b-3p expression (139). The noted 
reduction of IFN- γ in peripheral blood of SPMS patients compared to RRMS (192) 
may contribute to our observed reduction of miR-29b-3p in SPMS patients. 
Over-expression of miR-29b in systemic lupus erythematosus (SLE) has been linked 
to hypomethylation of DNA in CD4+ T-cells (193). While there are currently no 
studies on DNA methylation in SPMS, it would be interesting to see if the down-
regulation of miR-29b that we have identified here in CD4+ T-cells is associated with 
genome-wide hypermethylation in SPMS. 
Increased miR-21-5p promotes differentiation of Th17 cells in the EAE mouse model 
and miR-21-5p knock-out mice have a defective Th17 differentiation pathway, 
resulting in resistance to EAE (194). Fenoglio et al. found increased miR-21-5p 
expression in RRMS (active relapse phase) PMBCs compared to controls, though no 
difference in SPMS. Again, this may be contributed to the relatively small sample size 
(n=6) (129). As with our other significantly dysregulated miRNAs, miR-21-5p has a 
demonstrated mechanism of increasing T-cell activity.  
Also of interest, we previously reported miR-20a-5p down-regulation in the whole 
blood of all MS subtypes (195).  This miRNA was one of the 42 dysregulated miRNAs 
identified by NGS and is significantly down-regulated in SPMS compared to HC. 
However, it narrowly missed the 800 read cut-off for qPCR confirmation. miR-20a-5p 
is also predicted to target SOCS6. 
  
 56 
All ten miRNAs showed down-regulation in RT-qPCR, however the difference was 
statistically significant in only five. Recently, molecules responsible for microRNA 
biogenesis (Drosha, Dicer and DGCR8) were found to be over-expressed in the 
PBMCs of RRMS compared to healthy controls (114). It would be interesting to see if 
this is still the case in SPMS or if a down-regulation of the machinery may be the 
cause of the observed reduction of miRNA expression observed in this study.  
Eight of the top ten dysregulated miRNA were predicted to target SOCS6 by 
MirSystem.  Consistent with this, increased expression of SOCS6 in the SPMS 
cohort is in direct negative correlation with the miRNA expression profiles, strongly 
indicating a mRNA:miRNA relationship. To our knowledge, this is the first study to 
identify SOCS6 as a gene of interest in MS. It is a highly conserved gene with very 
low expression levels in healthy thymus and brain tissues and is down-regulated in 
gastric, colorectal and pancreatic cancers (196-199). In colorectal cancer, 
methylation changes have been ruled out as the mechanism of down-regulation 
(198), therefore this down-regulation may be due to altered miRNA expression. MiR-
424-5p is responsible for the down-regulation of SOCS6 in pancreatic cancer (199) 
however we found no differences in miR-424-5p expression between SPMS and HC 
in this study. 
The function of SOCS6 as a negative regulator of T-cell activation (187) and its 
observed over-expression in SPMS CD4+ T-cells, supports the notion of reduced 
immune activity in SPMS. Very little is known about SOCS6 and mores studies are 
required to determine if it may be a novel therapeutic target. 
This is the first study to use NGS miRNA profiling to assess miRNA expression in the 
CD4+ T-cells of SPMS patients. Future studies should focus on using the same 
technique in treatment naïve RRMS patients to determine if this is a SPMS exclusive 
trend and remove the confounding factor of treatment effects. Furthermore, miRNA 
expression profiles of other cell subtypes should be investigated, as whole blood 
analysis is likely masking significant changes in individual cell subsets. Ideally, all of 
our patients would have had inactive SPMS, however as SPMS is a difficult disease 
stage to define and collect we have included some active SPMS patients in this 
study. In this study, we chose to focus on CD4+ T-cells as they are traditionally 
thought to be the main cell infiltrates. Our previous studies also show that CD4+ T-
cells exhibit significant changes in methylation profiles in RRMS (98, 99). 
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Conclusions 
Here we have shown a general down-regulation of miRNAs in CD4+ T-cells 
compared to HC, with five miRNAs confirmed as significant in two independent 
assays. This indicates that miRNA expression may be over-normalising in SPMS 
CD4+ T-cells. SOCS6 is a predicted target of the majority of these miRNAs and, 
consistent with this, we found SOCS6 to be up-regulated in this cohort. These are 
novel findings that point towards a diminished role for CD4+ T-cells in SPMS, and 
adds further evidence of SPMS as a neurodegenerative disease stage, not an 
inflammation-driven one.  
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CHAPTER THREE – DNA methylation profile of SPMS CD4+ T-cells 
 
Methylation at the MHC locus is associated with MS progression independently  
of HLA-DRB1 
 
This chapter addresses my second research question: Are DNA methylation profiles 
of CD4+ T-cells different between in RRMS and SPMS, and are changes in 
microRNA expression caused by DNA methylation? 
 
Abstract 
Background: Multiple sclerosis (MS) is characterised by inflammatory attacks of the 
central nervous system that initially are followed by recovery.  In the secondary 
progressive stage the periods of recovery cease, leading to relentless accumulation 
of disability due to ongoing demyelination and neurodegeneration. DNA methylation 
is an epigenetic modification that is involved in gene expression.  In a previous study, 
we found that there are DNA methylation changes at HLA-DRB1 in relapsing-
remitting MS (RRMS) patients compared to controls in CD4+ but not CD8+ T-cells.  
This study aimed to confirm these findings in an MS cohort free of any treatment and 
to compare the global DNA methylation profiles of CD4+ T-cells in secondary 
progressive (SPMS) and RRMS patients.   
Methods: Total DNA was extracted from the CD4+ T-cells of 27 female RRMS and 25 
matched healthy controls and 23 female SPMS and 19 matched healthy control 
subjects. DNA was bisulfite converted and hybridised to Illumina 450K arrays. Beta 
values were analysed using a multi-CpG penalised regression approach (GLMNet) to 
identify MS-associated CpGs. 
Results: We were able to confirm our previous data that demonstrated a differentially 
methylated region at the HLA-DRB1 locus in RRMS patients. In addition, we 
identified a striking differential signal at RNF39 in RRMS patients, a gene previously 
reported to be associated with MS. Surprisingly, we found the majority of associated 
sites are unique to their respective patient subgroup, with only 16 overlapping 
differentially methylated sites in RRMS and SPMS. Also surprisingly, the majority of 
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these sites were contained within the RNF39 DMR and not the HLA-DRB1 DMR.  
Globally, we find RRMS patients to have equal hypo- and hypermethylation 
compared to healthy controls compared to a striking global hypermethylation in 
SPMS patients (75%) compared to healthy controls. 
Conclusions: Our findings provide the first global comparison of DNA methylation 
profiles in RRMS and SPMS patients. We find a substantial difference between the 
two disease subgroups in CD4+ T-cells, and larger studies are warranted to further 
understand how this contributes to MS pathophysiology. 
 
Introduction 
 MS is an autoimmune disease characterized by lymphocyte mediated inflammation 
causing demyelination and axonal degeneration.  In the RRMS phase of disease, 
lymphocytes move from the periphery into the CNS, where they initiate an immune 
response that results in demyelination and corresponding symptoms (relapse). This 
is followed by a phase of recovery and repair (remission). Approximately 60% of 
patients will progress from RRMS to SPMS (32), which is characterised by increasing 
disability (measured by EDSS) in the absence of relapses (8).  This stage is thought 
to be more neurodegenerative in nature and the role of inflammation is less clear. 
MS aetiology is assumed to be a combination of genetic predisposition and 
environmental exposures.  Despite several large genome-wide association studies 
(GWAS), there remains a large proportion of unexplained heritability in terms of MS 
risk (80, 200).  Epigenetics can influence the genome in the absence of DNA 
sequence changes.  Environmental exposures such as smoking and sunlight 
exposure have been demonstrated to modify epigenetic mechanisms, providing a 
plausible link between environmental factors and disease (49, 201).  One such 
epigenetic mechanism is DNA methylation, which is the addition of a methyl group to 
CpG dinucleotides.  We, and others, have used genome-wide DNA methylation 
technologies to assess differentially methylated regions (DMRs) of CD4+ and CD8+ 
T-cells in RRMS patients compared to healthy controls (94, 98, 99, 101).  We found a 
striking methylation signal located on chromosome 6p21 with a peak signal at HLA-
DRB1, in relapsing-remitting patients compared to healthy controls, that was only 
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present in CD4+ T-cells (98). There are no studies to date that provide a comparison 
between the methylation profiles of RRMS and SPMS patients. 
Furthermore, DNA methylation is capable of regulating other epigenetic mechanisms. 
In diseases other than MS, microRNA (miRNA) expression is affected by DNA 
methylation in miRNA promoter regions (113). Previously, we reported broad down-
regulation of miRNA in CD4+ T-cells (202) but the mechanism behind this remains 
unclear. DNA hypermethylation in promotor regions may be a contributing factor to 
this miRNA dysregulation. 
 
In this study, we performed a genome-wide DNA methylation study of CD4+ T-cells 
from RRMS, SPMS patients and healthy controls to (1) replicate our initial results in 
RRMS in a group of patients who were not on any immunomodulatory therapy, (2) 
determine if the methylation signal we found in CD4+ T-cells is unique to RRMS 
patients, or ubiquitous across all MS patients, and (3) determine if there are unique 
methylation changes specific to SPMS, and whether these may affect expression of 
miRNAs. Identification of epigenetic loci associated with the different stages of 
disease could provide potential targets for new therapies and help explain the 
transition from RRMS to SPMS. 
 
Patients and Methods 
Sample collection 
Whole blood was collected from 25 female RRMS patients and 27 age-matched 
female healthy donors, and 23 female SPMS patients and 19 age-matched female 
controls (Table 3.1).  All patients were diagnosed with MS according to the McDonald 
criteria (183).  SPMS patients were defined as those who demonstrated EDSS 
progression without evidence of relapse in the 24 months prior to collection (8).  
RRMS patients were treatment naïve (18 patients) or had not taken 
immunomodulatory or steroid treatment for a minimum of 3 months (9 patients). 
SPMS patients had not taken immunomodulatory or steroid treatment for a minimum 
of 6 months.  Healthy control samples were collected from volunteers off the Hunter 
Medical Research Institute Register. 
 
  
 62 
Table 3.1: Characteristics of patients and controls 
 RRMS HC RRMS SPMS HC SPMS 
Total 27 25 19 23 
Age in yrs (mean ±SD) 38.2 ± 11.1 38.6 ± 12.7 57.6 ± 12.1 58.4 ± 9.4 
EDSS (mean ±SD) n/a 2.1 ± 1.5 n/a 6.6 ± 1.3 
Disease duration in yrs 
(mean ±SD) 
n/a 7.6 ± 11.4 n/a 25 ± 11.0 
EDSS = Expanded Disability Status Score 
 
Ethics statement 
The Hunter New England Health Research Ethics Committee and the University of 
Newcastle Ethics committee approved this study (05/04/13.09 and H-505-0607 
respectively), and methods were carried out in accordance with institutional 
guidelines on human subject experiments. Written and informed consent was 
obtained from all patient and control subjects. 
 
Blood sample processing and DNA methylation arrays 
PBMCs were isolated from whole blood by density gradient centrifugation using 
Lymphoprep (Axis-Shield PoC AS, Norway) following standard laboratory 
procedures.  Total CD4+ T-cells were extracted from the PBMC population using 
EasySep negative magnetic separation according to the manufacturers’ instructions 
(StemCell Technologies, Canada).  After isolation, cell purity was assessed by flow 
cytometry.  Cells were stained with a FITC-conjugated CD4 antibody (60016F1 
StemCell Technologies) and collected on a BD FACSCanto II flow cytometer, then 
analysed using FACSDiva software (BD Biosciences).  All samples met the minimum 
purity cut-off of 90%. DNA was extracted with the Qiagen microDNA extraction kit 
(Qiagen, USA) and bisulfite converted using the MethylEasy Xceed kit according to 
the manufacturers’ instructions.  Converted DNA was then applied to the Illumina 
Infinium Human450K Beadchip arrays (service provided by Diamantina, 
Queensland).  
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Data analysis  
Data was analysed as previously described.  An in-house data analysis pipeline that 
used a combination of R/Bioconductor and custom scripts was designed.  Illumina 
450k raw intensity data (idat files) were parsed into the Bioconductor MINFI package 
(203).  Methylation data was background-corrected and control-normalised according 
to MINFI routines (204).  Data was cleaned by removing (failed) CpG probes for 
which the intensity of both the methylated and unmethylated probes was <1000 units 
across all samples.  A threshold of 1000 units was selected based on the profile of 
the available negative control probes.  Y chromosome probes were filtered out.  All 
probe sequences were mapped to the human genome (buildHg19) using BOWTIE 
(205) to identify potential hybridisation anomalies.  In total 33457 CpG probes were 
identified to align to the human genome multiple times and were filtered out of 
subsequent analysis. 
Measures of methylation level (β values) were produced for each probe and ranged 
from 0 [completely unmethylated] to 1 [completely methylated].  Data was corrected 
for HLA-DRB1 genotype, and as differential methylation has been seen in CD4+ T-
cells and not in CD8 or CD19 (unpublished data), it can be said that HLA is not 
influencing results. Likewise, differences in RRMS vs. SPMS are not due to HLA 
genotype as the same distribution is seen in both groups. To identify DMRs 
associated with MS subtypes in this female cohort a penalised ridge-regression 
mixed with lasso in an elastic-net framework was used as implemented via the R 
package glmnet (206). Briefly, glmnet fits a generalized linear model via penalized 
maximum likelihood. The regularization path is computed for the lasso or elastic-net 
penalty at a grid of values for the regularization parameter lambda λ. The elastic-net 
penalty is controlled by α, and bridges the gap between lasso (α=1, the default) and 
ridge α=0. The tuning parameter (α=1) controls the overall strength of the penalty. 
The ridge penalty shrinks the coefficients of correlated predictors towards each other 
while the lasso tends to pick one of them and discard the others. The elastic-net 
penalty mixes these two; if predictors are correlated in groups, an α=0 tends to select 
the groups in or out together. In our testing, cross-validation suggested that a λ of 
425 was appropriate, so this was used to fit the final model for identification of DMRs.  
In order to 'rank' the sites we defined the absolute range for each CpG site, that is 
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the absolute value of the largest observed beta minus the smallest observed beta for 
a given CpG site. 
 
Statistical analyses 
Given the relatively modest sample size, this study was underpowered to detect 
significant differentially methylated positions (DMP) at the methylome-wide level and 
thus we used a series of prioritisation steps to identify the most robust loci. 
Specifically, a DMP was defined as containing CpGs i) that yielded a p<0.05 ie. 
nominally associated with MS and ii) that yielded a ∆meth of ±10% ie. a relatively 
large differential methylation. Subsequently, a DMR was defined as a DMP iii) that 
had ≥2 adjacent CpGs within 1000 bp physical distance and iv) whereby adjacent 
CpGs yielded a ∆meth in the same direction ie. all 3 CpGs in the DMR were 
consistently hypo- or hyper- methylated. 
 
Results 
We recruited 25 RRMS patients and 27 age-matched healthy donors, and 23 female 
SPMS patients and 19 age-matched female controls. Clinical characteristics are 
shown in Table 3.1.  
 
Methylation profiles in RRMS  
The methylation profiles of RRMS patient CD4+ T-cells were analysed using Illumina 
Infinium Human450K Beadchip arrays, and compared against controls. CD4+ T-cells 
from RRMS patients have 275 significantly deregulated CpGs across 153 genes and 
80 locations with no gene association compared to age-matched controls. Of the 275 
CpGs, 49% (n=134) were hypermethylated and 51% (n=141) were hypomethylated 
(Figure 3.1). Table 3.2 shows the top 10% (27 total) of CpGs which are differentially 
methylated, (for full list see Appendix 3, table A3.1).   Within the 275 sites, 14% are 
located within the MHC region.  Nine of these CpG sites that were identified in our 
previous work and five of these are located in the HLA-DRB1 gene (98). The percent 
change at the HLA-DRB1 locations is slightly lower for each CpG site in this study 
than our previous study; however, they all are dysregulated in the same direction 
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(primary hypomethylation).  In addition to the previously identified sites, we also 
identified 3 new CpGs within the HLA-DRB1 cluster. All except one are located within 
the same 400bp region. We also observed hypermethylated regions at HLA-DRB5 
and HLA-DQB1 that were identified in our previous study (table A3.1) (98).  At the 
HLA-DRB5 region we identified one previously identified probe plus an additional 2 
sites. We did not see any change in methylation at the CpG sites in HLA-DRB6 
previously identified, but did find two new hypermethylated sites (Table 3.2 and Table 
A3.1).  
In addition to the cluster of HLA associated CpGs, there was another cluster within 
the MHC locus at RNF39 (Ring Finger Protein 39). We observed 11 hypermethylated 
CpGs in the top-ranked differentially methylated probes, which map to RNF39 and 
are tightly clustered within a 312bp region. This region spans the boundary between 
intron 3 and exon 4, and spreads into exon 4.  Also within the MHC region, there is a 
smaller cluster of 3 CpGs within a 45bp span at the transcription start site (TSS) of 
HCG4P6 (table A3.2). 
To identify additional regions of potential interest that were not within the MHC locus, 
we considered DMRs as regions where genes had 2 or more differentially methylated 
CpG sites that were less than 500bp apart. Using this criterion, we identified 3 
additional DMRs (table A3.3).  C21orf56 has 4 hypomethylated CpG sites within 
153bp, ERICH1 has 4 CpGs in a 122bp region, and PM20D1 has 6 CpGs in 163bp 
(table A3.3).  One of the probes within C21orf56 was identified in our previous cohort; 
however, the other two DMRs are unique to this study. 
None of the other major MS genes outside the HLA identified in the GWAS by the 
IMSGC (80) (i.e. CD58, THADA, EOMES, MLANA, IL2RA, STAT3) revealed any 
significantly CpG site changes as judged by the assay used for this study. 
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Figure 3.1: A genome-wide differential methylation plot of RRMS CD4+ T-cells. Data 
points outside the circle (red) represent increased methylation in RRMS patients 
compared to healthy controls (i.e. Δmeth), whereas Data points inside the circle (blue) 
represent decreased methylation in the RRMS group. 
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Table 3.2: Top 10% of differentially methylated CpGs in RRMS patient CD4+ T-cells. 
Probe ID Chr Position Gene Median  
(case) 
Median  
(control) 
Δmeth Adj p  
value 
p FDR Feature 
cg23403836 7 1616229 KIAA1908 0.750865 0.435553 0.315312 1.60E-05 0.00284 Body 
cg20536971 13 100989375 PCCA 0.639244 0.345777 0.293467 0.00178 0.01576 Body 
cg22071943 5 1225434 SLC6A18 0.368136 0.643653 -0.27552 0.002769 0.01755 TSS200 
cg15602423 6 32552095 HLA-DRB1 0.387082 0.658822 -0.27174 0.00434 0.01844 Body 
cg03398919 2 173118470 
 
0.474625 0.73943 -0.26481 0.004671 0.01844 
 cg07844442 10 129144269 DOCK1 0.465688 0.728887 -0.2632 0.013719 0.02760 Body 
cg08822897 11 64258103 
 
0.284157 0.533063 -0.24891 0.000367 0.01349 
 cg20374173 10 14227415 FRMD4A 0.339618 0.587672 -0.24805 0.001926 0.01576 Body 
cg08912652 11 130779479 SNX19 0.851534 0.6036 0.247934 0.003191 0.01755 Body 
cg10415021 11 110890228 
 
0.486528 0.731505 -0.24498 0.00319 0.01755 
 
cg05248234 17 79495519 FSCN2 0.261872 0.492531 -0.23066 0.015893 0.02909 
1stExon; 
5'UTR 
cg16706502 14 31927974 C14orf126 0.597671 0.367749 0.229923 0.008531 0.02385 TSS1500 
cg22802014 1 31732891 SNRNP40 0.675691 0.902554 -0.22686 0.000434 0.01349 3'UTR 
cg19774683 6 32522400 HLA-DRB6 0.576704 0.355419 0.221285 0.039277 0.04526 Body 
cg06052372 16 83967808 
 
0.550688 0.766873 -0.21619 0.012049 0.02733 
 cg16999994 11 1001560 AP2A2 0.453497 0.238958 0.214539 0.015443 0.02909 Body 
cg13232075 1 204556835 
 
0.42867 0.215897 0.212773 0.016589 0.02925 
 cg08136432 16 88902276 GALNS 0.645258 0.857102 -0.21184 0.015855 0.02909 Body 
cg03706056 21 37437565 SETD4 0.531861 0.32023 0.211631 0.014348 0.02808 TSS1500 
cg07909498 4 79627477 
 
0.486084 0.280086 0.205998 0.001949 0.01576 
 cg13423887 6 32632694 HLA-DQB1 0.294241 0.49987 -0.20563 0.004161 0.01844 Body 
cg01341801 6 32489203 HLA-DRB5 0.454757 0.249419 0.205338 0.040802 0.04535 Body 
cg14645244 6 32552205 HLA-DRB1 0.317864 0.521037 -0.20317 0.017405 0.02991 Body 
cg23128510 2 175922785 
 
0.860042 0.657146 0.202896 0.001749 0.01576 
 cg02100397 19 646890 
 
0.446869 0.648013 -0.20114 0.009409 0.02385 
 cg05875700 8 638208 ERICH1 0.120484 0.319176 -0.19869 0.004548 0.01844 Body 
cg18662228 2 236867804 AGAP1 0.422887 0.621416 -0.19853 0.035895 0.04330 Body 
Bold font indicates common probes between this study and our previous work (98). 
 
Methylation profiles in SPMS patients 
The methylation profiles of SPMS patient CD4+ T-cells were analysed using Illumina 
Infinium Human450K Beadchip arrays, and compared against controls. CD4+ T-cells 
from SPMS patients had 243 significantly deregulated CpGs spanning 145 genes, 
and 77 probes that map to locations without gene association (Figure 3.2). Of the 
243 CpGs, 75% (183) were hypermethylated and 25% (60) were hypomethylated.  
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Table 3.3 shows the top 10% of differentially methylation sites, the full list of 
differentially methylated sites that met a significance threshold of p<0.05 is shown in 
Appendix 3, table A3.4.  Surprisingly, none of the HLA regions identified in RRMS 
patients were also identified in SPMS patients. However, there were 2 single CpG 
sites within the top ranked probes that map to HLA genes – a unique site at HLA-
DRB1 (cg15820961), and one at HLA-DQA1 (cg24969496). There were no probes 
located within any of the non-MHC variants identified in the GWAS studies by the 
IMSGC (80). 
When filtered for DMRs that contained at least 2 probes within 500bp of each other, 
there were 7 DMRs (Table A3.5). Intriguingly, the largest DMR maps to the MHC 
locus at RNF39. At RNF39 in SPMS patients, we find 8 CpGs within a 72bp span, 7 
of which are shared sites between SPMS and RRMS patients.  However, all of these 
sites are hypomethylated, as opposed to the hypermethylation seen in the RRMS 
cohort.  We also find a smaller DMR at the transcriptional start site of DUSP22 that 
contains 3 probes within a 420bp region.  There are 5 additional small DMRs outside 
the MHC locus at POU6F2, PARD6G, SLC17A9 and APOL2. Similar to RRMS 
patients, none of the other major MS genes outside the MHC identified in the GWAS 
by the IMSGC (80) revealed any significantly CpG site changes as judged by the 
assay used for this study. 
As DNA methylation can affect the expression of miRNAs, as well as mRNAs, 
differentially methylated CpGs were cross-examined for their potential effect on 
miRNA TSS. Using miRStart (207), a database of miRNA transcriptional start sites, 
the location of differentially methylated CpGs in SPMS CD4+ T-cells (tables 3.2 and 
A3.4) were cross compared with known miRNA TSS. There was no overlap in 
genomic location of CpGs identified in table 3.3 and miRNA TSS. 
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Figure 3.2: A genome-wide differential methylation plot of SPMS CD4+ T-cells. Data 
points outside the circle (red) represent increased methylation in SPMS patients 
compared to healthy controls (i.e. Δmeth), whereas data points inside the circle (blue) 
represent decreased methylation in the RRMS group. 
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Table 3.3: Top 10% of differentially methylated CpGs in SPMS patient CD4+ T-cells. 
Probe ID Chr Position Gene 
Median 
(case) 
Median 
(control
) Δmeth 
Adj P 
value P FDR Feature 
cg17666981 6 28878192 TRIM27 0.91827 0.80185 0.116422 0.00013 0.01258 Body 
cg04913265 11 133939627 JAM3 0.64597 0.51509 0.130878 0.00015 0.01258 Body 
cg21901928 7 55139847 EGFR 0.80165 0.66480 0.136848 0.00016 0.01258 Body 
cg04579183 15 88119834 
NCRNA0
0052 0.81117 0.46961 0.341567 0.00020 0.01258 TSS1500 
cg11553311 5 66541588 
 
0.55113 0.38735 0.163781 0.00041 0.01579 
 cg06182923 1 33985406 CSMD2 0.72875 0.61344 0.115305 0.00051 0.01579 Body 
cg16706502 14 31927974 
C14orf12
6 0.48565 0.10314 0.382514 0.00063 0.01579 TSS1500 
cg04750100 2 136595281 LCT 0.34751 0.44905 -0.10153 0.00066 0.01579 TSS1500 
cg10543947 22 36635882 APOL2 0.07416 0.20949 -0.13532 0.00068 0.01579 
TSS200; 
1stExon; 
5'UTR 
cg16121206 22 36636055 APOL2 0.39490 0.51881 -0.12399 0.00074 0.01579 
TSS200; 
TSS1500 
cg20802616 1 211590292 C1orf97 0.53618 0.42629 0.10989 0.00081 0.01579 Body 
cg05792312 11 61781116 
 
0.62427 0.30122 0.323044 0.00082 0.01579 
 cg14170201 7 155191709 
 
0.89102 0.65896 0.23206 0.00084 0.01579 
 cg07733481 3 122694286 SEMA5B 0.09248 0.20363 -0.11114 0.00091 0.01579 5'UTR 
cg25377865 4 72669944 
 
0.74934 0.64726 0.102076 0.00107 0.01711 
 cg24867279 6 28853021 
 
0.55999 0.44089 0.119097 0.00119 0.01711 
 cg23596425 2 1494263 TPO 0.84194 0.71555 0.126387 0.00123 0.01711 Body 
cg24305906 2 241352106 
 
0.85492 0.71616 0.138752 0.00126 0.01711 
 cg08610773 2 184896169 
 
0.88075 0.77837 0.102381 0.00149 0.01818 
 cg04245305 3 195940754 
 
0.95732 0.7168 0.240529 0.00161 0.01818 
 cg01406776 4 8386748 ACOX3 0.86822 0.65601 0.212212 0.00163 0.01818 Body 
cg09756125 7 158250978 PTPRN2 0.51451 0.74159 -0.22708 0.00171 0.01818 Body 
cg07093060 3 174092757 
 
0.47112 0.68013 -0.20901 0.00172 0.01818 
  
Comparison between MS subtypes 
To determine which CpGs sites were common to MS patients versus those which are 
unique to each of the MS subtypes, we did a pairwise comparison of the full list of 
deregulated probes (275 RRMS and 243 SPMS CpG probes).  Surprisingly, there are 
only 16 probes that are shared between the two patient subgroups, only 4 of which 
show change in the same direction (Table A3.4). Interestingly, 7 of these are the 
RNF39 CpG sites; however, they are dysregulated in opposite directions.   
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Discussion 
Our study is the first to compare the genome-wide methylation levels in CD4+ T-cells 
of RRMS and SPMS patients.  Our most striking result is the lack of shared CpGs 
between RRMS and SPMS patients.  When comparing the two patient subgroups, 
we found RRMS patients show equal hypo- and hyper methylation (51% and 49% 
respectively) compared to a tendency towards hypermethylation (75%) in SPMS 
patients.  This translated to only 16 overlapping CpGs between RRMS and SPMS 
patients, suggesting that RRMS and SPMS patients have unique CD4+ T-cell 
methylation profiles.  Surprisingly, although we confirmed 5 of the CpGs in HLA-
DRB1, from our previous study (98) in RRMS patients, we saw only one CpG at this 
site in SPMS patients. This was not one of the sites identified in either of our studies.  
In addition, we have identified a new DMR in the MS associated gene, RNF39 in both 
RRMS and SPMS patients.  Interestingly, while this DMR is hypermethylated in 
RRMS patients, it is hypomethylated in SPMS patients.  Taken together, our data 
suggest that DNA methylation is dynamic and may change with disease course. 
One consideration for the lack of shared CpGs between RRMS and SPMS could be 
confounding effects due to treatment over time. The effects of immunomodulatory 
therapy on methylation in MS patients is unknown, although there is some evidence 
that immunomodulatory therapy used for other diseases, such as multiple myeloma, 
can alter the expression of DNA methyltransferases (208). Given that the majority of 
SPMS patients would have been given treatment at some stage during their disease, 
it is possible this could cause lasting methylation changes.  Future studies would 
benefit from following patients longitudinally during various treatments to determine 
the effect over time on epigenetic profiles.  DNA methylation changes with 
chronological age (91) although we find it unlikely that this is a confounding factor in 
our results as each cohort was compared to a separate age- and gender-matched 
cohort to correct for effects of aging. It is therefore possible that hypermethylation is a 
hallmark of disease progression; however, larger scales studies will be required to 
confirm this. At present, the underlying cause of this hypermethylation in SPMS is 
unknown. In CD4+ T-cells of systemic lupus erythematosus (SLE) patients, the up-
regulation of miR-29b results in under-expression of its target genes (DNMT3a and 
DNMT3b), causing global hypomethylation in these cells (193). As miR-29b was one 
of our previously reported down-regulated miRNAs in SPMS CD4+ T-cells (202), it 
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will be worth analysing expression of these DNA methyltransferase genes to 
determine if the hypermethylation observed here is a consequence of miRNA 
expression changes. There were no differentially methylated CpGs in miRNA 
promoters, indicating that DNA methylation does not affect miRNA expression in 
CD4+ T-cells; further analysis will indicate whether miRNA expression instead affects 
DNA methylation.  
In our previous study, we found a tight cluster of 8 hypomethylated CpGs in HLA-
DRB1 (98).  In the current study, we were able to confirm 5 of these CpG sites, plus 
an additional 3 CpG sites clustered within the same 358bp region.  These sites were 
only present in RRMS, although a single site in a distant region of HLA-DRB1 was 
identified in SPMS patients.  Although there is a lower effect size in the new study, 
the dysregulation is occurring in the same direction (primarily hypomethylation). This 
is a region heavily populated by SNPs, though the absence of this signal in the 
SPMS cohort provides support for its independence from the HLA-DRB1*1501 
genotype. The frequency of the HLA-DRB1*1501 allele does not change between the 
RRMS and SPMS cohorts (data not shown), but the methylation signal at this 
location does. Additionally, we assessed the global methylation levels in CD8+ T-
cells, in the cohort from the Graves et al. (9) study and found no change in HLA-
DRB1 methylation signal in this cell type. This is further support for the SNP-
independent nature of this signal. 
This is the first evidence of differential methylation in RNF39 being associated with 
MS, and the hypermethylation of this locus in early stage of disease may represent a 
major effect epigenetics locus for MS.  However, its use as a biomarker would be 
impractical due to the time-consuming nature of analysing a single DMR in an 
isolated cell subtype. The biological relevance of this locus can only be speculated at 
this point; however, it resides within the gene body and spans an intron/exon 
boundary so it is plausible that hypermethylation is involved in aberrant expression of 
alternately spliced transcripts or a regulatory element for nearby genes. Interestingly, 
one of the sites identified in the RRMS cohort (cg10568066) was also identified in a 
recent study which investigated the role methylation of CpG sites and ageing (209).  
RNF39 is a poorly characterized gene. In rats, RNF39 encodes a protein that plays a 
role in the early phase of synaptic plasticity (210). In humans, SNP rs9393989 has 
been previously associated with MS (211).  However, this SNP is located greater than 
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30kb upstream of the DMR in intron 3 so it is unlikely that it is contributing to the 
differential methylation signal.   
RNF39 is also associated with other autoimmune conditions, such as Bechet’s 
disease, a chronic relapsing inflammatory disease (212). This study found a SNP 
near RNF39 associated with the disease, although the functional consequences of 
this are not yet unknown.  In addition, hypermethylation of 11 CpGs sites within 
RNF39 was seen in the naïve CD4+ T-cells of patients with SLE who had a history of 
discoid rash (213). Interestingly, 8 of these sites are the same sites we have 
identified in this study (cg10568066, cg12633154, cg13401893, cg10930308, 
cg03343571, cg13185413, cg09279736, cg00947782) and have similar ΔMETH values 
to our RRMS cohort (meanRRMS = 0.13; meanSLE = 0.16) (213). Future studies on 
RNF39 in MS should investigate differential gene expression within MS disease 
stages and then potentially explore the function of this gene within MS 
pathophysiology. 
It is also interesting to note that although there is an overrepresentation of probes 
located within the MHC region in the top ranked probes in RRMS patients, this is not 
the case in SPMS patients. This may be reflective of the diminishing role of systemic 
inflammation in the progressive stages of disease (32). The largest DMR found in 
SPMS patients is also RNF39, but in SPMS patients this locus is hypomethylated 
rather than hypermethylated.  
This is the first study to compare genome-wide differences in the methylation profiles 
of CD4+ T-cells of RRMS and SPMS patients. Our findings confirm our previous 
results at the MS risk locus HLA-DRB1 but suggest that changes in methylation at 
this locus are specific to the early stages of disease. We also demonstrated 
dysregulation of methylation in a new MHC locus, RNF39. In RRMS patients we find 
this to be hypermethylated, but hypomethylated in SPMS patients. Taken together 
our results underline the fact that methylation is a dynamic process and highlight the 
importance of the MHC locus in MS.  
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CHAPTER FOUR – microRNA biogenesis, miR-29b, and DNA 
methylation 
 
Interplay of microRNA biogenesis, miR-29b and DNA methylation in MS CD4+ T-cells 
 
This chapter addresses my third and fourth research questions – Are microRNA 
biogenesis molecules differentially expressed in SPMS CD4+ T-cells, and does this 
have an effect on microRNA expression? And, is DNA methylation affected by 
changes in microRNA expression, specifically miRNA-29b?  
 
Abstract 
Background: The production of microRNAs (miRNA) involves processing by a 
number of molecules including the RNase III enzymes, Drosha and Dicer, plus 
Drosha’s regulatory subunit, DGCR8. In secondary progressive multiple sclerosis 
(SPMS), miRNAs are broadly down-regulated in CD4+ T-cells. This study aims to 
determine whether changes in expression of miRNA biogenesis molecules could be 
contributing to the wide scale down-regulation of miRNAs in SPMS, whether this is 
the same in relapsing-remitting MS (RRMS), and if this may result in DNA 
hypermethylation by miRNA-mediated differential expression of DNA 
methyltransferases. 
Methods: Total RNA was extracted from 22 RRMS and 21 SPMS patients and 22 and 
21 healthy controls (HC) age and gender-matched to the RRMS and SPMS cohorts 
respectively. RT-qPCR was used to measure expression of DROSHA, DGCR8, 
DICER and Drosha’s transcription factor, C-MYC. 
Results: DROSHA and DGCR8 were down-regulated in both RRMS and SPMS 
CD4+ T-cells. Down-regulation was greater in the SPMS cohort. There were no 
changes in expression of DICER or C-MYC.  
Conclusions: The change in expression of miRNA biogenesis molecules correlates 
with the broad down-regulation of miRNAs in SPMS CD4+ T-cells including miR-29b. 
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This may facilitate increased expression of DNMT3b, resulting in previously reported 
hypermethylation in these cells. The impact in RRMS remains unclear. 
 
Introduction 
Multiple Sclerosis (MS) is a neuroinflammatory disease of the central nervous system 
(CNS) characterized by lymphocyte-mediated attack causing demyelination and 
axonal degeneration.  The underlying cause of MS remains unclear, but risk of 
developing MS is influenced by a combination of genetic and environmental factors.  
Epigenetic mechanisms can impact gene expression without changes to the DNA 
sequences. Importantly, these differences can be modified by environmental factors.  
Epigenetics is emerging as an important concept in MS susceptibility and disease 
progression.   
One epigenetic mechanism of regulation is microRNA (miRNA) mediated 
transcriptional silencing. miRNA are small non-coding RNAs that regulate gene 
expression by binding to the 3’untranslated region of mRNAs. Canonically (Figure 
1.3), their production pathway commences in the cell nucleus, where miRNA genes 
are transcribed by RNA polymerase II, producing a primary miRNA (pri-miRNA) 
structure (107). The pri-miRNA is cleaved by Drosha, bound by its regulatory subunit 
DGCR8 (DiGeorge critical region 8), to stem-loop structure (pre-miRNA), 
approximately 60-70nt long (214). A 2nt overhang is produced by Drosha’s RNase III 
activity and marks the pre-miRNA for export to the cytoplasm performed by Exportin 
5 associated with Ran cofactor coupled to GTP. Once in the cytoplasm, Exportin 5 
releases the pre-miRNA when GTP is replaced by GDP. Dicer (another RNase) then 
cleaves the pre-miRNA to produce a miRNA duplex approximately 22nt (108). The 
duplex then associates with Argonaute (Ago) proteins where it is unwound; one strain 
is retained as the mature miRNA and forms an RNA-induced silencing complex 
(RISC) and is then capable of mRNA regulation. 
miRNA expression patterns in MS have been the focus of numerous studies in recent 
years (182) but few studies have focused on the molecules responsible for miRNA 
biogenesis: Drosha, DGCR8, and Dicer. Last year, Jafari et al. (114) found that these 
three molecules were up-regulated in RRMS patients’ peripheral blood mononuclear 
cells compared to healthy controls. Furthermore, levels of DICER inversely correlate 
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with disability (expanded disability status scale, EDSS), and expression increases 
with treatment with interferon β, demonstrating a positive effect (lower EDSS) from 
treatment (115). 
Previously, we have shown that 97% of dysregulated miRNA in SPMS CD4+ T-cells 
are down-regulated (202). In that study, miR-29b was significantly down-regulated in 
the SPMS samples. This miRNA targets the mRNAs of DNA methyltransferases; 
DNMT3a and DNMT3b directly, and DNMT1 via SP1 (215-217). DNA 
methyltransferases catalyse the addition of a methylation group to CpG 
dinucleotides. We, and others, have previously assessed the DNA methylation levels 
in CD4+ and CD8+ T-cells and CD19+ B-cells in relapsing-remitting MS patients 
(RRMS) and found the most significant changes in the methylation profiles of CD4+ 
T-cells (94, 98, 99, 101) (Graves et al, unpublished).  In a follow-up study, we 
compared methylation in the CD4+ T-cells of RRMS and SPMS patients and found 
distinct differences between the two disease stages (Chapter Three).  Most notably, 
we notice slight overall hypomethylation in RRMS patients (51%) but overall 
hypermethylation in SPMS patients (75%). 
This study aims to determine whether down-regulation of miRNA biogenesis 
molecules in CD4+ T-cells is the underlying cause of miRNA down-regulation in 
SPMS, and compare this to RRMS. We also sought to determine if levels of DNA 
methyltransferase enzymes correlated with miRNA-29b levels, and if this may be the 
underlying cause of hypermethylation observed in Chapter Three.  
Dysregulation of miRNA levels plays a key role in disease by causing altered cell 
growth and activity, apoptosis and irregular tissue differentiation (detailed review 
(218)). In MS, it is not clear whether miRNA dysregulation contributes to disease 
onset/progression or if it is a reflection of the affected cell’s response to disease; it is 
likely both. Identifying the underlying cause of miRNA dysregulation will further our 
understanding of MS. 
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Patients and methods 
Sample collection 
Whole blood was collected at the John Hunter Hospital from 22 RRMS and 21 SPMS 
female patients, plus 22 healthy controls (HC) age and gender-matched to the RRMS 
cohort, and 21 HC matched to the SPMS cohort (Table 4.1). All patients were 
diagnosed with MS according to the McDonald criteria (183), and SPMS when they 
had demonstrated EDSS progression without evidence of relapse. The RRMS cohort 
was treatment naïve and the SPMS cohort was free of MS specific treatments for a 
minimum period of 6 months prior to collection. We also sought to determine if levels 
of DNA methyltransferase enzymes correlated with miRNA-29b levels. 
 
Table 4.1: Details of RRMS and SPMS patients and their matched healthy control 
cohorts. 
 RRMS HC (RRMS 
matched) 
SPMS HC (SPMS 
matched 
Number 22 22 21 21 
Age in yrs (mean ±SD) 38.8 ±10.7 38.2 ±10.5 59.6 ±10.6 58.8 ±10.1 
EDSS (mean ±SD) 2.4 ±1.4 NA 6.8 ±1.0 NA 
Disease duration in yrs (mean 
±SD) 
5.2 ±6.1 NA 27.8 ±14.7 NA 
Progression duration  
(mean ±SD) 
NA NA 9.4 ±4.6 NA 
EDSS = expanded disability status scale, SD = standard deviation, NA = not 
applicable. 
 
Ethics statement 
The Hunter New England Health Research Ethics Committee, University of 
Newcastle Ethics committee and Bond University Human Research Ethics 
Committee approved this study (05/04/13.09, H-505-0607 and RO1382 respectively), 
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and methods were carried out in accordance with institutional guidelines on human 
subject experiments. Written and informed consent was obtained from all patient and 
control subjects. 
 
Blood sample processing  
PBMCs were isolated from 45mL of heparinised whole blood by density gradient 
centrifugation on lymphoprep (Axis-Shield PoC AS, Norway). CD4+ T-cells were 
enriched from the PBMCs using EasySep magnetic negative selection according to 
manufacturer’s protocol (StemCell Technologies, Canada). The purity of the CD4+ 
selection was assessed by flow cytometry using a FITC conjugated anti-CD4 
antibody (anti-human CD4 antibody, clone OTK4, FITC, catalogue# 60016FI, 
StemCell Technologies, Canada) on a BD FACSCanto II flow cytometer, then 
analysed using FACSDiva software (BD Biosciences, USA) at the Analytical 
Biomolecular Research Facility of the University of Newcastle. All samples met a 
minimum purity threshold of >90%.  
 
RNA isolation 
Total RNA was isolated from the CD4+ T-cells using the miRNeasy Mini kit (Qiagen, 
USA) following the manufacturer’s instructions. The quality of the RNA was assessed 
using the RNA 6000 Nano kit on a 2100 Bioanalyzer (Agilent Technologies, USA); all 
samples had a minimum RNA integrity number (RIN) greater than 8. Purity was 
measured on an Epoch spectrophotometer (BioTek, USA) and concentration was 
measured using the high sensitivity RNA kit on Qubit 2.0 Fluorometer (Life 
Technologies, Thermo Fisher Scientific, USA).  
 
RT-qPCR 
500ng of total RNA was reverse transcribed using high-capacity cDNA reverse 
transcription kits (Applied Biosystems, Thermo Fisher Scientific, USA). Initially qPCR 
was performed using previously published primer sets (114) (Table 4.2) and SYBR 
green (KAPA SYBR FAST qPCR kit, KAPA Biosystems, USA). However, the DGCR8 
primer set produced more than one product therefore an exon-spanning TaqMan 
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probe (ref: Hs00256062) was used intead. Exon-spanning TaqMan probes for C-
MYC (ref: Hs00153408) DNMT1 (ref: Hs0094875), DNMT3a (ref: Hs01027166), 
DNMT3b (ref: Hs00171876) and SP1 (ref: Hs00916521) were also used. Expression 
of these genes was determined relative to the housekeeping genes GAPDH (ref: 
4326317E) and β-actin (ref: 4326215E) using a ViiA 7 Real-Time PCR system 
(Applied Biosystems, Thermo Fisher Scientific, USA).  
 
miR-29b RT-qPCR 
10ng total RNA was reverse transcribed using the TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems, Thermo Fisher Scientific, USA). A mature 
miRNA TaqMan assay (Applied Biosystems, Thermo Fisher Scientific, USA) was 
used to determine expression of miR-29b (assay ID: 000413) with RNU44 (ref: 
001094) as an endogenous control.  
 
Table 4.2: Primers used by Jafari et al. (2015) for qPCR. The DROSHA and DICER 
primers were used in this study; DGCR8 was excluded as it had multiple products. 
Target Sequence Amplicon size (bp) 
DROSHA F 5’-CATGTCACAGAATGTCGTTCCA-3’ 115 
DROSHA R 5’-GGGTGAAGCAGCCTCAGATTT-3’ 115 
DICER F 5’-
TTAACCTTTTGGTGTTTGATGAGTGT-3’ 
94 
DICER R 5’-GGACATGATGGACAATTTTCACA-3’ 94 
DGCR8 F 5’-GCAAGATGCACCCACAAAGA-3’ 93 
DGCR8 R 5’-TTGAGGACACGCTGCATGTAC-3’ 93 
bp = base pairs, F = forward primer, R = reverse primer. 
 
Statistical analysis 
The two-sample Kolmogorov-Smirnov test (K-S test) was used to test whether 
differences in relative expression was statistically significant between the RRMS and 
SPMS groups and the respective control groups. 
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Results 
miRNA biogenesis machinery 
We recruited 22 RRMS patients and 22 age matched controls and 21 SPMS patients 
and 21 age matched controls. Due to the substantial age difference between the two 
patient groups (see table 4.1), we assessed each patient subgroup to a separate 
control cohort to control for age effects. To determine if down-regulation of miRNA 
biogenesis machinery could be the cause of overall down regulation of miRNA in MS 
patients seen in our previous study (202) we measured the levels of the miRNA 
processing machinery (DROSHA, DGCR8 and DICER).  We initially performed RT-
qPCR using previously published primers from Jafari et al 2015 and found that 
DROSHA was significantly down-regulated in RRMS and SPMS (figure 1 A-B) 
compared to HC (pRRMS=0.010 and pSPMS=0.018). There was no significant change in 
expression of either or DGCR8 or DICER in either patient group (Dicer: pRRMS=0.53; 
pSPMS=0.20) (data not shown and figure 4.1). However, upon assessment of the PCR 
products, we found that the primers designed for DGCR8 amplification resulted in 
two products 200 bp apart (data not shown).  To determine if this was confounding 
the results, we used Taqman probes which span exon boundaries to DGCR8.  Using 
this new primer/probe set, we found DGCR8 to be significantly down-regulated in 
both patient groups (pRRMS=0.028; pSPMS=0.028) (figure 4.1 E-F).  
 
miRNA-29b 
We have previously reported down-regulation of miR-29b in SPMS CD4+ T-cells 
(202). To confirm these results in this cohort, we used RT-qPCR to assess changes 
in miR-29b (Figure 4.2).  We find in this cohort that miR-29b is significantly 
downregulated in SPMS patients compared to controls (p=0.034), however, we do 
not observe any change in miR-29b expression in RRMS compared to controls 
(p=0.85).  
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Figure 4.1: Tukey boxplots of expression relative to GAPDH of DROSHA, DGCR8, 
and DICER in HC (blue) compared to RRMS (pink) (A,C,E), and HC (green) 
compared to SPMS (grey) (B,D,F). Whiskers represent data within 1.5 interquartile 
range (IQR) of the upper and lower quartile. Data points outside of the 1.5 IQR are 
represented by black dots.  ** p<0.01. 
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Figure 4.2: Tukey boxplot of miR-29b-3p expression relative to RNU44 in (A) HC 
(blue) and RRMS (pink), and (B) HC (green) and SPMS (grey).  Whiskers represent 
data within 1.5 IQR of the upper and lower quartile. Data points outside of the 1.5 
IQR are represented by black dots.  *p<0.05. 
 
DNA methyltransferase enzymes 
miR-29b has been shown to directly target DNMT3a and DNMT3b and indirectly 
target DNMT1 in acute myeloid leukaemia and lung cancer (215, 216).  The aberrant 
expression of miR-29b in these two cancers resulted in global changes in DNA 
methylation. To assess whether miR-29b could be responsible for the 75% 
hypomethylation we have previously seen in SPMS patients, but not RRMS, we 
investigated the relative expression levels of the three DNA methyltransferases 
DNMT1, DNMT3a and DNMT3b. 
As shown in Figure 4.3, DNMT1 is downregulated in RRMS patients compared to HC 
(p=0.028), but there is no change in SPMS patients (p=0.18). Previously published 
data demonstrated that DNMT1 is targeted indirectly by miR-29b through the 
transcription factor SP1 (216). Therefore, we investigated the levels of SP1 in both 
RRMS and SPMS patients. Consistent with the downregulation of DNMT1 in RRMS 
patients, we find SP1 to be significantly downregulated in RRMS patients compared 
to healthy controls (p=0.028).  Interestingly, we also find significant downregulation of 
SP1 in SPMS patients compared to healthy controls. 
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Figure 4.3: Tukey boxplot of expression relative to GAPDH of DNMT1 in (A) HC 
(blue) and RRMS (pink), and (B) HC (green) and SPMS (grey); and SP1 (C) HC 
(blue) and RRMS (pink), and (D) HC (green) and SPMS (grey). Whiskers represent 
data within 1.5 IQR of the upper and lower quartile. Data points outside of the 1.5 
IQR are represented by black dots.  *p<0.05, **p<0.01. 
 
To investigate the expression of DNMT3a and DNMT3b (figure 4.4), we used RT-
qPCR to assess levels of these transcripts. We find no change in DNMT3a in SPMS 
compared to their respective control groups (p=0.86) but a slight downregulation of 
DNMT3a in RRMS (p=0.03).  There was no change in relative expression of 
DNMT3b in RRMS patients (p=0.79) but a significant upregulation of DNMT3b in 
SPMS patients (p=0.0024). 
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Figure 4.4: Tukey boxplot of DNMT3a expression relative to GAPDH in (A) HC (blue) 
and RRMS (pink), and (B) HC (green) and SPMS (grey); and DNMT3b (C) HC (blue) 
and RRMS (pink), and (D) HC (green) and SPMS (grey). Whiskers represent data 
within 1.5 IQR of the upper and lower quartile. Data points outside of the 1.5 IQR are 
represented by black dots.  **p<0.01. 
 
Discussion 
In this study, we characterized the expression of the miRNA biogenesis machinery 
and DNA methyltransferases in MS patients and healthy controls.  Our data show 
that DROSHA and DGCR8 are significantly down regulated in both RRMS and 
SPMS patients compared to healthy controls, but DICER is not affected. This is 
consistent with our published data on SPMS patients, where we demonstrated an 
overall decrease in miRNA expression.  One of the most significantly down regulated 
miRNA in that study was miR-29b, which targets the DNA methyltransferases 
DNMT1, DNMT3a and DNMT3b.  Consistent with this, we were able to show a 
subsequent increase in DNMT3b expression in SPMS patients. This is the first study 
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to compare the levels of miRNA biogenesis machinery in different disease states of 
MS. 
A recent study by Jafari and colleagues evaluated the expression miRNA biogenesis 
machinery and found DROSHA, DICER and DGCR8 all to be upregulated in RRMS 
patients (114).  We initially used the primers from this study in our study, however, we 
found that the DGCR8 primers were sub-optimal; therefore, we chose to use TaqMan 
probes.  Additionally, Jafari et al. used RPL38 as a housekeeping gene, as opposed 
to our study, which used GAPDH or β-actin. RPL38 expression is decreased in some 
MS patients and is therefore an unreliable housekeeping gene (219). Finally, we 
used CD4+ T-cells in our study compared to PBMCs which were used in the Jafari 
study.  It is possible that the miRNA biogenesis machinery is significantly upregulated 
in one of the other cell types compared to CD4+ T-cells, which would mask the subtle 
differences we find in our study. In fact, a study of CD19+ B-cells in MS patients 
demonstrated that DICER transcript and protein levels are decreased in patients 
compared to controls (181). This correlated with increased expression of the co-
stimulatory molecules CD80 and CD86 (181). 
The initial stage in post-transcriptional processing, is pri-miRNA cleavage by Drosha, 
bound by its regulatory subunit DGCR8, (called the microprocessor complex) to the 
stem-loop structure (pre-miRNA) (214).  Consistent with this, we see decrease of 
both of these transcripts in both disease stages.  After export to the cytoplasm the 
RNase, Dicer, cleaves the pre-miRNA to produce the mature miRNA duplex 
approximately 22nt (108). We did not find any change in DICER in either disease 
stage, however, there are several factors that contribute to DICER expression (220), 
so it is likely regulated in a different manner than DROSHA and DGCR8. 
Based on our findings, we propose that in SPMS patients, decreased biogenesis 
molecules (specifically the microprocessor complex) results in a global decrease in 
miRNA, including miR-29b, resulting in increased DNMT3b, and overall 
hypermethylation in SPMS patients (Figure 4.5).  At this time, we can only speculate 
as to how this process starts, however, the transcription factor c-myc is known to 
modulate miRNA processing via regulation of Drosha (221). Additionally, C-MYC 
expression was affected in a squamous cell carcinoma cell line by vitamin D 
exposure (205), a known environmental risk factor of MS (52). We investigated C-
MYC in our patient groups, but found no significant changes in expression (Appendix 
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4).  It is possible that other undetermined factors, such as DNA methylation, may 
affect DROSHA and DGCR8. 
In RRMS patients, the results are less clear. While DROSHA and DGCR8 expression 
are both decreased in these patients, the levels of miR-29b are unchanged.  
DNMT3a and DNMT3b remain unchanged but levels of DNMT1 and its transcription 
factor, SP1, decrease. While this may explain the slight decrease in global 
methylation we have seen in RRMS patients, it suggests that the DNA 
methyltransferase enzymes are regulated by mechanisms other than or in additional 
to miRNA. 
This is the first study to investigate the levels of miRNA biogenesis machinery in the 
CD4+ T-cells of RRMS and SPMS patients. We propose a mechanism where the 
miRNA microprocessor complex (Drosha-DGCR8) is downregulated by an unknown 
mechanism. This potentially leads to a cascade of events, resulting in global 
hypermethylation in SPMS patients. Future studies should focus on elucidating the 
mechanism by which Drosha and DGCR8 are downregulated in progressive patients, 
and confirming differential expression at the protein level. 
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Figure 4.5: Schematic representation of miRNA biogenesis (specific to miR-29b) in 
(A) controls and (B) SPMS patients. 
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CHAPTER FIVE – microRNA expression profile of SPMS NAWM 
 
microRNA expression profile of SPMS normal appearing white matter 
 
This chapter addresses my fifth research question – is there differential microRNA 
expression in SPMS normal appearing white matter compared to controls, and how 
does this compare to microRNA expression patterns seen in CD4+ T-cells? 
 
Abstract 
Background: In MS, the normal appearing white matter (NAWM) is the site of 
pathology initiation. Previous studies have identified differences between NAWM in 
MS patients and control WM indicating NAWM is in an alerted, though 
immunosuppressed state. Previous studies have analysed miRNA expression in 
NAWM across MS disease subtypes; this is the first study to analyse miRNA 
expression in solely secondary progressive MS (SPMS) NAWM. 
Methods: Using NanoString nCounter technology, the expression of 800 miRNAs 
was analysed in formalin-fixed, paraffin-embedded (FFPE) brain tissue samples (10 
SPMS NAWM and 10 control white matter). Differential expression was confirmed 
using RT-qPCR with mature miRNA TaqMan probes in 13 SPMS and 10 control 
samples.  
Results: Three miRNAs were confirmed to be down-regulated in SPMS NAWM 
compared to controls, miR-29b-3p, miR-219-5p and miR-451a. miR-29b-3p has also 
been confirmed down-regulated in SPMS CD4+ T-cells. There is no other overlap in 
miRNA dysregulation between NAWM and peripheral CD4+ T-cells. 
Conclusions: These three miRNAs target genes in focal adhesion and adherens 
junction pathways, crucial to blood-brain barrier functioning. As well as playing a 
crucial role in oligodendrocyte maturation. Their dysregulation in NAWM likely 
contributes to priming the region for development of MS pathology.  
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Introduction 
The normal appearing white matter (NAWM) in MS is the site where pathology 
initiates prior to development of symptomatic lesions. Light microscopic analysis 
shows its morphology is no different to healthy brains. However, diffusion tensor 
imaging (43) and molecular analyses, including gene expression (222) and DNA 
methylation (100) studies, demonstrate that there are differences that likely 
contribute to future development of lesions. In particular, Melief et al. (41) found that 
microglia in the NAWM region of the MS brain are in an alerted though 
immunosuppressed state. 
The role of miRNAs in regulating gene expression makes them key molecules of 
interest in tissues associated with disease. The majority of studies on miRNA in the 
MS brain have focused on lesions, where differentially expressed miRNAs have been 
associated with phagocytosis promotion, Th17 differentiation, impaired neurosteroid 
synthesis and decreased memory performance (141, 143, 158, 162). Recently, a 
study on miRNA expression in periventricular NAWM was conducted (140), however 
the subtypes of MS from which the samples were derived are not disclosed.  
As in previous chapters, samples from SPMS donors have been used here. This 
allows comparison of miRNA expression profiles with those of CD4+ T-cells of 
patients with the same disease subtype. The brain tissue samples used in this study 
are from archived banks, and some have been stored for up to 12 years. mRNA and 
DNA are susceptible to significant degradation over such a period of time, and 
amplification of gene transcripts is highly heterogeneous amongst samples (223). 
However, miRNA integrity is remarkably robust over many years of storage (224) and 
is comparable with frozen tissue for sensitivity, with only minor reductions in 
amplification (223). As such, this study focuses on results of miRNA expression only, 
and will hypothesise on the effects on gene expression using target prediction and 
pathway analysis software. 
In this study, miRNA expression profiles of NAWM from SPMS patients are compared 
to controls. NanoString nCounter technology profiles the expression of 800 miRNAs 
using unique fluorescent-coded probes which can be counted in a sample using 
microscopy; thus removing the need to amplify the sample. Advantages of this 
methodology include highly accurate quantification of miRNA species and low total 
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RNA input (225); both essential features when working with valuable samples such 
as post-mortem FFPE brain tissue. The results of this investigation will reveal 
whether NAWM of SPMS patients differs in miRNA expression from normal control 
brain, and how this compares both to similar studies and CD4+ T-cells from the same 
MS subtype. 
 
Materials and Methods 
Samples 
Post-mortem FFPE brain tissue sections were obtained from the UK Multiple 
Sclerosis Tissue Bank (MS and control samples) and the Multiple Sclerosis Research 
Australia brain bank (MS samples only). Each section was pre-cut by the respective 
tissue banks to a thickness of 5µm. The majority of MS samples came from SPMS 
donors, and control samples from individuals who passed from non-inflammatory and 
non-neurodegenerative illnesses. Due to the limited availability of tissues, the sample 
characteristics (table 5.1) are quite varied between SPMS and control samples. 
Among the control samples, the gender ratio was 1:4 female to male, which is not 
representative of MS epidemiology (1). Furthermore, we received three primary 
progressive MS (PPMS) samples; these were included in the experiments, however 
all analysis presented here is from SPMS samples only. Any cases where 
significance was rescinded by addition of the PPMS samples is noted. 
 
Ethics Statement 
Prior to death, patients gave their consent for using their brain tissues for research 
purposes according to local ethical guidelines. MS was diagnosed according to the 
McDonald criteria (183). Cases were excluded if the post-mortem interval exceeded 
48 hours, and if gender and type of MS was unknown. Ethics approval was also 
obtained from Hunter New England Health (HNE 09/04/15/5.13), the University of 
Newcastle, Australia (UoN H-2009-0365), and Bond University (RO1382). 
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Table 5.1: Details of the SPMS and control brain tissue samples. 
 SPMS Controls 
 NanoString nCounter qPCR nCounter & qPCR 
Number 10 13 (9 same as 
nCounter) 
10 
Age in years 
(mean ±SD) 63.0 ±9.4 63.2 ±7.8 74.1 ±16.5 
Female 7 8 2 
PMI in hours 
(mean ±SD) 18.2 ±6.8 22.1 ±17.3 20.0 ±14.1 
Brain region PFC (n=3), TEMP 
(n=5), other (n=2) 
PFC (n=4), TEMP 
(n=5), other (n=4) 
PFC (n=6), TEMP 
(n=2), other (n=2) 
Abbreviations: PMI – post-mortem interval, SD – standard deviation, PFC – prefrontal 
cortex, TEMP – temporal lobe, other brain regions – parietal, superior frontal gyrus, 
Brodmann areas 9 and 11. 
 
Histology 
One section from each SPMS sample was stained with Luxol Fast Blue - Periodic 
Acid-Schiff (LFB-PAS). LFB is a myelin-specific stain, and PAS was used to identify 
myelin by-products. The protocol for LFB-PAS staining and the criteria for identifying 
pathological regions can be found in Appendix 5. In the LFB-PAS stained MS 
sections, 27 regions of NAWM, 74 chronic lesions, 58 remyelinated areas and 1 
active lesion were identified. Due to the constraints of RNA yield outlined below, 
sample acquisition was limited to NAWM regions (figure 5.1 A-B), specifically 
samples with clearly defined NAWM with an area >25mm2. 
 
Trouble-shooting tissue dissection 
Laser capture microdissection: miRNA extraction was attempted from areas of 
NAWM, chronic lesions and remyelinated areas. Due to the small size of these areas, 
laser capture microdissection (LCM) using a PALM MicroBeam (Carl Zeiss 
Microscopy) was utilised. LCM uses a navigated laser to dissect around an area of 
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tissue to be collected, and with a series of defocused ultraviolet (UV) laser bursts, 
catapults pieces of tissue into a microfuge tube cap containing 10µl of buffer. The 
surface tension of the buffer provides an adherent surface to collect the sample.  
LCM is very time consuming, 1 sample per day. Furthermore, as it is a UV laser, long 
exposure to the radiation may degrade the miRNA as it is captured. Samples 
collected using purely LCM continually produced low RNA yields (<50ng). 
Collection buffer: Two collection buffers were trialled with LCM to identify which 
captured the most material and was most compatible with miRNA extraction. Xylene 
(100%) and PKD buffer (Qiagen, USA) produced comparable RNA yields. PKD buffer 
was selected over xylene to streamline the collection process; PKD buffer is used in 
the first step of the miRNeasy FFPE tissue extraction kit (Qiagen, USA) protocol. In 
contrast, tissue collected with xylene must be extricated from the xylene using 
centrifugation and evaporation prior to RNA extraction. 
miRNA extraction kits: Initially, total RNA was extracted using Qiagen’s miRNeasy 
FFPE tissue kit, and RNA yields from LCM were very low. To determine if this low 
yield was a consequence of the extraction kit, six samples were extracted using 
Quick-RNA MiniPrep (Zymo Research, USA). No significant difference in RNA yield 
was detected between the extraction methods and thus experiments were continued 
with the Qiagen kits and its proprietary PKD buffer. 
Region of collection: Areas of NAWM, chronic lesions and remyelinated lesions 
were collected with LCM, and RNA extracted. This was done to determine whether it 
was feasible to compare miRNAs in NAWM and pathological areas of the tissue 
sections. Areas of pathology yielded very low RNA quantities (<50ng). LFB-PAS 
staining shows few cells in chronic lesions, and remyelinated regions have reduced 
populations of oligodendrocytes compared to NAWM. This reduced cellularity in 
pathological regions is the likely cause of low RNA yields. Thus, NAWM remained the 
sole focus of this study. 
To overcome these issues, the method of tissue dissection and RNA extraction was 
adjusted to that described below. 
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NAWM acquisition 
Sections for RNA extraction were deparaffinised using sequential absolute ethanol 
and xylene washes. Areas of NAWM were delineated using navigated laser 
microdissection (PALM MicroBeam, Carl Zeiss Microscopy) (226) and the tissue 
areas removed (figure 5.1 C-D) using the MesoDissection system (AvanSci Bio, 
USA) or scalpel. PKD buffer (Qiagen, USA) from the RNA extraction kit was used as 
the lifting agent. 3-5 consecutive sections were pooled for RNA extraction. The 
number of sections used depended on the size of the NAWM area.  
 
Figure 5.1: Images showing sample staining, characterisation and tissue extraction. 
(A) Macroscopic view of section stained with LFB-PAS. The NAWM can be easily 
identified by its consistent blue colour in the centre of the slide. It is surrounded by 
purple-stained grey matter. (B) 200x magnification of NAWM in the same section. 
The myelin is consistent and densely packed; the defining feature of NAWM. (C) 
Unstained, consecutive section. The NAWM outline has been scored using laser 
microdissection. (D) The same section following NAWM sample removal using the 
MesoDissection system. 
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RNA extraction and concentration 
MicroRNA was extracted from the tissue using miRNeasy FFPE tissue extraction kit 
(Qiagen, USA). The concentration and purity of the extracted RNA was measured on 
a Qubit 2.0 Fluorometer (Life Technologies, USA) and an Epoch Micro-Volume 
Spectrophotometer System (BioTek, USA) respectively. A value of  >1.8 on the 
optical density 260/280 ratio was considered suitable purity for downstream gene 
expression experiments (227). Further quality control (QC) of the RNA’s integrity 
would normally be tested on a Bioanalyzer (Agilent, USA), however determination of 
the RNA integrity number depends on 18S and 28S ribosomal RNA subunit ratio 
which is not indicative of miRNA quality, thus Bioanalyzer QC was not deemed 
appropriate for these samples and down-stream experiments. 
Total RNA for downstream nCounter (NanoString, USA) analysis was concentrated to 
33ng/µl using RNAstable tube kit (Biomatrica, USA) and vacuum centrifugation at 
ambient temperature. 
 
NanoString nCounter 
The expression of 800 miRNAs was analysed using nCounter Human v2 miRNA 
expression assay (NanoString, USA) following manufacturer’s guidelines. Briefly, 
100ng of purified total RNA was added to the sample preparation reaction in 3µl. 
miRNAs were annealed to a bridging code and ligated with a miRNA specific tag 
sequence. Un-ligated tags were removed with enzymatic purification. Samples were 
hybridised overnight at 65°C to probe pairs. These pairs include a capture probe with 
3’ biotin molecule for attachment to the nCounter cartridge, and a reporter probe 
comprising four fluorescent colours in six positions at its 5’ end. The sequence of 
colours on the reporter probe allows the identity of specific miRNAs to be resolved 
during data collection.  
After 24 hours, sample reactions were loaded onto the nCounter Prep Station for 
automated, post-hybridisation removal of excess probes and immobilisation to the 
cartridge. The cartridge was then loaded onto the Digital Analyzer where reporter 
probe counts were tabulated into a CSV file. All samples passed QC against six 
positive and six negative miRNA assay controls, and were normalised against the 
geometric mean of the top 100 miRNA counts. 
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The nCounter’s limit of detection is ~10 copies/cell, and has a reproducibility rate 
greater than RT-qPCR (225, 228). Therefore, as with my NGS study in Chapter Two, 
selection criteria were established to determine which of the miRNAs the nCounter 
identified as differentially expressed, would be selected for confirmation with RT-
qPCR. These criteria comprised: miRNA exhibits >1.8-fold difference between SPMS 
and control samples, >100 copies of the miRNA must have been detected in at least 
one of the sample cohorts, and a mature miRNA TaqMan probe (Applied Biosystems, 
USA) must be commercially available. 
 
RT-qPCR 
Differential expression of the seven miRNAs identified using the nCounter system 
were validated using RT-qPCR (224). 10ng of total RNA per miRNA target was 
reverse transcribed using TaqMan MicroRNA Reverse Transcription Kit (Applied 
Biosystems, Thermo Fisher Scientific, USA). Mature miRNA TaqMan assays were 
used to determine expression of hsa-let-7c (ref: 000379), hsa-miR-29b-3p (ref: 
000413), hsa-miR-219-5p (ref: 000522), hsa-miR-320e (ref: 243005), miR-451a (ref: 
001141), hsa-miR-630 (ref: 001563), hsa-miR-664-3p (ref: 002897) with hsa-miR-26b 
(ref: 000407) as an endogenous control, using a ViiA 7 Real-Time PCR system 
(Applied Biosystems, Thermo Fisher Scientific, USA). RNU6B (ref: 001093) was 
considered as an alternative endogenous control, however it failed to amplify in some 
samples. This was likely because of its larger amplicon size compared to miR-26b 
(42bp vs. 21bp respectively) being inherently incompatible with the degraded nature 
of the FFPE samples.  
 
Comparison with CD4+ T-cells of differentially expressed miRNA  
The overall aim of this thesis is to compare the miRNA profiles of blood and brain 
tissue in MS patients. The miRNAs identified as significantly different in CD4+ T-cells 
were analysed in the MS NAWM tissue. However, due to substantial limitations on 
RNA quantity, a reduced number of samples were analysed. Mature miRNA TaqMan 
assays were used to determine expression of hsa-miR-21-5p (ref: 000397) (9 SPMS, 
9 control), hsa-miR-142-3p (ref: 000464) (9 SPMS, 7 control) and hsa-miR-155-5p 
(ref: 002623) (3 SPMS, 3 control) with hsa-miR-26b as an endogenous control. 
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Statistical analysis 
A t-test was initially performed on the nCounter data using NanoString’s software, 
nSolver. However, due to the wide distribution of the data sets between SPMS and 
HC groups, a non-parametric, two-sample Kolmogorov-Smirnov test (K-S test) was 
used to compare cumulative distributions, and determine significant differences in 
expression of each miRNA for both nCounter and RT-qPCR data. Our statistical 
significance threshold allowing for multiple testing correction was determined using 
the FDR procedure of Benjamini-Hochberg (185). The significance threshold was set 
at p<0.05. 
 
Gene target prediction and pathway analysis 
miRSystem integrates seven different target gene prediction algorithms and contains 
experimentally validated data on miRNA:mRNA interactions (106). This integration 
system was used to identify genes that may be targeted by more than one of our 
identified dysregulated miRNAs. 
miRPath v3 from DNA Intelligent Analysis (DIANA) (230) combines gene targets from 
TarBase v7 (231) to determine KEGG pathways that may be affected by miRNA 
expression changes.  Using this software, pathways with targets of more than one of 
the key miRNAs were identified. 
 
Results 
NanoString nCounter 
miRNA from the white matter of 10 SPMS and 10 control subjects was profiled using 
the NanoString nCounter system. Of the 800 miRNAs examined, 57 showed 
significantly different expression, and seven met the cut-off criteria (see methods 
section) to be further analysed with RT-qPCR. Let-7c (p=0.003), miR-320e 
(p=0.003), and miR-630 (p=0.015) were up-regulated in SPMS NAWM compared to 
controls, whereas miR-29b-3p (p=0.05), miR-219-5p (p=0.015), miR-451a (p=0.003) 
and miR-664-3p (p=0.015) are down-regulated in SPMS NAWM tissue (figure 5.2). 
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Figure 5.2: Tukey box plot of the top 7 differentially expressed miRNAs in SPMS 
NAWM identified using NanoString nCounter system. Whiskers represent data within 
1.5 interquartile range (IQR) of the upper and lower quartile. Data points outside of 
the 1.5 IQR are represented by black dots. * p<0.05, ** p<0.01. 
 
Despite miR-26b being differentially expressed in SPMS CD4+ T-cells (Chapter Two), 
it demonstrated consistent expression within SPMS and control white matter samples 
in the NanoString dataset (p=0.84) adding assurance to its use as an endogenous 
control for RT-qPCR. 
 
RT-qPCR  
The expression of the seven miRNAs identified using NanoString nCounter were re-
analysed with RT-qPCR in the same 20 samples, plus a further three SPMS samples 
(10 control and 13 SPMS). All seven of the miRNAs demonstrated differences in 
expression in the same direction indicated by the nCounter data, however only three 
reached statistical significance (figure 5.3). miR-29b-3p (p=0.017), miR-219-5p 
(p=0.009) and miR-451a (p=0.002) were confirmed as down-regulated in SPMS 
NAWM compared to controls. 
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Figure 5.3: Tukey box plot demonstrating RT-qPCR data of the top 7 differentially 
expressed miRNAs in SPMS NAWM. miR-29b-3p, miR-219-5p and miR-451a were 
confirmed to be significantly down-regulated in SPMS NAWM compared to control 
white matter. Whiskers represent data within 1.5 IQR of the upper and lower quartile. 
Data points outside of the 1.5 IQR are represented by black dots. * p<0.05, ** 
p<0.01. 
 
Gene targets and pathway analysis 
miRSystem identified no common gene target of the three miRNAs confirmed with 
RT-qPCR, however 59 genes are targeted by combinations of two out of the three 
miRNAs. When looking at gene targets for all seven miRNAs identified by nCounter, 
Ataxin-1 (ATXN1) is targeted by four, however, the direction of change amongst 
these miRNAs is inconsistent (two up-regulated and two down-regulated, with similar 
fold-changes) indicating that collectively these miRNAs probably are not having an 
effect on expression of ATXN1.  
KEGG pathway analysis using DIANA identified a number of pathways targeted by 
both miR-29b-3p and miR-451a (table 5.2). Many are related to cancer, however 
focal adhesion (both miRNAs target AKT1 and BCL2) and adherens junction are 
particularly interesting due to their strong links with blood-brain barrier (BBB) 
function. No targets for miR-219-5p were identified with TarBase v7. 
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Table 5.2: KEGG pathways containing genes targeted by both miR-29b-3p and miR-
451a. Significance threshold set at p<0.0001. 
KEGG pathway p value No. of genes 
Colorectal cancer (hsa05210) 2.702e-08 22 
Viral carcinogenesis (hsa05203) 1.529e-07 32 
Endometrial cancer (hsa05213) 5.116e-06 17 
Amoebiasis (hsa05146) 6.517e-06 22 
Hepatitis B (hsa05161) 5.293e-05 29 
Focal adhesion (hsa04510) 8.590e-05 42 
Adherens junction (hsa04520) 8.733e-05 15 
Glioma (hsa05214) 8.733e-05 16 
Pathways in cancer (hsa05200) 9.768e-05 60 
 
Comparison with CD4+ T-cell miRNA  
In Chapter Two, five miRNAs were confirmed to be dysregulated in the CD4+ T-cells 
of SPMS patients: miR-21-5p, miR-26b-5p miR-29b-3p, miR-142-3p and miR-155-5p. 
Of these five miRNAs, miR-29b-3p was the only one to be confirmed as down-
regulated in both SPMS NAWM and CD4+ T-cells (Figures 2.2 and 4.3). In this study, 
miR-26b-5p has been selected as the endogenous control based on advice from 
TaqMan application notes (229). Interestingly, miR-155-5p failed to be detected by 
nCounter and RT-qPCR, and neither miR-21-5p (p=0.36) nor miR-142-3p (p=0.23) 
showed significant expression changes in SPMS NAWM (figure 5.4). 
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Figure 5.4: Comparison of miR-21-5p and miR-142-3p expression profiles in NAWM 
(A,B) and CD4+ T-cells (C,D) of SPMS individuals using RT-qPCR. Whiskers 
represent data within 1.5 IQR of the upper and lower quartile. Data points outside of 
the 1.5 IQR are represented by black dots. * p<0.05, ** p<0.01. 
 
Discussion 
Here we have performed a comprehensive analysis of miRNA expression in the 
NAWM of SPMS individuals using NanoString nCounter technology. Three miRNAs 
(miR-29b-3p, miR-219-5p and miR-451a) were found to be significantly down-
regulated in SPMS samples compared to controls. Comparisons to other studies in 
NAWM, and possible implications of dysregulation of these miRNAs will be discussed 
here. However, studies on NAWM in the experimental autoimmune encephalomyelitis 
(EAE) model will not be discussed, as chemical induction of disease likely cannot 
provide an accurate representation of NAWM. 
Two previous studies have profiled miRNA expression in MS NAWM. Guerau-de-
Arellano (140) used NanoString nCounter to compare undefined-MS subtype, 
periventricular NAWM with half the number of control samples (n=5) that we have 
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used here. It is unclear whether their samples were fresh-frozen or FFPE, and how it 
was established that the regions analysed were pathology free. While there is no 
overlap in identified miRNAs with this study, another member of the mature miR-29 
family (miR-29c) was significantly down-regulated in their MS samples, and 
miRSystem found miR-29b-3p and miR-29c-3p to have ~95% of their targets in 
common with each other. In Noorbakhsh et al.’s (158) study, they found up-regulation 
of miR-219-5p in MS NAWM; directly contradicting our finding of miR-219-5p down-
regulation. However, both of these previous studies were limited by low sample 
numbers and using undefined MS samples. Without knowing more details about the 
types of samples used, it is unreasonable to directly compare our findings. 
miR-29b-3p and its role in methylation has been previously established in CD4+ T-
cells in Chapter Three and by Qin et al. (193). Here, it is down-regulated in SPMS 
NAWM, just as we have seen in SPMS CD4+ T-cells. If miR-29b’s effect on 
methylation is replicated in the brain as we saw in CD4+ T-cells, it can be expected 
that differentially methylated regions in NAWM will preferentially demonstrate 
hypermethylation. A recent study on methylation patterns in MS NAWM showed that 
of 539 DMRs, 59% were hypermethylated (100), indicating that miR-29b may be 
affecting methylation in NAWM, but not to the extent that it does in CD4+ T-cells.  
Previously, miR-451a was identified as differentially expressed in SPMS CD4+ T-
cells, though this could not be confirmed with RT-qPCR (Appendix 2). Here, common 
target and pathway analysis identified two genes in the focal adhesion pathway 
targeted by both miR-451a and miR-29b-3p. These were serine/threonine kinase 
(AKT1), a mediator of neuronal survival via oligodendrocytes (232), and apoptosis 
regulator BCL2 (BCL2). 15 genes in the adherens junction pathway are also targeted 
by either miR-29b-3p or miR-451a. Proper functioning of both of these pathways is 
essential to normal BBB function, and disruption of protein expression in these 
pathways has been linked to BBB disruption in MS (157, 233). miRNA-mediated 
changes may be affecting the efficacy of these pathways in NAWM, either priming 
the region for macrophage infiltration, or mounting a defence against autoimmune 
attack. Without miRNA interaction and gene expression studies however, we are 
unable to hypothesise which of these scenarios may be reality. 
The role of miR-219-5p in oligodendrocyte differentiation and precursor cell (OPC) 
maturation is particularly interesting. miR-219 is enriched in normal white matter, 
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particularly in oligodendrocytes (234). A study on topographical cues and gene 
silencing with miRNAs, found that electrospun microfibres incorporated with miR-219 
were effective in driving OPC differentiation and oligodendrocyte maturation, and 
then remyelination (235). In this study, we identified down-regulation of miR-219-5p 
in SPMS NAWM, indicating a diminished influence on oligodendrocyte remyelination 
activity. This is supported by Juncker et al.’s (141) study which found miR-219-5p 
down-regulated in inactive MS lesions compared to normal brain. It would appear 
that regions of the MS brain with inactive disease (NAWM and inactive lesions) have 
reduced miR-219-5p expression, which in turn reduces oligodendrocyte presence or 
activity, ultimately perpetuating pathology. 
Of the miRNAs dysregulated in this study only one, miR-29b-3p, has overlapping 
results with SPMS CD4+ T-cells. Both miR-21-5p and miR-142-3p were analysed to 
determine if they too were down-regulated in NAWM, however we find that they show 
a trend of up-regulation, though not significantly. A limitation of this study was the 
small quantity of RNA available for RT-qPCR, and the sample number for these 
miRNAs was reduced. This may have resulted in lost significance, however as these 
miRNAs were up-regulated in NAWM, it is unlikely that a few more samples would 
have changed the expression pattern to that seen in CD4+ T-cells.  
Another limitation was the absence of miR-155-5p expression data. In many studies, 
miR-155-5p has been of key interest and is up-regulated in MS samples. Its 
expression appears to be highest in active lesions and reduces through chronic 
lesions and NAWM to a baseline low in control white matter (141, 157, 158). Using 
both NanoString nCounter and RT-qPCR, miR-155-5p was undetected in our 
samples. The reason for this is unknown; it may be that it is not present in these 
samples, our samples may reflect severely “burned out” MS, or that both methods 
independently failed to amplify it.  
This is the first study to profile miRNA expression in SPMS NAWM. Three miRNAs 
were identified to be down-regulated compared to control white matter. These 
miRNAs play crucial roles in maintaining BBB integrity, oligodendrocyte function and 
methylation. Future studies will work on identifying the specific cell types in which this 
dysregulation occurs using in situ hybridisation to further our understanding of the 
impact this dysregulation has in the SPMS brain. 
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CHAPTER SIX – DISCUSSION 
 
This project has explored microRNA (miRNA) expression and the cause of 
dysregulation in CD4+ T-cells of secondary progressive (SPMS) patients, and used 
this information to guide an exploratory miRNA-profiling study in the normal 
appearing white matter (NAWM) of SPMS brain tissue donors. 
 
miRNA expression in CD4+ T-cells 
A key initial finding that inspired following chapters was the observation of broad 
down-regulation of miRNAs in CD4+ T-cells of SPMS patients. The literature review 
of miRNA dysregulation in MS (Chapter One), demonstrated the dynamic up- and 
down-regulation of miRNAs seen in MS-associated tissues. The study in Chapter 
Two bucked that trend, and showed that 97% of all miRNAs that demonstrated 
dysregulation were under-expressed compared to controls (202). NGS was used for 
initial expression profiling, which has the advantage over other methodologies in that 
all miRNAs present in a sample are identified, as such, the statement of “broad 
down-regulation” is valid. However, the cause of this down-regulation had to be 
established, and changes in DNA methylation and expression of miRNA biogenesis 
molecules was explored. 
While DNA methylation was predominantly hypermethylated in SPMS CD4+ T-cells 
compared to controls, none of the differentially methylated CpGs were within miRNA 
transcription start sites (TSS). Therefore, it is unlikely that this is the underlying cause 
for miRNA down-regulation in SPMS. However, following the lead of Jafari et al. 
(114), expression of miRNA biogenesis molecules was analysed, and significant 
down-regulation of DROSHA and DGCR8, the nuclear molecules responsible for 
cleaving the pri-miRNA structure from the pre-miRNA, was found. In the absence of 
this RNase and its cofactor, miRNAs cannot be manufactured; the down-regulation 
these two molecules is thus a significant contributor to broad miRNA down-regulation 
seen in SPMS CD4+ T-cells. The instigator of DROSHA and DGCR8 down-
regulation however remains unclear; there were no differentially methylated regions 
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near their TSSs, and so a mechanism other than methylation must be affecting their 
expression.  
One hypothesis for this was that an external factor, such as vitamin D, might target 
C-MYC, the transcription factor of DROSHA, resulting in a decrease in DROSHA’s 
expression. This theory was attractive because of the strong relationship between C-
MYC expression and vitamin D (205), a well-studied environmental MS risk factor 
(52). C-MYC’s expression in SPMS was found to be stable (appendix 4), however 
without measuring vitamin D serum levels of study participants, it cannot be 
concluded that C-MYC is causing down-regulation of DROSHA or if there is another 
cause independent of its transcription factor. This warrants further investigation.  
 
Methylation and miRNAs 
While DNA methylation changes aren’t in miRNA TSSs and have thus been ruled out 
as the cause for miRNA down-regulation here, there was still a very interesting 
finding; RRMS and SPMS DNA methylation profiles in CD4+ T-cells are distinct. 
RRMS CD4+ T-cells demonstrated nearly equal proportions of hypo- and 
hypermethylation (51% and 49% respectively). In contrast, SPMS strongly geared 
towards hypermethylation; 75% of differentially methylated CpGs were 
hypermethylated compared to age and gender matched controls.  
In a study of DNA methylation in SLE CD4+ T-cells, over-expression of miR-29b was 
found to cause hypomethylation (193). miR-29b directly targets the 3’ UTR of 
DNMT3a and DNMT3b, DNA methyltransferases responsible for producing de novo 
methylation sites. In Chapter Two, miR-29b is found to be significantly down-
regulated in CD4+ T-cells. To determine its possible effect on DNA methylation, the 
expression of miR-29b and the DNMTs were analysed in a female-only cohort 
(Chapter Four) with significant sample crossover with the DNA methylation SPMS 
cohort (Chapter Three). miR-29b was re-confirmed to be down-regulated in SPMS 
CD4+ T-cells, and associated up-regulation of DNMT3b was observed.  
A chain of events leading to DNA hypermethylation in SPMS CD4+ T-cells thus 
presents itself. miRNA biogenesis molecules, DROSHA and DGCR8 are down-
regulated (mechanism unknown), causing broad down-regulation of miRNAs. One of 
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these miRNAs (miR-29b) is significantly reduced, and its target (DNMT3b) becomes 
over-expressed. This leads to de novo methylation, ultimately manifesting as DNA 
hypermethylation in these cells. A result of this would be transcriptional silencing, 
reducing the activity of CD4+ T-cells in SPMS. 
 
Reduced CD4+ T-cell activity 
The role of the immune system in SPMS is poorly understood, though it is 
predominantly thought that this disease stage is driven by neurodegeneration, rather 
than inflammation. The findings presented within this thesis support that postulation 
by demonstrating a series of changes within CD4+ T-cells that hinder their activity. 
Eight of the ten most dysregulated miRNAs identified using NGS have a common 
target, suppressor of cytokine signalling 6 (SOCS6). The expression of SOCS6 is 
negatively correlated to the expression of these miRNAs, i.e. SOCS6 is up-regulated 
in SPMS CD4+T-cells (Chapter Two). SOCS6 is a negatively regulator of T cell 
activation (187); thus, its up-regulation seen here indicates that it will act to prevent T 
cell activation, reducing immune system activity in SPMS. 
Another consequence of broad miRNA down-regulation was the reduction in miR-29b 
leading to DNA hypermethylation and transcriptional silencing. The dominance of 
hypermethylated regions in SPMS compared to the inflammatory-driven RRMS 
disease stage, indicates that there is a genome-wide push towards reducing cell 
activity in SPMS. 
Furthermore, one of the most highly expressed miRNAs in MS studies, miR-155, was 
down-regulated in these cells. miR-155 can be classed as an inflammatory miRNA as 
its expression may be activated by proinflammatory cytokines and it acts to disrupt 
the BBB (144). Also, its absence in EAE ameliorates disease (165). Its down-
regulation in SPMS may have the effect of reducing its inflammatory activity with 
respect to the BBB and CD4+ T-cell disruption and migration across the barrier. 
Each of these changes is a cause or consequence of disease progression. The effect 
of ageing can be excluded as a contributing factor in these changes as all 
parameters were compared to age- and gender-matched controls. Altogether, these 
factors limit the activity of CD4+ T-cells in the SPMS disease stage, and supports the 
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hypothesis that disability accumulation in SPMS is caused more by 
neurodegeneration than systemic inflammation.  
 
NAWM in SPMS 
Unlike SPMS CD4+ T-cells, the miRNA expression profiles of NAWM tissue exhibited 
both up- and down-regulation of miRNA. This analysis was performed using the 
NanoString nCounter system, a non-amplification based method of detecting 
expression nuances. Using RT-qPCR, three miRNAs were confirmed to be down-
regulated in these SPMS NAWM samples compared to controls. The predicted role 
of these miRNAs includes maintenance of BBB integrity, and oligodendrocyte 
maturation and activity. Potential alterations to the activity of these pathways 
corroborates other works on miRNA in the CNS, specifically lesions and BECs (141, 
157, 234), and demonstrates a common thread between classically disease-active 
tissues and NAWM, which is normal in appearance only. 
Of the three dysregulated miRNAs, only one (miR-29b) overlapped with our findings 
in CD4+ T-cells. Methylation profiling of NAWM was not performed in this study, 
however previous works by Huynh et al. (100) found a moderate lean (59%) towards 
hypermethylated DMRs in NAWM tissue. This indicates that miR-29b might also be 
having an effect on methylation in NAWM, but it cannot be ascertained without 
performing simultaneous methylation and miR-29b expression profiling in a larger 
sample cohort. 
Correlation of miRNA expression between CD4+ T-cells and NAWM in SPMS 
samples was investigated. Comparison of the three NAWM miRNAs (miR-29b, miR-
219 and miR-451a) to CD4+ T-cell NGS data established significant down-regulation 
of miR-29b was common between both data sets, and was able to be corroborated 
with RT-qPCR in both instances. Further, NGS showed miR-451a was up-regulated 
in CD4+ T-cells; the only miRNA in these samples to demonstrate change in that 
direction. However, expression of this miRNA was very low (<45 copies/sample), and 
attempts to confirm this dysregulation with RT-qPCR failed; even demonstrating 
significant down-regulation in the replication cohort. The third candidate, miR-219, 
was stably expressed in CD4+ T-cells. 
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Using RT-qPCR, the other miRNAs dysregulated in CD4+ T-cells (Chapter One) 
were analysed in NAWM. miR-26b was stably expressed, and miR-21 and miR-142 
demonstrated slight up-regulation, though this was not significant. miR-155-5p was 
not detected in NAWM by either NanoString nCounter or RT-qPCR indicating that 
this miRNA may be severely down-regulated/not expressed in these samples, 
however methodological or sample error cannot be excluded. 
The common down-regulation of miR-29b in NAWM and CD4+ T-cells in SPMS is 
interesting and the cause remains unknown. Up-regulation of a specific miRNA in a 
tissue may be the result of unrelated cells over-expressing it, and then either 
apoptosing or releasing exosomes containing that miRNA into a circulating body fluid 
where they may present as over-expression in another tissue (236). However, down-
regulation of miRNAs is not transmissible in this way, and cannot account for the 
decreased expression of miR-29b. It may also be coincidence that miR-29b is 
dysregulated in the same direction in these tissues. 
 
Limitations and future directions 
The priority of future investigation should be to establish causal relationships 
between DROSHA, DGCR8, microRNAs (both general and miR-29b), and DNMT3b 
within CD4+ T-cells. Following this, functional characterisation should be performed 
to determine the effect that these factors have on CD4+ T-cells and how that 
contributes to progressive MS; with the aim of exploiting these differences for 
therapeutic gain. 
MiRNAs are regulators of gene expression though there are molecules that add a 
further level of regulation by regulating expression of miRNAs themselves. Circular 
miRNA sponges were reported in Nature in February 2013 (237) and the existence of 
numerous circular RNAs (circRNAs) has been demonstrated, including a circRNA 
sponge for miR-7 with over 70 binding sites for the single miRNA (237). This has 
obvious implications for the clarification of miRNA dysregulation. For miRNAs found 
to be under-expressed, miRNA expression may be normal but the expression of as-
of-yet unidentified circRNAs is dysregulated. miRNA has a demonstrated impact on 
MS pathophysiology, and circRNAs may be a further confounding factor in 
understanding this disease. Unfortunately, due to the relatively recent observation of 
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circRNA sponges, it was not possible to detect their presence in the study samples, 
though this would be an exceptional addition to future miRNA-profiling projects. 
Indeed, if they can be incorporated into exosomes, then they could be cause for 
simultaneous down-regulation of miR-29b in NAWM and CD4+ T-cells observed 
here. 
Considering Munoz-Culla’s paper on sex-differences in miRNA expression in RRMS 
(164), it would be beneficial to repeat experiments from Chapters Two and Five in 
larger cohorts with female and male samples analysed separately. Their study 
highlighted the existence of a mirror pattern of miRNA expression in relapse and 
remission disease state, however only 80% of miRNAs dysregulated in a mixed-
gender cohort were also confirmed in female-only analyses. Thus, differences in 
miRNA expression seen in CD4+ T-cells and NAWM here, may not be representative 
of male or female patients in isolation. 
Differential gene expression data reported within this thesis was not established at 
the protein level, and therefore caution must be exercised when interpreting the 
functional consequences of differential gene expression within MS. A clear future 
research direction from this thesis’ findings would be to investigate the protein 
expression levels of these same genes, and following confirmation/refutation of 
differences, proceed with functional studies.  
The quantity and quality of RNA and DNA within our NAWM samples severely limited 
the molecular parameters that could be examined. Fragmentation of these molecules 
prevented profiling of large fragments including mRNA and DNA. Indeed, the short 
non-coding RNA RNU6B was unreliable as an endogenous control despite its short, 
42bp length. Thus, miRNA expression profiling was the only metric measured in this 
study. However, the absence of gene expression examination does not greatly hinder 
the conclusions reached regarding affected pathways, as analysis of differentially 
expressed miRNAs has been found to be more informative than differentially 
expressed genes regarding the identification of affected pathways (238). This is 
because multiple miRNAs often target groups of genes within a pathway together, 
whereas analysis of gene expression is more likely to be confounded by genes 
exhibiting spurious or random dysregulation. 
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Future studies of miRNA in NAWM would benefit from including DNA methylation 
profiling to explore the relationship of miR-29b and differential methylation. 
Furthermore, as has been clearly demonstrated here and in other literature, the 
profile of individual cell subsets can be masked, and often contradicted, when 
observed amongst a heterogeneous cell population such as whole blood, or in this 
case NAWM. Unfortunately, in the samples used here, the quantity of material 
required to consider oligodendrocytes, astrocytes, etc. in isolation was not available. 
However, future studies should endeavour to isolate these cell types and profile them 
independently to provide a clearer picture of miRNA expression dynamics in the 
SPMS CNS. 
 
Conclusion 
This thesis demonstrates the convergence of several factors, led by changes in 
miRNA expression, to reduce activity of CD4+ T-cells in SPMS. Broad down-
regulation of miRNAs was identified in these cells, a novel observation in MS miRNA 
studies, caused by decreased expression of miRNA biogenesis molecules. This 
resulted in: up-regulation of SOCS6, negatively regulating T cell activation; and de 
novo hypermethylation driven by miR-29b-associated up-regulation of DNMT3b. 
Each of these findings points towards CD4+ T-cells having a diminished role in 
SPMS disease activity, and therefore are less responsive to current approved 
therapies. Additionally, analysis of miRNA expression in NAWM further demonstrates 
that this tissue is only “normal” in its appearance, and dysregulated miRNAs here 
may act to prevent oligodendrocyte maturation and thus hinder remyelination efforts. 
This suggests that neurodegenerative mechanisms are fully operational in NAWM 
during SPMS. In conclusion, we are closer to understanding the mechanisms of 
disease progression in MS; miRNA down-regulation prompts CD4+ T-cells to take a 
backseat in this disease stage, and neurodegeneration assisted by miRNA 
dysregulation, is primed to occur in normal appearing brain tissue. Consequently, 
future research on treatments should move away from immunosuppression, and 
focus more on remyelination in this stage of disease. 
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APPENDIX ONE 
 
The main text of Chapter Two was published in Clinical Epigenetics, in 2016 (DOI 
10.1186/s13148-016-0253-y). Clinical Epigenetics is an open access journal and all 
articles are distributed under the terms of the Creative Commons Attribution 4.0 
International License. (CC BY 4.0) This license permits unrestricted use, distribution 
and reproduction provided appropriate credit is attributed to authors. Full details of 
the licence can be found at http://creativecommons.org/licenses/by/4.0.  
The following pages contain the published format of the article, Next-generation 
sequencing reveals broad down-regulation of microRNAs in secondary progressive 
multiple sclerosis CD4+ T-cells.    
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Abstract
Background: Immunoactivation is less evident in secondary progressive MS (SPMS) compared to relapsing-remitting
disease. MicroRNA (miRNA) expression is integral to the regulation of gene expression; determining their impact on
immune-related cell functions, especially CD4+ T cells, during disease progression will advance our understanding of
MS pathophysiology. This study aimed to compare miRNA profiles of CD4+ T cells from SPMS patients to healthy
controls (HC) using whole miRNA transcriptome next-generation sequencing (NGS). Total RNA was extracted from CD4
+ T cells and miRNA expression patterns analyzed using Illumina-based small-RNA NGS in 12 SPMS and 12 HC samples.
Results were validated in a further cohort of 12 SPMS and 10 HC by reverse transcription quantitative polymerase chain
reaction (RT-qPCR).
Results: The ten most dysregulated miRNAs identified by NGS were selected for qPCR confirmation; five (miR-21-5p,
miR-26b-5p, miR-29b-3p, miR-142-3p, and miR-155-5p) were confirmed to be down-regulated in SPMS (p < 0.05). SOCS6
is targeted by eight of these ten miRNAs. Consistent with this, SOCS6 expression is up-regulated in SPMS CD4+ T cells
(p < 0.05). This is of particular interest as SOCS6 has previously been shown to act as a negative regulator of T cell
activation.
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  Background
Multiple sclerosis (MS) is an autoimmune disease char-
acterized by multifocal inflammatory attacks in the CNS
[1]. In the relapsing-remitting (RRMS) stage of the dis-
ease, CD4+ T cells are among the primary infiltrators
moving from the periphery, through the blood-brain
barrier, and into the CNS [2]. These cells then initiate an
immune response that results in localized demyelination
and corresponding symptoms. The later stage of MS,
secondary progressive (SPMS), is characterized by com-
pounding neurodegeneration and increasing disability;
however, the relevance of inflammation is unclear [3].
As key regulators of gene expression, microRNAs (miR-
NAs) may be affecting the immune-related functions of
CD4+ T cells in SPMS and may help to elucidate the ac-
tions of these cells in SPMS.
MiRNAs are short, non-coding RNA molecules
(~22 bp) that regulate gene expression at the posttran-
scriptional stage by targeting the 3′ untranslated region
of target genes. Their small size and stable structure
make them ideal biomarkers. In recent years, miRNA
expression patterns in MS have been the focus of nu-
merous studies, many of which have concentrated on
using miRNAs as biomarkers for diagnosis and progno-
sis [4]. These studies predominantly use easily acquired
(and often highly heterogeneous) samples such as whole
blood, peripheral blood mononuclear cells (PBMCs),
serum, and plasma. Numerous dysregulated miRNAs
have been identified, however which cell types are actu-
ally responsible for differing miRNA profiles, and the
consequences of altered miRNA expression is not clear
in many studies. Furthermore, it is likely that these het-
erogeneous samples are masking the signal of differen-
tially expressed miRNA in specific cell subtypes. To
overcome this, we have focused on CD4+ T cells in this
study on SPMS.
Next-generation sequencing (NGS) allows for stringent
examination of cell-specific miRNA expression profiles
as well as discovery of previously uncharacterized miR-
NAs. Here, we have used small-RNA NGS analysis of
CD4+ T cells from SPMS patients and healthy controls
(HC). The total coverage approach of NGS generates ex-
pression information on all small RNA species including
all known and novel miRNAs, as well as other small
RNA species (isomiRs and snoRNAs)—a clear advantage
over microarray and candidate approach assays. Three
previous studies in MS have used NGS to effectively
identify miRNA expression profiles in the whole blood
[5, 6], serum [6], and PBMCs [7] from RRMS patients.
However, NGS techniques have not been used for spe-
cific cell types or in SPMS samples.
The miRNA expression profile of CD4+ T cells, either
as instigating molecules or by-products of erroneous
molecular mechanisms, will provide insight into the
function of these cells in SPMS. Here, we used NGS to
provide a comprehensive analysis of the miRNA expres-
sion profiles of CD4+ T cells from SPMS patients and
healthy controls (HC) and confirmed these results using
targeted expression assays.
Methods
Sample collection
Whole blood was collected at a single study center from
an initial cohort of 12 SPMS patients and 12 HC and a
replication cohort of 12 SPMS and 10 HC. All patients
were diagnosed with SPMS according to the McDonald
criteria [8] and demonstrated EDSS progression without
evidence of relapse in the 24 months prior to collection.
Controls were age (±5 years) and gender matched
(Table 1). The SPMS patient group was free of MS-
specific treatments for a minimum period of 6 months
prior to collection. Samples were collected at the John
Hunter Hospital, and laboratory work was conducted at
the Hunter Medical Research Institute, Newcastle.
Blood sample processing
PBMCs were isolated from 45 mL of heparinized whole
blood by density gradient centrifugation on lymphoprep
(Axis-Shield PoC AS, Norway). CD4+ T cells were
enriched from the PBMCs using EasySep magnetic nega-
tive selection according to the manufacturer’s protocol
(StemCell Technologies, Canada). The purity of the CD4
Table 1 Details of SPMS and healthy control individuals
Next generation sequencing Replication cohort
SPMS HC SPMS HC
Number 12 12 12 10
Female 9 9 8 5
Age in years (mean ± SD) 60.2 ± 8.3 61.3 ± 9.5 61.4.0 ± 6.5 60.1 ± 5.9
EDSS (mean ± SD) 6.9 ± 0.9 NA 5.9 ± 1.0 NA
Active SPMS 3 NA 4 NA
Disease duration in years (mean ± SD) 25.6 ± 11.1 NA 18.3 ± 6.5 NA
Progression duration (mean ± SD) 10.8 ± 8.1 NA 8.9 ± 6.2 NA
EDSS expanded disability status scale, SD standard deviation, NA not applicable
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+ selection was assessed by flow cytometry using a
FITC-conjugated anti-CD4 antibody (anti-human CD4
antibody, clone OTK4, FITC, catalog# 60016FI, StemCell
Technologies, Canada) on a BD FACSCanto II flow cyt-
ometer and then analyzed using FACSDiva software (BD
Biosciences, USA) at the Analytical Biomolecular Re-
search Facility of the University of Newcastle. All sam-
ples met a minimum purity threshold of >90 %.
RNA isolation
Total RNA was isolated from the CD4+ T cells using the
miRNeasy Mini kit (Qiagen, USA) following the manu-
facturer’s instructions. The quality of the RNA was
assessed using the RNA 6000 Nano kit on a 2100 Bioa-
nalyzer (Agilent Technologies, USA); a RNA integrity
number greater than 8 was deemed suitable for sequen-
cing and reverse transcription quantitative polymerase
chain reaction (RT-qPCR). Purity was measured on an
Epoch spectrophotometer (BioTek, USA), and concen-
tration was measured using the high-sensitivity RNA kit
on Qubit 2.0 Fluorometer (Life Technologies, Thermo
Fisher Scientific, USA).
miRNA sequencing and analysis
A cohort of 12 SPMS and 12 HC samples was run
through NGS at the Diamantina Institute, University of
Queensland, Brisbane, Australia. Samples were individu-
ally barcoded and then sequenced in two multiplexed
pools each containing 12 samples. The sequencing li-
braries were prepared from 1-μg total RNA, using the
TruSeq small RNA preparation kit (Illumina, USA) and
sequenced using the 50-bp fragment protocol on the
HiSeq 2500 platform. The sequencing generated four to
nine million reads per sample, more than sufficient for
expression and discovery applications. The sample se-
quencing reads were demultiplexed using the CASAVA
1.8 software package (Illumina, USA). The Illumina
adapter sequences were trimmed from the fastq files
using Trimmomatic [9]. All reads were aligned and
counted against miRBase 21 [10].
RT-qPCR
Mature miRNA TaqMan assays (Applied Biosystems,
Thermo Fisher Scientific, USA) were used to determine
expression of the ten most differentially expressed miR-
NAs in the initial NGS cohort as well as a replication
cohort of 12 SPMS and 10 HC (assay IDs in miRNA nu-
merical order: 000397, 000399, 000407, 000408, 000409,
000413, 002223, 000464, 002623, 000524). The small
RNA RNU44 (ref: 001094) was used as an endogenous
control. RNU44 has previously been demonstrated to be
a stable control in CD4+ T cells [11], and its stability has
been shown in our 47 samples (mean ± standard devi-
ation Ct value of 23.58 ± 0.63). RNU44 was used for
normalization using the ΔCt method. The relative ex-
pression (2−ΔCt) of all samples (24 SPMS and 22 HC)
was calculated.
Statistical analysis
The two-sample Kolmogorov-Smirnov test (K-S test)
was used to test whether differences in expression levels
were statistically significant between the case and con-
trol groups as implemented in R. The K-S test was
chosen (over the F test comparison of means) because of
the non-normality of the expression level distributions
among miRNAs. Our statistical significance threshold
allowing for multiple testing correction was determined
using the False Discovery Rate (FDR) procedure of
Benjamini-Hochberg [12]. Based on the number of
miRNA elements, this threshold was set at 1.2 × 10−4.
We also considered a relaxed (or nominal) significance
threshold of 0.05. In addition to using statistical signifi-
cance thresholds for miRNA selection, we also included
a count threshold of >800 to exclude miRNAs that had
very low expression levels and were unlikely to be repli-
cated with the less-sensitive RT-qPCR. The K-S test was
also used to determine significant differential miRNA
and SOCS6 expression from the RT-qPCR relative ex-
pression data.
Correlation to patient characteristics
The Pearson correlation coefficient was calculated
using RT-qPCR data for MS samples (n = 24) and pa-
tient characteristics: EDSS, age, disease duration, and
progression duration. A correlation coefficient (r value)
>±0.5 was considered strong, ±0.3–0.49 moderate, and
<±0.29 weak.
Gene target prediction
miRSystem integrates seven different target gene predic-
tion algorithms and contains experimentally validated
data on miRNA:mRNA interactions [13]. This integra-
tion system was used to identify genes that may be tar-
geted by more than one of our identified dysregulated
miRNAs.
Analysis of SOCS6 expression
Five hundred nanograms of total RNA was reverse tran-
scribed using high-capacity cDNA reverse transcription
kits (Applied Biosystems, Thermo Fisher Scientific,
USA) in 21 SPMS and 21 HC samples. qPCR was per-
formed using an exon-spanning TaqMan probe for
SOCS6 (ref: Hs00377781_m1). Expression of SOCS6 was
determined as relative expression to the housekeeping
genes GAPDH (ref: 4326317E) and β-actin (ref:
4326215E) using a ViiA 7 (Applied Biosystems, Thermo
Fisher Scientific, USA).
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Results
We used NGS to establish miRNA expression profiles in
CD4+ T cells from a cohort of 12 SPMS and 12 HC
samples. RT-qPCR was then employed to validate differ-
ences in miRNA expression in the NGS cohort as well
as a replication cohort of 12 SPMS and 10 HC samples
(total 24 SPMS and 22 HC).
NGS
We observed three statistically significant miRNAs
(miR-451a, miR-1246, and miR-144-5p) at the FDR-
corrected threshold (Additional file 1: Figure S1), which
probably reflects the modest sample size. These miRNAs
were very lowly expressed (<100 reads per sample), and
we were unable to confirm this dysregulation with RT-
qPCR. We also observed 42 miRNAs at the nominal
significance threshold (97 % of these were down-
regulated). Of these 42 miRNAs, only 10 met our sec-
ondary criteria of having a read count >800: miR-21-5p
(p = 0.031), miR-23a-3p (p = 0.007), miR-26b-5p (p =
0.031), miR-27a-3p (p = 0.031), miR-27b-3p (p = 0.031),
miR-29b-3p (p = 0.007), miR-30e-5p (p = 0.031), miR-
142-3p (p = 0.031), miR-155-5p (p = 0.031), and miR-
221-3p (p = 0.031). Each of these miRNAs was found to
be down-regulated in SPMS as summarized in Fig. 1 and
was forwarded for replication testing in an independent
cohort.
RT-qPCR
To confirm our NGS findings, the top ten most dysregu-
lated miRNAs were selected for further analysis in 24
SPMS and 22 HC samples using RT-qPCR (including
the 12 SPMS and 12 HC samples that underwent NGS
analysis). Of these ten miRNAs, RT-qPCR confirmed
significant down-regulation of miR-21-5p (p = 0.0048),
miR-26b-5p (p = 0.007) miR-29b-3p (p = 0.00001), miR-
142-3p (p = 0.05), and miR-155-5p (p = 0.001) in SPMS
CD4+ T cells (Fig. 2). These five miRNAs were
confirmed in the original NGS cohort, the replication
cohort, and the combined cohort. This provides statisti-
cally significant evidence of replication, indicating that
these five miRNAs are very unlikely to be false positives.
A trend of down-regulation of miRNA in SPMS samples
was still observed across all ten miRNAs.
Comparison of methods
Concordance of differential expression can vary between
quantitation methods [14]. To determine the magnitude
of fold-change in SPMS vs. HC, we compared RT-qPCR
and NGS results and found no change in the degree of
decreased expression between NGS and RT-qPCR
methods in the miRNAs confirmed by RT-qPCR (Fig. 3).
Correlation to patient characteristics
No strong correlations between miRNA expression and
patient characteristics were identified (Table 2). How-
ever, moderate positive correlation between EDSS and
miR-21-5p, miR-26b-5p, and miR-29b-3p was seen. Fur-
ther positive correlation was also found between disease
duration and miR-21-5p and miR-155-5p. All miRNAs
demonstrated weak correlation to patient age and pro-
gression duration.
Correlation of miRNA expression and age of HC has
also been calculated as a reference point for age of pa-
tients. Moderate correlations are in bold text.
Target prediction
miRNA fold-change was <2 for all miRNAs. It is there-
fore unlikely that any one particular miRNA is causing a
significant effect on gene expression alone. It is more
likely to be a combination of multiple miRNAs targeting
a few specific genes. Furthermore, as RT-qPCR is a less-
sensitive methodology than NGS, and the trend of
down-regulation is still observed (though not significant)
in the other miRNAs, all ten miRNAs were cross-
analyzed for potential gene targets. miRSystem was used
Fig. 1 Tukey boxplot demonstrating the ten most significantly dysregulated microRNAs identified using NGS. Data is presented as log10 of the
read count and clearly exhibits the down-regulation of miRNAs in SPMS (purple) compared to HC (gray). Whiskers represent data within 1.5
interquartile range (IQR) of the upper and lower quartile. Data points outside of the 1.5 IQR are represented by black dots. *p < 0.05, **p < 0.01
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to identify genes that have multiple target genes in com-
mon, both in the five confirmed miRNAs and all ten
miRNAs identified by NGS. One gene, bromodomain
and WD repeat domain containing 1 (BRWD1), is tar-
geted by all five confirmed miRNAs. No genes are tar-
geted by all ten miRNAs; however, eight genes are
targeted by eight of the miRNAs (Table 3).
These genes are involved in transmembrane ligand
binding, regulation of actin filaments, or are transcrip-
tion factors. However, only one gene is specifically linked
to immune cell function, SOCS6 (suppressor of cytokine
signaling 6). This gene has previously been reported to
negatively regulate T cell activation by promoting
ubiquitin-dependent proteolysis [15] and was conse-
quently selected for further investigated.
SOCS6 expression
Gene expression analysis using RT-qPCR was conducted
to determine whether SOCS6 is up-regulated in SPMS
CD4+ T cells in direct negative correlation to the
miRNA expression (Fig. 4). Both the preliminary and
validation cohorts were analyzed, and SOCS6 expression
is increased in SPMS compared to HC. Normalization
against GAPDH and β-actin generated the same results
(data for β-actin not shown).
Discussion
This is the first study in MS to utilize NGS for miRNA
expression profiling in the CD4+ T cells of SPMS pa-
tients. We found 42 miRNAs that are dysregulated in
the CD4+ T cells of SPMS patients as compared to con-
trols: 97 % of which were down-regulated. TaqMan as-
says confirmed five of these miRNAs (miR-21-5p, miR-
26b-5p, miR-29b-3p, miR-142-3p, and miR-155-5p) to
be down-regulated in SPMS. Each of these miRNAs (ex-
cluding miR-26b) has been reported on previously in
MS though not necessarily in SPMS or CD4+ T cells.
Lindberg et al. [11] identified seven miRNAs dysregu-
lated in CD4+ T cells from RRMS patients but did not
identify dysregulation in any of the five miRNA in this
study. Thus, down-regulation of these miRNAs may be
exclusive to SPMS.
Here, we report a decrease in miR-155-5p expression
in MS. miR-155-5p has a pro-inflammatory role in MS
and is up-regulated in a number of tissues. Studies of
postmortem brain tissue find a gradient of miR-155-5p
expression that peaks in active lesions [16] and associ-
ated neurovascular units [17] and decreases through
chronic lesions and normal appearing white matter to a
low baseline in healthy control (non-MS) white matter
[17, 18]. This increased expression of miR-155 has been
associated with the suppression of CD47 in active lesions
that creates a permissive environment for myelin phago-
cytosis [16]; focal adhesion and cell-cell complex mole-
cules in the blood-brain barrier, thus increasing
permeability [17] and; AKR1C1 and AKR1C2, essential
for biosynthesis of allopregnanolone (a neuroprotective
steroid) [18].
Interestingly, a study of miR-155 in the EAE mouse
model found that miR-155 expression in CD4+ T cells
Fig. 2 Tukey boxplot of top ten miRNAs expression (relative to RNU44) using RT-qPCR. Significant down-regulation of miR-21-5p, miR-26b-3p,
miR-29b-3p, miR-142-3p, and miR-155-5p in SPMS was confirmed. Whiskers represent data within 1.5 interquartile range (IQR) of the upper and
lower quartile. Data points outside of the 1.5 IQR are represented by black dots. p < 0.05, **p < 0.01, ***p < 0.001
Fig. 3 Comparison of miRNA fold-change between NGS and RT-qPCR.
Magnitude of change is consistent between NGS and RT-qPCR
methods
Sanders et al. Clinical Epigenetics  (2016) 8:87 Page 5 of 8
  
 
 
  
increases during EAE and that miR-155−/− mice had an
attenuation of EAE [19]. Specifically, Th17 cells lacking
miR-155-5p are unable to cause EAE [20]. miR-155-5p is
required for normal immune function [21], and together,
these studies confirm that the significant role miR-155-
5p over-expression plays in the inflammatory process of
MS. In contrast, our finding of miR-155-5p down-
regulation may be exclusive to SPMS patients and/or
CD4+ T cells and is consistent with SPMS as a non-
inflammatory mediated disease.
miR-155-5p and miR-142-3p have been identified as
dysregulated in RRMS PBMCs [22], and a recent study
on autologous hematopoietic stem cell transplant
(AHSCT) also found co-dysregulation of miR-155-5p
and miR-142-3p [23]. Contrary to our results, Arruda
et al. found these miRNAs to be up-regulated in MS pa-
tient CD4+ T cells before treatment (cohort was 75 %
SPMS). However, AHSCT is most effective in active MS
disease, and six of the 19 SPMS patients enrolled in the
Arruda et al. study presented with gadolinium-
enhancing lesions in the year approaching the treatment
indicating inflammatory activity. Further, the average
disease duration in the Arruda et al. study was 8.1 years,
as opposed to 25.6 (primary cohort) or 18.6 (replication
cohort) years in our study. Our data is corroborated fur-
ther by NGS expression analysis, which is a more sensi-
tive measure of expression changes.
In a study of potential biomarkers in Alzheimer’s
disease (AD), miR-26b-5p was shown to be down-
regulated in the serum and CSF of AD patients when
compared to patients with inflammatory neurological dis-
eases [24], supporting the predominantly neurodegenera-
tive pathology of SPMS. Over-expression of miR-29b
insystemic lupus erythematosus (SLE) has been linked
to hypomethylation of DNA in CD4+ T cells [25].
While there are currently no studies on DNA methyla-
tion in SPMS, it would be interesting to see if the
down-regulation of miR-29b that we have identified
here in CD4+ T cells is associated with genome-wide
hypermethylation in SPMS.
Increased miR-21-5p promotes differentiation of Th17
cells in the EAE mouse model, and miR-21-5p knock-
out mice are resistant to EAE [26]. Fenoglio et al. found
increased miR-21-5p expression in RRMS (active relapse
phase) PMBCs compared to controls, though no differ-
ence in SPMS. Again, this may be attributed to the rela-
tively small sample size (n = 6) [27].
Also of interest, we previously reported miR-20a-5p
down-regulation in the whole blood of all MS sub-
types [28]. This miRNA was one of the 42 dysregu-
lated miRNAs identified by NGS and is significantly
down-regulated in SPMS compared to HC. However,
it narrowly missed the 800 read cut-off for qPCR
confirmation. miR-20a-5p is also predicted to target
SOCS6.
Eight of the top ten dysregulated miRNAs were pre-
dicted to target SOCS6 using MirSystem. Consistent
with this, increased expression of SOCS6 in the SPMS
cohort is in direct negative correlation with the miRNA
expression profiles, strongly indicating a mRNA:miRNA
Table 2 Correlation coefficients calculated from RT-qPCR data against patient characteristics
miR-21-5p miR-26b-5p miR-29b-3p miR-142-3p miR-155-5p
EDSS 0.34 0.42 0.41 0.28 0.26
Age (HC) 0.22 0.17 0.31 0.21 −0.08
Age (SPMS) −0.07 −0.17 −0.17 −0.30 −0.01
Disease duration 0.49 0.15 0.23 −0.08 0.49
Progression duration 0.12 0.12 0.11 −0.07 0.17
Table 3 Genes identified by miRSystem targeted by eight of the ten microRNAs
miR-21-5p miR-23a-3p miR-26b-5p miR-27a-3p miR-27b-3p miR-29b-3p miR-30e-5p miR-142-3p miR-155-5p miR-221-3p
ACVR2B V V V V V V V V
ZBTB41 V V V V V V V V
BRWD1 V V V V V V V V
CAMTA1 V V V V V V V V
CFL2 V V V V V V V V
SOCS6 V V V V V V V V
MIER3 V V V V V V V V
KLF12 V V V V V V V V
Verified targeting miRNAs are identified with a “V”
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relationship. To our knowledge, this is the first study to
identify SOCS6 as a gene of interest in MS. It is a highly
conserved gene with very low expression levels in
healthy thymus and brain tissues and is down-regulated
in gastric, colorectal, and pancreatic cancers [29–32]. In
colorectal cancer, methylation changes have been ruled
out as the mechanism of down-regulation [31]; there-
fore, down-regulation may be due to altered miRNA
expression. MiR-424-5p is responsible for the down-
regulation of SOCS6 in pancreatic cancer [32]; however,
we found no differences in miR-424-5p expression be-
tween SPMS and HC in this study.
The function of SOCS6 as a negative regulator of T
cell activation [15] and its observed over-expression in
SPMS CD4+ T cells supports the notion of reduced im-
mune activity in SPMS. Very little is known about
SOCS6, and more studies are required to determine if it
may be a novel therapeutic target.
This is the first study to use NGS miRNA profiling to
assess miRNA expression in the CD4+ T cells of SPMS
patients. Future studies should focus on using the same
technique in treatment naïve RRMS patients to deter-
mine if this is a SPMS exclusive trend and remove the
confounding factor of treatment effects. Furthermore,
miRNA expression profiles of other cell subtypes should
be investigated, as whole blood analysis is likely masking
significant changes in individual cell subsets. Ideally, all
of our patients would have had inactive SPMS; however,
as SPMS is a difficult disease stage to define and collect,
we have included some active SPMS patients in this study.
In this study, we chose to focus on CD4+ T cells as they
are thought to be the main cell infiltrates. Our previous
studies also show that CD4+ T cells exhibit significant
changes in methylation profiles in RRMS [33, 34].
Conclusions
Here, we have shown a general down-regulation of miR-
NAs in CD4+ T cells compared to HC, with five miR-
NAs confirmed as significant in two independent assays.
This indicates that miRNA expression may be over-
normalizing in SPMS CD4+ T cells. SOCS6 is a pre-
dicted target of the majority of these miRNAs and, con-
sistent with this, we found SOCS6 to be up-regulated in
this cohort. These are novel findings that point towards
a diminished role for CD4+ T cells in SPMS and add fur-
ther evidence for SPMS being a neurodegenerative dis-
ease stage, not an inflammation-driven one.
Additional file
Additional file 1: Figure S1. Volcano plot of differentially expressed
miRNAs identified with NGS. The FDR-corrected significance threshold is
demarked with a green line at p < 1.2 × 10−4. Three miRNAs were identified
at the threshold. Mean read counts were low in all three miRNAs: miR-451a
(SPMS mean = 76.3, HC mean = 18.9), miR-1246 (SPMS mean = 94.9, HC
mean = 51.9), and miR-144-5p (SPMS mean = 15.1, HC mean = 5.5).
Differential expression could not be replicated with RT-qPCR. (PNG 57 kb)
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APPENDIX TWO 
 
In Chapter Two, the decision was made to validate miRNAs that had a NGS read 
count of >800 with RT-qPCR. In this appendix, I will present the initial data that was 
used to set this threshold. 
 
Identification of differentially expressed miRNAs with NGS 
The statistical significance threshold allowing for multiple testing correction was 
determined using the False Discovery Rate (FDR) procedure of Benjamini-Hochberg 
(185).  Based on the number of miRNA elements, this threshold was set at 1.2´10-4. 
As can be seen in Figure A2.1, only three miRNAs were found to meet this threshold. 
Therefore, a relaxed significance threshold of 0.05 was also considered.  
  
Figure A2.1: Volcano plot of differentially expressed miRNAs identified with NGS. The 
significance threshold is demarked with a green line at p<1.2x10-4. 
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The top five identified by NGS (Figure A2.2) were selected for validation with RT-
qPCR. 
 
Figure A2.2: Five most dysregulated miRNAs identified in SPMS by NGS (with 
standard error bars). Box plot showing the distribution of read counts across the 
miRNAs. The outlier at miR-182-5p is 746 reads. * p<0.05, ** p<0.01, *** p<0.001. 
 
RT-qPCR validation 
At the time of validation, there was no TaqMan probe for miR-1246 on the market. 
The two remaining miRNAs below the threshold, miR-451a and miR-144-5p, were 
validated with RT-qPCR, as well as a further three miRNAs with significant (Table 
A2.1).  
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Table A2.1: Significantly different miRNAs, mean NGS read count, and TaqMan ID. 
miRNA P value SPMS mean HC mean Assay ID 
miR-451a 1.19E-07	 76.3 18.9 001141 
miR-144-5p 0.00011	 15.1 5.5 002148 
miR-222-5p 0.00033	 9.7 3.2 002097 
miR-3609 0.00111	 73.0 59.1 466233_mat 
miR-182-5p 0.00143	 190.6 103.1 002334 
 
Each miRNA was analysed with RT-qPCR in 11 SPMS and 12 HC samples (the RNA 
from one of the SPMS samples was exhausted by NGS analysis). miR-451a was the 
only miRNA to replicate the significant difference observed by NGS (Figure A2.3).  
 
 
Figure A2.3: RT-qPCR results of the five most dysregulated miRNAs identified by 
NGS. Expression relative to RNU44. Only miR-451a is significantly different. ** 
p<0.01. 
 
A further cohort of 12 SPMS and 10 HC was collected to determine if the results of 
miR-451a dysregulation in the CD4+ T-cells of SPMS could be replicated. The 
outcome was p=0.002, however, the direction of change was reversed (data not 
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shown). When both cohorts were combined, SPMS was still shown to be up-
regulated, however without significance. 
This result highlights the volatility of differential expression in targets that are 
expressed at low quantities. NGS is a more sensitive technique than RT-qPCR, 
however to confirm results, expression of miRNAs must be high enough for accurate 
detection by RT-qPCR (186). In this study (Chapter Two), we set a read count 
threshold of >800 reads to increase the likelihood of confirming dysregulated 
miRNAs; half of our selected miRNAs were verified subsequently verifed. This is a 
substantial improvement on our initial miRNA selection shown in this appendix.  
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APPENDIX THREE 
 
Additional data tables for Chapter Three, listing all sites of differential methylation in 
RRMS and SPMS samples.
 Table A3.1: All differentially methylated RRMS probes 
Probe	ID	 Chr	 Position	 Gene	 Median	(case)	 Median	
(control)	
Δmeth	 Adj	P	value	 P	FDR	 Feature	
cg22802014	 1	 31732891	 SNRNP40	 0.675691	 0.9025544	 0.226863	 0.00043379	 0.01349928	 3'UTR	
cg13232075	 1	 204556835	 	 0.42867	 0.2158971	 0.212773	 0.016589302	 0.02925311	 	
cg26354017	 1	 205819088	 PM20D1	 0.598945	 0.410684	 0.188261	 0.01409406	 0.02788393	 1stExon	
cg17178900	 1	 205818956	 PM20D1	 0.646248	 0.4698254	 0.176423	 0.013796407	 0.0276007	 Body	
cg14159672	 1	 205819179	 PM20D1	 0.616326	 0.4436191	 0.172707	 0.017227167	 0.02991532	 1stExon	
cg14893161	 1	 205819251	 PM20D1	 0.497891	 0.3284282	 0.169463	 0.008958083	 0.02385308	 5'UTR;1stExon	
cg10759817	 1	 92101219	 HSP90B3P	 0.746079	 0.5770942	 0.168985	 0.000691305	 0.01349928	 Body	
cg11965913	 1	 205819406	 PM20D1	 0.466796	 0.3025438	 0.164252	 0.024620965	 0.03518624	 TSS200	
cg24503407	 1	 205819492	 PM20D1	 0.560205	 0.4035858	 0.156619	 0.014934774	 0.02888959	 TSS1500	
cg15600437	 1	 17309539	 MFAP2	 0.584121	 0.7395363	 0.155416	 0.049651594	 0.0498328	 TSS1500	
cg03526459	 1	 146549940	 	 0.334275	 0.488696	 0.154421	 0.029448057	 0.03893373	 	
cg11733135	 1	 81878937	 	 0.691877	 0.8432839	 0.151407	 0.034438784	 0.04266066	 	
cg26824678	 1	 19777949	 CAPZB	 0.723739	 0.5762676	 0.147471	 0.042979316	 0.04616919	 Body	
cg24853868	 1	 146555624	 	 0.33628	 0.4827652	 0.146485	 0.012223783	 0.02733567	 	
cg16060930	 1	 117487269	 PTGFRN	 0.794897	 0.6562882	 0.138609	 0.021352909	 0.03299767	 Body	
cg02487331	 1	 146550467	 	 0.337817	 0.4739996	 0.136182	 0.04962751	 0.0498328	 	
cg09226051	 1	 247611502	 NLRP3	 0.513351	 0.6480892	 0.134739	 0.000627387	 0.01349928	 Body	
cg09476440	 1	 109693377	 KIAA1324	 0.723577	 0.5908203	 0.132757	 0.045201623	 0.04762623	 Body	
cg26034147	 1	 40359924	 	 0.907444	 0.7772675	 0.130177	 0.021506643	 0.03304093	 	
cg13064658	 1	 212003989	 LPGAT1	 0.146288	 0.2734523	 0.127164	 0.047417682	 0.0486562	 5'UTR;1stExon	
ch.1.230734885R	 1	 232668262	 	 0.229938	 0.1045985	 0.125339	 0.004810853	 0.0184486	 	
cg03954786	 1	 156218113	 PAQR6	 0.623975	 0.5069909	 0.116984	 0.029728269	 0.03911614	 TSS1500	
cg11680857	 1	 152635200	 LCE2D	 0.678225	 0.7931205	 0.114896	 0.030685671	 0.03966728	 TSS1500	
cg01533966	 1	 90363165	 LRRC8D	 0.617605	 0.7303915	 0.112787	 0.016187833	 0.02909578	 5'UTR	
cg23961843	 1	 183623675	 RGL1;APOBEC4	 0.555658	 0.6674704	 0.111813	 0.005133492	 0.0184486	 5'UTR;TSS1500	
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cg05750824	 1	 64786354	 	 0.625354	 0.5136841	 0.11167	 0.003900629	 0.0184486	 	
cg11734019	 1	 156258991	 TMEM79	 0.827758	 0.9369172	 0.109159	 0.005435173	 0.0184486	 Body	
cg03847896	 1	 112154295	 	 0.725538	 0.8346475	 0.109109	 0.002473373	 0.01729845	 	
cg03737629	 1	 78343253	 FAM73A	 0.70336	 0.8081955	 0.104835	 0.019325419	 0.03126171	 3'UTR	
cg13111532	 1	 1886543	 KIAA1751	 0.700034	 0.5955732	 0.104461	 0.005148969	 0.0184486	 3'UTR	
cg00124902	 1	 34645109	 C1orf94	 0.307761	 0.4121305	 0.10437	 0.009282805	 0.02385308	 Body;5'UTR	
cg24928141	 1	 92154087	 TGFBR3	 0.822321	 0.9265897	 0.104268	 0.026602678	 0.03657868	 Body	
cg22729008	 1	 245581518	 KIF26B	 0.608356	 0.7122467	 0.103891	 0.001076896	 0.01349928	 Body	
cg15602298	 1	 157670825	 FCRL3	 0.688728	 0.7905508	 0.101822	 0.02415317	 0.03495854	 TSS200	
cg07844442	 10	 129144269	 DOCK1	 0.465688	 0.728887	 0.263199	 0.013719484	 0.0276007	 Body	
cg20374173	 10	 14227415	 FRMD4A	 0.339618	 0.5876724	 0.248054	 0.00192587	 0.01576607	 Body	
cg14368220	 10	 88024553	 MIR346;GRID1	 0.523063	 0.3444181	 0.178645	 0.012888037	 0.0276007	 TSS200;Body	
cg05818501	 10	 1451648	 ADARB2	 0.624073	 0.4863054	 0.137767	 0.013779848	 0.0276007	 Body	
cg07506153	 10	 131665884	 EBF3	 0.849761	 0.7262866	 0.123475	 0.045389875	 0.04764205	 Body	
cg17686260	 10	 131412764	 MGMT	 0.736152	 0.8591174	 0.122965	 0.045677968	 0.04776213	 Body	
cg16871435	 10	 65682643	 	 0.571437	 0.4509912	 0.120446	 0.048720828	 0.0495028	 	
ch.10.6667087F	 10	 6627081	 	 0.201843	 0.0856604	 0.116183	 0.016102692	 0.02909578	 	
cg11963436	 10	 93567261	 TNKS2	 0.421508	 0.5361234	 0.114615	 0.023574769	 0.03448437	 Body	
cg06749524	 10	 111152929	 	 0.636387	 0.5255409	 0.110846	 0.039532404	 0.04526519	 	
cg16255663	 10	 131350999	 MGMT	 0.786541	 0.8955565	 0.109016	 0.031567164	 0.04027247	 Body	
cg08822897	 11	 64258103	 	 0.284157	 0.5330633	 0.248906	 0.000366993	 0.01349928	 	
cg08912652	 11	 130779479	 SNX19	 0.851534	 0.6035999	 0.247934	 0.003191097	 0.01755103	 Body	
cg10415021	 11	 110890228	 	 0.486528	 0.7315048	 0.244976	 0.003190267	 0.01755103	 	
cg16999994	 11	 1001560	 AP2A2	 0.453497	 0.2389582	 0.214539	 0.015443339	 0.02909578	 Body	
cg27049594	 11	 124439146	 OR8A1	 0.702716	 0.5144453	 0.18827	 0.00888529	 0.02385308	 TSS1500	
cg10528424	 11	 1858572	 SYT8	 0.515347	 0.683099	 0.167752	 0.037348548	 0.04427091	 Body	
cg08849813	 11	 17825098	 SERGEF	 0.818926	 0.6647311	 0.154195	 0.040697202	 0.04535861	 Body	
cg26155681	 11	 20384377	 HTATIP2	 0.204587	 0.076961	 0.127626	 0.011812851	 0.02730792	 TSS1500	
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cg11820026	 11	 117696743	 FXYD2	 0.466212	 0.5827476	 0.116535	 0.033705763	 0.0421322	 Body;TSS1500	
cg10470368	 11	 64146517	 	 0.713807	 0.8274771	 0.11367	 0.047249041	 0.0486562	 	
cg09233619	 11	 23421870	 	 0.79124	 0.6833519	 0.107888	 0.04818827	 0.0492631	 	
ch.11.96117892F	 11	 96612684	 	 0.171835	 0.0690581	 0.102777	 0.009319399	 0.02385308	 	
cg05279513	 11	 9880619	 SBF2	 0.368282	 0.2664416	 0.101841	 0.013784607	 0.0276007	 Body	
cg23432430	 12	 125538377	 	 0.688214	 0.885203	 0.196989	 0.003950116	 0.0184486	 	
cg08922148	 12	 120156140	 CIT	 0.946986	 0.7632092	 0.183777	 0.005242721	 0.0184486	 Body	
cg19353052	 12	 113516445	 DTX1	 0.717358	 0.5367952	 0.180563	 0.016056516	 0.02909578	 Body	
cg05929129	 12	 132698423	 GALNT9	 0.637537	 0.8180473	 0.18051	 0.040151024	 0.04535861	 Body	
cg22543924	 12	 9065171	 	 0.748225	 0.567864	 0.180361	 0.039662413	 0.04526519	 	
cg16749614	 12	 43203955	 	 0.363636	 0.5267235	 0.163087	 0.005081544	 0.0184486	 	
cg26864661	 12	 76661181	 	 0.329825	 0.1789349	 0.15089	 0.024519194	 0.03518624	 	
cg18675623	 12	 108165306	 	 0.774635	 0.9189088	 0.144274	 0.007974389	 0.02317632	 	
cg12050434	 12	 43030949	 	 0.478141	 0.5882205	 0.11008	 0.025451687	 0.03571028	 	
cg15876417	 12	 40014132	 ABCD2	 0.311083	 0.2104378	 0.100646	 0.006819605	 0.02155622	 TSS1500	
cg20536971	 13	 100989375	 PCCA	 0.639244	 0.3457767	 0.293467	 0.00178004	 0.01576607	 Body	
cg12195446	 13	 110424497	 IRS2	 0.602628	 0.7640382	 0.16141	 0.044592222	 0.04730496	 Body	
cg16151959	 13	 42704154	 DGKH	 0.597791	 0.7570254	 0.159234	 0.031941558	 0.04047893	 Body	
cg23209353	 13	 21728944	 SKA3	 0.748578	 0.9055555	 0.156977	 0.007335443	 0.02216755	 3'UTR	
cg00587941	 13	 114741241	 	 0.775566	 0.9197742	 0.144208	 0.042582922	 0.04616919	 	
cg05918715	 13	 26622819	 SHISA2	 0.624138	 0.4839725	 0.140166	 0.036421154	 0.04335852	 Body	
cg21117559	 13	 33750464	 STARD13	 0.598822	 0.7271982	 0.128377	 0.001312928	 0.01349928	 5'UTR;Body	
cg08861434	 13	 112062652	 	 0.811541	 0.6949501	 0.116591	 0.038072259	 0.04475967	 	
cg17602481	 13	 114890515	 RASA3	 0.425003	 0.5350984	 0.110095	 0.022587514	 0.03357603	 Body	
cg24492140	 13	 34392781	 RFC3	 0.347627	 0.2429989	 0.104628	 0.013036336	 0.0276007	 Body	
ch.13.80513820F	 13	 81615819	 	 0.231031	 0.1267289	 0.104302	 0.00708215	 0.02173612	 	
ch.13.721274R	 13	 51955414	 INTS6	 0.183218	 0.083083	 0.100135	 0.005568123	 0.0184486	 Body	
cg16706502	 14	 31927974	 C14orf126	 0.597671	 0.3677487	 0.229923	 0.008531065	 0.02385308	 TSS1500	
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cg23489384	 14	 21199099	 	 0.431048	 0.6273493	 0.196302	 0.027078348	 0.03704749	 	
cg19555075	 14	 96038687	 	 0.486176	 0.646259	 0.160083	 0.035452879	 0.04313957	 	
cg09849871	 14	 90794949	 C14orf102	 0.590174	 0.7229734	 0.1328	 0.044724688	 0.04730496	 5'UTR;Body	
cg05057827	 14	 98670848	 	 0.535752	 0.6684415	 0.132689	 0.01828521	 0.03029176	 	
cg21123519	 14	 69095679	 	 0.528684	 0.3981703	 0.130513	 0.001257521	 0.01349928	 	
cg26419287	 14	 52482697	 NID2	 0.81378	 0.6968667	 0.116913	 0.028720062	 0.03852691	 Body	
cg02299497	 14	 69095570	 	 0.512602	 0.3987508	 0.113851	 0.002516138	 0.01729845	 	
cg15874048	 14	 45369753	 C14orf28	 0.776834	 0.8838401	 0.107007	 0.008090642	 0.02317632	 Body	
cg10193711	 14	 22917797	 	 0.286659	 0.1811468	 0.105512	 0.041879099	 0.04606701	 	
cg22688471	 15	 79788143	 	 0.434047	 0.6017523	 0.167706	 0.000441644	 0.01349928	 	
cg26261358	 15	 24043142	 	 0.439735	 0.303435	 0.1363	 0.042666802	 0.04616919	 	
cg18258571	 15	 31589348	 	 0.796013	 0.6773533	 0.11866	 0.007679102	 0.02270702	 	
cg16580742	 15	 81491460	 IL16	 0.660663	 0.7639649	 0.103302	 0.015903548	 0.02909578	 5'UTR	
cg22724998	 15	 60288082	 	 0.730351	 0.628135	 0.102216	 0.006922507	 0.02163283	 	
cg27370471	 15	 101932559	 PCSK6	 0.341079	 0.2390524	 0.102027	 0.0122265	 0.02733567	 Body	
cg06052372	 16	 83967808	 	 0.550688	 0.7668728	 0.216185	 0.012048532	 0.02733567	 	
cg08136432	 16	 88902276	 GALNS	 0.645258	 0.857102	 0.211844	 0.015854896	 0.02909578	 Body	
cg06520095	 16	 66458043	 	 0.461162	 0.6356145	 0.174452	 0.013384386	 0.0276007	 	
cg03940883	 16	 14380714	 	 0.522861	 0.3633758	 0.159485	 0.027537276	 0.03730419	 	
cg04963199	 16	 87868947	 SLC7A5	 0.76144	 0.6093043	 0.152135	 0.044041231	 0.04711273	 Body	
cg09351263	 16	 85864047	 	 0.358325	 0.20894	 0.149385	 0.030472362	 0.03966728	 	
cg08072101	 16	 7855274	 	 0.577858	 0.699078	 0.12122	 0.013091957	 0.0276007	 	
cg03444934	 16	 83171314	 CDH13	 0.637991	 0.5213834	 0.116607	 0.021667375	 0.03310293	 Body	
cg26764761	 16	 87682142	 JPH3	 0.822179	 0.7076038	 0.114575	 0.039668768	 0.04526519	 Body	
cg05248234	 17	 79495519	 FSCN2	 0.261872	 0.4925312	 0.230659	 0.015892741	 0.02909578	 1stExon;5'UTR	
cg26536949	 17	 57053	 	 0.599729	 0.7673243	 0.167595	 0.022438678	 0.03353607	 	
cg17225604	 17	 22193895	 	 0.626322	 0.7815582	 0.155236	 0.04718926	 0.0486562	 	
cg15189015	 17	 72707255	 RAB37;CD300LF	 0.311868	 0.190029	 0.121839	 0.00644531	 0.02061	 Body	
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cg01978703	 17	 973713	 ABR	 0.639712	 0.7612032	 0.121491	 0.035058278	 0.0430403	 Body	
cg07073561	 17	 79615824	 	 0.419376	 0.304418	 0.114958	 0.030724114	 0.03966728	 	
cg21997403	 17	 80436296	 NARF	 0.794696	 0.9057571	 0.111061	 0.018113968	 0.03018995	 Body	
cg00348031	 18	 77236278	 NFATC1	 0.575922	 0.7665373	 0.190615	 0.031487177	 0.04027247	 Body	
cg21848624	 18	 77219388	 NFATC1	 0.700386	 0.8837675	 0.183382	 0.011916185	 0.02730792	 Body	
cg02100397	 19	 646890	 	 0.446869	 0.6480127	 0.201144	 0.009409183	 0.02385308	 	
cg06688803	 19	 45457306	 CLPTM1	 0.595637	 0.7879626	 0.192326	 0.025131932	 0.03544247	 TSS1500	
cg18624102	 19	 39523840	 FBXO27	 0.594034	 0.4025173	 0.191516	 0.013778059	 0.0276007	 TSS1500	
cg02872767	 19	 1525453	 PLK5P	 0.67122	 0.8520397	 0.18082	 0.018108722	 0.03018995	 Body	
cg06684911	 19	 1792217	 ATP8B3	 0.804177	 0.647139	 0.157038	 0.01736245	 0.02991532	 Body	
cg06417478	 19	 12876846	 HOOK2	 0.299338	 0.4543382	 0.155	 0.047326404	 0.0486562	 Body	
cg15793258	 19	 4638503	 TNFAIP8L1	 0.695698	 0.8382843	 0.142586	 0.016382074	 0.02925311	 TSS1500	
cg04515524	 19	 17489148	 PLVAP	 0.048768	 0.1661439	 0.117376	 0.023245425	 0.03432775	 TSS1500	
cg03159252	 19	 639161	 FGF22	 0.698331	 0.8120778	 0.113746	 0.00355935	 0.01812632	 TSS1500	
cg15765251	 19	 888814	 MED16	 0.83004	 0.7199737	 0.110066	 0.003341693	 0.01801893	 Body	
cg17713488	 19	 10077935	 COL5A3	 0.64599	 0.5361738	 0.109816	 0.040905216	 0.04535861	 Body	
cg03162251	 19	 6230240	 MLLT1	 0.91844	 0.8179302	 0.100509	 0.041335932	 0.04565213	 Body	
cg03398919	 2	 173118470	 	 0.474625	 0.7394302	 0.264806	 0.004671297	 0.0184486	 	
cg23128510	 2	 175922785	 	 0.860042	 0.6571458	 0.202896	 0.001749153	 0.01576607	 	
cg18662228	 2	 236867804	 AGAP1	 0.422887	 0.6214159	 0.198528	 0.035894928	 0.04330606	 Body;Body	
cg18109430	 2	 26700908	 OTOF	 0.455952	 0.6410422	 0.18509	 0.013250986	 0.0276007	 5'UTR;1stExon	
cg17600943	 2	 207803547	 CPO	 0.530004	 0.6897406	 0.159736	 0.038411938	 0.04475967	 TSS1500	
cg15176306	 2	 224813276	 	 0.825838	 0.6763457	 0.149492	 0.042928436	 0.04616919	 	
cg07227024	 2	 202163482	 ALS2CR12	 0.131089	 0.278768	 0.147679	 0.000475902	 0.01349928	 Body	
cg06292076	 2	 105464104	 	 0.36969	 0.2521428	 0.117547	 0.008409699	 0.02384193	 	
cg19052272	 2	 3704530	 ALLC	 0.739728	 0.8551447	 0.115416	 0.00133052	 0.01349928	 TSS1500	
cg04021592	 2	 145280784	 	 0.471238	 0.3596413	 0.111597	 0.002902851	 0.01755103	 	
cg17375248	 2	 66811157	 	 0.347265	 0.2406005	 0.106665	 0.004949084	 0.0184486	 	
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cg16781264	 2	 101087575	 NMS	 0.170287	 0.2740618	 0.103775	 0.011871476	 0.02730792	 Body	
cg10481584	 2	 104708897	 	 0.652542	 0.7535819	 0.10104	 0.003726548	 0.0184486	 	
cg18757817	 2	 208572165	 	 0.778124	 0.6778044	 0.10032	 0.004511609	 0.0184486	 	
cg00704664	 20	 60500578	 CDH4	 0.345943	 0.5201933	 0.17425	 0.025603849	 0.03574141	 Body	
cg11979743	 20	 814510	 FAM110A	 0.056549	 0.2171236	 0.160575	 0.049933172	 0.04993317	 1stExon;5'UTR	
cg16310958	 20	 25281332	 ABHD12	 0.881089	 0.734672	 0.146418	 0.029395652	 0.03893373	 Body;3'UTR	
cg22181382	 20	 16559406	 	 0.737036	 0.8609042	 0.123868	 0.03228775	 0.04072996	 	
cg13877999	 20	 42194607	 SGK2	 0.832059	 0.7171075	 0.114952	 0.00545094	 0.0184486	 5'UTR;TSS200	
cg25155022	 20	 42285962	 	 0.141135	 0.2439266	 0.102792	 0.00873656	 0.02385308	 	
cg10463299	 20	 54987330	 CASS4	 0.246572	 0.144518	 0.102054	 0.005117605	 0.0184486	 5'UTR;1stExon	
cg07135405	 20	 62573077	 UCKL1;MIR1914	 0.669006	 0.5670104	 0.101996	 0.017805707	 0.03016535	 Body;TSS200	
cg03706056	 21	 37437565	 SETD4	 0.531861	 0.3202301	 0.211631	 0.014347968	 0.02808617	 TSS1500	
cg05200811	 21	 47581042	 	 0.60568	 0.7461273	 0.140447	 0.001374472	 0.01349928	 	
cg11766577	 21	 47581405	 C21orf56	 0.658041	 0.7862002	 0.128159	 0.001007457	 0.01349928	 Body	
cg10296238	 21	 47605174	 C21orf56	 0.426374	 0.3058234	 0.120551	 0.005318879	 0.0184486	 TSS1500	
cg07747299	 21	 47604052	 C21orf56	 0.293361	 0.1868764	 0.106484	 0.003174026	 0.01755103	 5'UTR	
cg13126279	 21	 47581558	 C21orf56	 0.684086	 0.7874304	 0.103344	 0.002959042	 0.01755103	 Body	
cg13306870	 22	 39527583	 CBX7	 0.480372	 0.2822077	 0.198164	 0.009185058	 0.02385308	 3'UTR	
cg11942221	 22	 29686496	 EWSR1	 0.789882	 0.8933278	 0.103446	 0.008822572	 0.02385308	 3'UTR;Body	
cg08977311	 3	 168308798	 C3orf50	 0.301847	 0.4850454	 0.183199	 0.009869976	 0.02401985	 Body	
cg20979384	 3	 22422855	 	 0.752234	 0.5764904	 0.175744	 0.009810956	 0.02401985	 	
cg25692928	 3	 139724110	 CLSTN2	 0.416727	 0.2501755	 0.166552	 0.003989108	 0.0184486	 Body	
cg22542451	 3	 182883005	 	 0.708108	 0.8613532	 0.153246	 0.010537683	 0.02541985	 	
cg26845082	 3	 13555664	 	 0.14589	 0.289814	 0.143924	 0.03163219	 0.04027247	 	
cg19996396	 3	 121946297	 CASR	 0.83526	 0.7166261	 0.118634	 0.023998369	 0.03491826	 5'UTR	
cg15116298	 3	 176070137	 	 0.714921	 0.8239822	 0.109061	 0.013040165	 0.0276007	 	
cg03865648	 3	 173113856	 	 0.365423	 0.2594162	 0.106007	 0.003008476	 0.01755103	 	
cg13143743	 3	 177570694	 	 0.557152	 0.6626737	 0.105521	 0.030109502	 0.03942911	 	
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cg06821582	 3	 133115942	 TMEM108	 0.642777	 0.7465181	 0.103741	 0.00919548	 0.02385308	 3'UTR	
cg07909498	 4	 79627477	 	 0.486084	 0.2800855	 0.205998	 0.001949259	 0.01576607	 	
cg08669168	 4	 53757661	 SCFD2	 0.835372	 0.6463968	 0.188975	 0.008062758	 0.02317632	 Body	
cg04277055	 4	 185749877	 	 0.77836	 0.937318	 0.158958	 0.015022586	 0.02888959	 	
cg07952421	 4	 69435601	 UGT2B15	 0.702727	 0.8546197	 0.151893	 0.016130477	 0.02909578	 TSS1500	
cg08395784	 4	 708242	 PCGF3	 0.886842	 0.7529529	 0.133889	 0.040320094	 0.04535861	 5'UTR	
cg26398228	 4	 33062845	 	 0.700324	 0.5668501	 0.133474	 0.017376575	 0.02991532	 	
cg12486486	 4	 69179905	 YTHDC1	 0.649333	 0.7736884	 0.124356	 0.006065826	 0.01962473	 Body	
cg17858192	 4	 16077807	 PROM1	 0.119375	 0.2420208	 0.122646	 0.013286271	 0.0276007	 5'UTR;TSS200	
cg08343347	 4	 36076000	 ARAP2	 0.674576	 0.7965573	 0.121981	 0.009490741	 0.02385308	 Body	
cg20419181	 4	 38063874	 TBC1D1	 0.226535	 0.1087169	 0.117818	 0.004324672	 0.0184486	 Body	
cg01218619	 4	 25090298	 	 0.131097	 0.2462354	 0.115139	 0.000880088	 0.01349928	 	
cg23057687	 4	 91760659	 TMSL3;FAM190A	 0.775173	 0.8900736	 0.1149	 0.00226485	 0.01639036	 TSS1500;Body	
cg11459852	 4	 176983371	 	 0.611287	 0.7149338	 0.103646	 0.027445628	 0.03730419	 	
cg09976051	 4	 178362394	 AGA	 0.516853	 0.6201499	 0.103296	 0.014400547	 0.02808617	 Body	
cg20311846	 4	 77356250	 SHROOM3	 0.504259	 0.40202	 0.102239	 0.003549557	 0.01812632	 TSS200	
cg05791544	 4	 129697855	 	 0.680316	 0.7817073	 0.101391	 0.023342866	 0.03432775	 	
ch.4.3427878R	 4	 186088653	 KIAA1430	 0.5876	 0.4872309	 0.100369	 0.004810046	 0.0184486	 Body	
cg22071943	 5	 1225434	 SLC6A18	 0.368136	 0.6436527	 0.275517	 0.002768542	 0.01755103	 TSS200	
cg13972557	 5	 116075820	 	 0.41291	 0.5923241	 0.179414	 0.035368203	 0.04313957	 	
cg20381404	 5	 34008215	 AMACR	 0.270747	 0.1127238	 0.158023	 0.034135756	 0.04247662	 5'UTR;1stExon	
cg09101062	 5	 43487508	 C5orf34	 0.629164	 0.7841494	 0.154986	 0.046098005	 0.04801876	 Body	
cg06611487	 5	 115284110	 	 0.428588	 0.5766908	 0.148103	 0.02135849	 0.03299767	 	
cg07021532	 5	 178322737	 ZFP2	 0.51678	 0.3795244	 0.137256	 0.019769955	 0.03166502	 TSS200	
cg00631759	 5	 178549790	 ADAMTS2	 0.693457	 0.823285	 0.129828	 0.013850533	 0.0276007	 Body	
cg17386240	 5	 135384080	 TGFBI	 0.750006	 0.6253156	 0.124691	 0.04233129	 0.04616919	 Body	
cg24861747	 5	 1228214	 SLC6A18	 0.38044	 0.498622	 0.118182	 0.034955787	 0.0430403	 Body	
cg23404351	 5	 21751337	 CDH12	 0.618356	 0.727346	 0.10899	 0.002190382	 0.01639036	 3'UTR	
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cg23208285	 5	 131879579	 IL5	 0.463846	 0.5711815	 0.107335	 0.00113185	 0.01349928	 TSS1500	
cg16362014	 5	 118321556	 DTWD2	 0.831087	 0.9335787	 0.102492	 0.020127963	 0.03183873	 Body	
cg15602423	 6	 32552095	 HLA-DRB1	 0.387082	 0.658822	 0.27174	 0.004339504	 0.0184486	 Body	
cg19774683	 6	 32522400	 HLA-DRB6	 0.576704	 0.355419	 0.221285	 0.039276661	 0.04526519	 Body	
cg13423887	 6	 32632694	 HLA-DQB1	 0.294241	 0.4998702	 0.205629	 0.004160722	 0.0184486	 Body	
cg01341801	 6	 32489203	 HLA-DRB5	 0.454757	 0.2494189	 0.205338	 0.040802068	 0.04535861	 Body	
cg14645244	 6	 32552205	 HLA-DRB1	 0.317864	 0.5210373	 0.203174	 0.017405278	 0.02991532	 Body	
cg15982117	 6	 32552106	 HLA-DRB1	 0.491871	 0.6840959	 0.192224	 0.01980503	 0.03166502	 Body	
cg09949906	 6	 32552350	 HLA-DRB1	 0.50703	 0.6988308	 0.191801	 0.028860633	 0.03852754	 Body	
cg10568066	 6	 30039442	 RNF39	 0.559707	 0.3719741	 0.187733	 2.07E-05	 0.00284003	 Body;Body	
cg09139047	 6	 32552042	 HLA-DRB1	 0.575764	 0.7543663	 0.178602	 0.02807999	 0.03785293	 Body	
cg12633154	 6	 30039435	 RNF39	 0.476967	 0.3096604	 0.167306	 7.72E-05	 0.00531071	 Body	
cg08578320	 6	 32552039	 HLA-DRB1	 0.588386	 0.7542884	 0.165903	 0.013641217	 0.0276007	 Body	
cg25644740	 6	 29894152	 HCG4P6	 0.612309	 0.4482485	 0.16406	 0.018615396	 0.0306541	 TSS1500	
cg13401893	 6	 30039432	 RNF39	 0.508331	 0.3499875	 0.158344	 5.96E-05	 0.00531071	 Body	
cg26566189	 6	 31096127	 PSORS1C1	 0.26758	 0.1107795	 0.156801	 0.007113638	 0.02173612	 5'UTR	
cg11082635	 6	 166856074	 RPS6KA2	 0.559012	 0.7146204	 0.155608	 0.044200307	 0.04711273	 Body	
cg01502466	 6	 29898751	 	 0.619984	 0.7718625	 0.151879	 0.048782754	 0.0495028	 	
cg04520169	 6	 29894195	 HCG4P6	 0.524282	 0.3766725	 0.14761	 0.009649986	 0.02390762	 TSS1500	
cg17129519	 6	 30618299	 C6orf136	 0.944813	 0.7976128	 0.1472	 0.002252759	 0.01639036	 Body	
cg10632894	 6	 32552453	 HLA-DRB1	 0.680863	 0.8247369	 0.143874	 0.038349852	 0.04475967	 Body	
cg07382347	 6	 30039408	 RNF39	 0.294639	 0.1527094	 0.141929	 0.000675493	 0.01349928	 Body	
ch.6.2893423F	 6	 150056792	 NUP43	 0.346538	 0.2055566	 0.140981	 0.002749507	 0.01755103	 Body	
cg00101728	 6	 2953027	 SERPINB6	 0.683052	 0.5434986	 0.139553	 0.013641541	 0.0276007	 Body	
cg26981746	 6	 32490012	 HLA-DRB5	 0.632837	 0.5007592	 0.132078	 0.03619832	 0.04330606	 Body	
cg05082466	 6	 2953123	 SERPINB6	 0.748285	 0.617495	 0.13079	 0.005338464	 0.0184486	 Body	
cg12015991	 6	 32490043	 HLA-DRB5	 0.777577	 0.6491037	 0.128473	 0.022145049	 0.03346093	 Body	
cg00689685	 6	 32139812	 AGPAT1	 0.855609	 0.729527	 0.126082	 0.033262206	 0.04176761	 5'UTR	
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cg10930308	 6	 30039476	 RNF39	 0.317058	 0.1925099	 0.124548	 0.000844306	 0.01349928	 Body	
cg03343571	 6	 30039175	 RNF39	 0.333766	 0.212244	 0.121522	 0.000565339	 0.01349928	 Body	
cg00807871	 6	 37617124	 MDGA1	 0.530052	 0.4092444	 0.120808	 0.020145232	 0.03183873	 Body	
cg13185413	 6	 30039202	 RNF39	 0.325802	 0.2064434	 0.119358	 0.001239273	 0.01349928	 Body	
cg17416722	 6	 32554385	 HLA-DRB1	 0.27086	 0.1522284	 0.118632	 0.035962454	 0.04330606	 Body	
cg23237314	 6	 29894197	 HCG4P6	 0.491808	 0.3743178	 0.11749	 0.011159773	 0.02668642	 TSS1500	
cg14494781	 6	 2615341	 	 0.747282	 0.8646492	 0.117367	 0.019087815	 0.0311596	 	
cg09279736	 6	 30039403	 RNF39	 0.403957	 0.2868337	 0.117124	 0.000450969	 0.01349928	 Body	
cg13838276	 6	 118158769	 	 0.350411	 0.4638685	 0.113458	 0.004597123	 0.0184486	 	
cg19178509	 6	 30850581	 DDR1	 0.447425	 0.3385171	 0.108908	 0.026587704	 0.03657868	 TSS1500	
cg00947782	 6	 30039142	 RNF39	 0.209929	 0.1017924	 0.108137	 0.000978311	 0.01349928	 Body	
cg06764333	 6	 133564466	 EYA4	 0.189686	 0.0821493	 0.107537	 0.004498488	 0.0184486	 5'UTR	
cg16078649	 6	 30039466	 RNF39	 0.450735	 0.3456927	 0.105042	 0.000632921	 0.01349928	 Body	
cg01360627	 6	 31544931	 TNF	 0.360477	 0.4640847	 0.103608	 0.002891433	 0.01755103	 Body	
cg08491487	 6	 30039130	 RNF39	 0.180668	 0.077568	 0.1031	 0.002686581	 0.01755103	 Body	
cg09637172	 6	 31545252	 TNF	 0.555132	 0.6581686	 0.103036	 0.007638552	 0.02270702	 Body	
cg04627110	 6	 29635507	 MOG	 0.784873	 0.6833891	 0.101484	 0.040490044	 0.04535861	 3'UTR;Body	
cg19383211	 6	 32527588	 HLA-DRB6	 0.823525	 0.7226065	 0.100918	 0.009541233	 0.02385308	 Body	
cg23403836	 7	 1616229	 KIAA1908	 0.750865	 0.4355525	 0.315312	 1.60E-05	 0.00284003	 Body	
cg13211008	 7	 158541253	 ESYT2	 0.197682	 0.3921768	 0.194495	 0.017879828	 0.03016535	 Body	
cg07846874	 7	 11568529	 THSD7A	 0.589262	 0.776991	 0.187729	 0.015589787	 0.02909578	 Body	
cg22953237	 7	 31425682	 	 0.697235	 0.5135543	 0.183681	 0.016594491	 0.02925311	 	
cg09281805	 7	 4751840	 FOXK1	 0.722338	 0.5407225	 0.181615	 0.024694342	 0.03518624	 Body	
cg27468880	 7	 965995	 ADAP1	 0.75221	 0.9269222	 0.174712	 0.038245078	 0.04475967	 Body	
cg13279926	 7	 157464161	 PTPRN2	 0.688199	 0.8381708	 0.149972	 0.000908014	 0.01349928	 Body	
cg07249765	 7	 4244643	 SDK1	 0.737384	 0.8765873	 0.139203	 0.049487898	 0.0498328	 Body	
cg05917273	 7	 116200522	 CAV1	 0.591951	 0.7247149	 0.132764	 0.024869568	 0.03525325	 3'UTR	
cg21823080	 7	 148096241	 CNTNAP2	 0.497508	 0.3699064	 0.127601	 0.036219616	 0.04330606	 Body	
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cg08355157	 7	 158809128	 LOC154822	 0.476048	 0.6012454	 0.125197	 0.020692036	 0.03251606	 Body	
cg19665696	 7	 949154	 ADAP1	 0.252647	 0.3680813	 0.115434	 0.011829421	 0.02730792	 Body	
cg06096382	 7	 43151725	 HECW1	 0.611506	 0.7252477	 0.113742	 0.038769732	 0.04498598	 TSS1500	
cg04130408	 7	 73703236	 CLIP2	 0.499443	 0.6114619	 0.112019	 0.011679302	 0.02730792	 TSS1500	
cg25612754	 7	 948567	 ADAP1	 0.241761	 0.3479876	 0.106227	 0.00132084	 0.01349928	 Body	
cg23144994	 7	 141431499	 FLJ40852	 0.655606	 0.7597921	 0.104187	 0.004297515	 0.0184486	 Body	
cg09506675	 7	 112727914	 GPR85	 0.603872	 0.5003716	 0.103501	 0.040284083	 0.04535861	 TSS1500;TSS200	
cg00981661	 7	 130984525	 MKLN1	 0.610023	 0.7134876	 0.103465	 0.004487339	 0.0184486	 Body	
cg19590115	 7	 157632890	 PTPRN2	 0.811536	 0.9149834	 0.103447	 0.005563624	 0.0184486	 Body	
cg03453431	 7	 157225567	 	 0.327601	 0.2248833	 0.102718	 0.001869502	 0.01576607	 	
cg12581298	 7	 1080836	 C7orf50	 0.856163	 0.7534656	 0.102698	 0.020991344	 0.03279897	 Body	
cg01827933	 7	 93960063	 	 0.401166	 0.2986182	 0.102547	 0.001616886	 0.01533254	 	
cg05875700	 8	 638208	 ERICH1	 0.120484	 0.3191762	 0.198692	 0.004547501	 0.0184486	 Body	
cg01053087	 8	 637909	 ERICH1	 0.163553	 0.3298633	 0.16631	 0.002127504	 0.01639036	 Body	
cg22029879	 8	 1790861	 ARHGEF10	 0.811315	 0.6783574	 0.132957	 0.04291427	 0.04616919	 5'UTR	
cg20601736	 8	 652315	 ERICH1	 0.885785	 0.7551862	 0.130599	 0.016011637	 0.02909578	 Body	
cg12641240	 8	 638330	 ERICH1	 0.068507	 0.1937307	 0.125224	 0.017514624	 0.02991628	 Body	
cg08682625	 8	 128470793	 LOC727677	 0.443527	 0.3212344	 0.122293	 0.000960086	 0.01349928	 Body	
cg04554929	 8	 105342491	 	 0.321258	 0.440364	 0.119106	 0.022002308	 0.03342892	 	
cg04687040	 8	 142427117	 	 0.565232	 0.6839672	 0.118735	 0.019148992	 0.0311596	 	
cg19128026	 8	 1792615	 ARHGEF10	 0.750262	 0.8583527	 0.108091	 0.008858247	 0.02385308	 Body	
cg05023707	 8	 39845127	 IDO2	 0.911901	 0.8059079	 0.105993	 0.003481524	 0.01812632	 Body	
cg21234082	 9	 124363848	 DAB2IP	 0.718972	 0.5899272	 0.129045	 0.022310569	 0.03352681	 Body	
cg10384133	 9	 45733081	 	 0.509316	 0.636885	 0.127569	 0.026563786	 0.03657868	 	
ch.9.25704165R	 9	 25714165	 	 0.207643	 0.0999138	 0.10773	 0.006062024	 0.01962473	 	
cg13990129	 9	 108311111	 FSD1L	 0.751863	 0.854377	 0.102514	 0.005248116	 0.0184486	 3'UTR	
Bold	font	indicates	probes	which	are	common	between	this	study	and	our	previous	work	(98).	
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Table	A3.2:	RRMS	DMRs	within	the	MHC	locus	
Probe ID Chr Position Gene Median 
(case) 
Median 
(control) 
Δmeth Adj. p 
value 
p FDR Feature 
cg00101728	 6	 2953027	 SERPINB6	 0.543499	 0.683052	 0.139553	 0.013642	 0.027601	 Body	
cg05082466	 6	 2953123	 SERPINB6	 0.617495	 0.748285	 0.13079	 0.005338	 0.018449	 Body	
cg25644740	 6	 29894152	 HCG4P6	 0.448248	 0.612309	 0.16406	 0.018615	 0.030654	 TSS1500	
cg04520169	 6	 29894195	 HCG4P6	 0.376672	 0.524282	 0.14761	 0.00965	 0.023908	 TSS1500	
cg23237314	 6	 29894197	 HCG4P6	 0.374318	 0.491808	 0.11749	 0.01116	 0.026686	 TSS1500	
cg15602423	 6	 32552095	 HLA-DRB1	 0.658822	 0.387082	 -0.27174	 0.00434	 0.018449	 Body	
cg14645244	 6	 32552205	 HLA-DRB1	 0.521037	 0.317864	 -0.20317	 0.017405	 0.029915	 Body	
cg15982117	 6	 32552106	 HLA-DRB1	 0.684096	 0.491871	 -0.19222	 0.019805	 0.031665	 Body	
cg09949906	 6	 32552350	 HLA-DRB1	 0.698831	 0.50703	 -0.1918	 0.028861	 0.038528	 Body	
cg09139047	 6	 32552042	 HLA-DRB1	 0.754366	 0.575764	 -0.1786	 0.02808	 0.037853	 Body	
cg08578320	 6	 32552039	 HLA-DRB1	 0.754288	 0.588386	 -0.1659	 0.013641	 0.027601	 Body	
cg10632894	 6	 32552453	 HLA-DRB1	 0.824737	 0.680863	 -0.14387	 0.03835	 0.04476	 Body	
cg17416722	 6	 32554385	 HLA-DRB1	 0.152228	 0.27086	 0.118632	 0.035962	 0.043306	 Body	
cg01341801	 6	 32489203	 HLA-DRB5	 0.249419	 0.454757	 0.205338	 0.040802	 0.045359	 Body	
cg26981746	 6	 32490012	 HLA-DRB5	 0.500759	 0.632837	 0.132078	 0.036198	 0.043306	 Body	
cg12015991	 6	 32490043	 HLA-DRB5	 0.649104	 0.777577	 0.128473	 0.022145	 0.033461	 Body	
cg19774683	 6	 32522400	 HLA-DRB6	 0.355419	 0.576704	 0.221285	 0.039277	 0.045265	 Body	
cg19383211	 6	 32527588	 HLA-DRB6	 0.722607	 0.823525	 0.100918	 0.009541	 0.023853	 Body	
cg10568066	 6	 30039442	 RNF39	 0.371974	 0.559707	 0.187733	 2.07E-05	 0.00284	 Body	
cg12633154	 6	 30039435	 RNF39	 0.30966	 0.476967	 0.167306	 7.72E-05	 0.005311	 Body	
cg13401893	 6	 30039432	 RNF39	 0.349987	 0.508331	 0.158344	 5.96E-05	 0.005311	 Body	
cg07382347	 6	 30039408	 RNF39	 0.152709	 0.294639	 0.141929	 0.000675	 0.013499	 Body	
cg10930308	 6	 30039476	 RNF39	 0.19251	 0.317058	 0.124548	 0.000844	 0.013499	 Body	
cg03343571	 6	 30039175	 RNF39	 0.212244	 0.333766	 0.121522	 0.000565	 0.013499	 Body	
cg13185413	 6	 30039202	 RNF39	 0.206443	 0.325802	 0.119358	 0.001239	 0.013499	 Body	
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cg09279736	 6	 30039403	 RNF39	 0.286834	 0.403957	 0.117124	 0.000451	 0.013499	 Body	
cg00947782	 6	 30039142	 RNF39	 0.101792	 0.209929	 0.108137	 0.000978	 0.013499	 Body	
cg16078649	 6	 30039466	 RNF39	 0.345693	 0.450735	 0.105042	 0.000633	 0.013499	 Body	
cg08491487	 6	 30039130	 RNF39	 0.077568	 0.180668	 0.1031	 0.002687	 0.017551	 Body	
Bold	font	indicates	probes	which	are	common	between	this	study	and	our	previous	work	(98).	
	
	
Table	A3.3:	RRMS	DMRs	outside	the	MHC	locus	
Probe ID Chr Position Gene Median 
(case) 
Median 
(control) 
Δmeth Adj. p 
value 
p FDR Feature 
cg11766577	 21	 47581405	 C21orf56	 0.7862	 0.658041	 -0.12816	 0.001007	 0.013499	 Body	
cg10296238	 21	 47605174	 C21orf56	 0.305823	 0.426374	 0.120551	 0.005319	 0.018449	 TSS1500	
cg07747299	 21	 47604052	 C21orf56	 0.186876	 0.293361	 0.106484	 0.003174	 0.017551	 5'UTR	
cg13126279	 21	 47581558	 C21orf56	 0.78743	 0.684086	 -0.10334	 0.002959	 0.017551	 Body	
cg05875700	 8	 638208	 ERICH1	 0.319176	 0.120484	 -0.19869	 0.004548	 0.018449	 Body	
cg01053087	 8	 637909	 ERICH1	 0.329863	 0.163553	 -0.16631	 0.002128	 0.01639	 Body	
cg20601736	 8	 652315	 ERICH1	 0.755186	 0.885785	 0.130599	 0.016012	 0.029096	 Body	
cg12641240	 8	 638330	 ERICH1	 0.193731	 0.068507	 -0.12522	 0.017515	 0.029916	 Body	
cg26354017	 1	 2.06E+08	 PM20D1	 0.410684	 0.598945	 0.188261	 0.014094	 0.027884	 1stExon	
cg17178900	 1	 2.06E+08	 PM20D1	 0.469825	 0.646248	 0.176423	 0.013796	 0.027601	 Body	
cg14159672	 1	 2.06E+08	 PM20D1	 0.443619	 0.616326	 0.172707	 0.017227	 0.029915	 1stExon	
cg11965913	 1	 2.06E+08	 PM20D1	 0.302544	 0.466796	 0.164252	 0.024621	 0.035186	 TSS200	
cg24503407	 1	 2.06E+08	 PM20D1	 0.403586	 0.560205	 0.156619	 0.014935	 0.02889	 TSS1500	
cg14893161	 1	 2.06E+08	 PM20D1	 0.328428	 0.497891	 0.169463	 0.008958	 0.023853	 5'UTR;1stExon	
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Table A3.4: All differentially methylated SPMS probes 
Probe	ID	 Chr	 Position	 Gene	 Median	
(case)	
Median	
(control)	
Δmeth	 Adj	p	
value	
P	FDR	 Feature	
cg06182923	 1	 33985406	 CSMD2	 0.613448	 0.728753	 0.115305	 0.000512	 0.015791	 Body	
cg20802616	 1	 211590292	 C1orf97	 0.426296	 0.536186	 0.10989	 0.000818	 0.015791	 Body	
cg07584620	 1	 2265881	 MORN1	 0.579576	 0.82636	 0.246784	 0.003764	 0.022817	 Body	
cg04798314	 1	 246668601	 SMYD3	 0.760551	 0.492173	 -0.26838	 0.00745	 0.027175	 Body	
cg15385476	 1	 196112818	 	 0.681472	 0.802111	 0.120639	 0.01076	 0.03144	 	
cg05392448	 1	 2266933	 MORN1	 0.668357	 0.809182	 0.140825	 0.015164	 0.034438	 Body	
cg14669863	 1	 155247706	 HCN3	 0.168098	 0.048754	 -0.11934	 0.021975	 0.039487	 Body	
cg05376227	 1	 171111193	 FMO6P	 0.610546	 0.720282	 0.109736	 0.023138	 0.040449	 Body	
cg16675581	 1	 19637256	 AKR7A2;PQLC2	 0.64618	 0.791704	 0.145524	 0.026244	 0.042515	 Body;TSS1500	
cg03961283	 1	 223566761	 C1orf65	 0.217803	 0.318535	 0.100732	 0.027373	 0.042902	 5'UTR;1stExon	
cg25771854	 1	 247420421	 VN1R5	 0.836948	 0.725852	 -0.1111	 0.029601	 0.04386	 1stExon	
cg13928473	 1	 6063654	 	 0.321326	 0.512242	 0.190916	 0.035688	 0.046343	 	
cg17753661	 1	 26441637	 PDIK1L	 0.812072	 0.916511	 0.10444	 0.04249	 0.048096	 Body	
cg20821187	 1	 200452917	 	 0.53509	 0.646455	 0.111365	 0.048929	 0.049693	 	
cg04750100	 2	 136595281	 LCT	 0.449045	 0.347519	 -0.10153	 0.000668	 0.015791	 TSS1500	
cg23596425	 2	 1494263	 TPO	 0.715555	 0.841943	 0.126387	 0.001234	 0.017112	 Body	
cg24305906	 2	 241352106	 	 0.716169	 0.854922	 0.138752	 0.001268	 0.017112	 	
cg08610773	 2	 184896169	 	 0.778373	 0.880754	 0.102381	 0.001495	 0.018181	 	
cg17455348	 2	 213406960	 	 0.390888	 0.596972	 0.206084	 0.00225	 0.019771	 	
cg20325573	 2	 236234204	 	 0.653175	 0.757113	 0.103938	 0.002563	 0.020762	 	
cg20862283	 2	 156838956	 	 0.564822	 0.666258	 0.101436	 0.002656	 0.020816	 	
cg05373263	 2	 3063115	 	 0.723954	 0.833038	 0.109084	 0.004048	 0.022817	 	
cg03489016	 2	 230124603	 PID1	 0.709549	 0.833569	 0.12402	 0.004874	 0.0252	 Body	
cg15837943	 2	 231734413	 ITM2C	 0.411754	 0.669383	 0.257629	 0.005362	 0.025548	 Body	
cg03028786	 2	 224897425	 SERPINE2	 0.638894	 0.785711	 0.146818	 0.006365	 0.026666	 5'UTR;TSS1500;Body	
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cg18663897	 2	 240900096	 NDUFA10	 0.585099	 0.795998	 0.210899	 0.01179	 0.03144	 3'UTR	
cg01290856	 2	 134324896	 NCKAP5	 0.718362	 0.873496	 0.155134	 0.023336	 0.040505	 5'UTR	
cg22836174	 2	 228231970	 TM4SF20	 0.608463	 0.814805	 0.206342	 0.027691	 0.042902	 Body	
cg10224537	 2	 168673805	 B3GALT1	 0.678081	 0.817123	 0.139043	 0.03421	 0.046044	 TSS1500	
cg14448393	 2	 164471195	 FIGN	 0.699979	 0.593757	 -0.10622	 0.035243	 0.046044	 Body	
cg18757817	 2	 208572165	 	 0.613568	 0.721836	 0.108268	 0.040246	 0.047246	 	
cg14973360	 2	 9800511	 	 0.847607	 0.953549	 0.105942	 0.042563	 0.048096	 	
cg18662228	 2	 236867804	 AGAP1	 0.310465	 0.55812	 0.247655	 0.045914	 0.049368	 Body	
cg07733481	 3	 122694286	 SEMA5B	 0.203631	 0.092489	 -0.11114	 0.00091	 0.015791	 5'UTR	
cg04245305	 3	 195940754	 	 0.7168	 0.957329	 0.240529	 0.001616	 0.018181	 	
cg07093060	 3	 174092757	 	 0.680138	 0.471123	 -0.20901	 0.001721	 0.018181	 	
cg27423959	 3	 126945870	 	 0.287779	 0.456109	 0.16833	 0.002074	 0.01938	 	
cg15001930	 3	 124306820	 KALRN	 0.578064	 0.769411	 0.191348	 0.003052	 0.022817	 Body	
cg05674046	 3	 64211994	 PRICKLE2	 0.803021	 0.909884	 0.106862	 0.003421	 0.022817	 TSS1500	
cg04814784	 3	 10182561	 VHL	 0.582548	 0.286998	 -0.29555	 0.003486	 0.022817	 TSS1500	
cg24524379	 3	 46600244	 LRRC2	 0.234935	 0.338452	 0.103517	 0.007604	 0.027175	 5'UTR	
cg06051312	 3	 73045440	 PPP4R2	 0.824415	 0.935549	 0.111135	 0.007899	 0.027818	 TSS1500	
cg04156077	 3	 149421196	 WWTR1	 0.557934	 0.745576	 0.187642	 0.014555	 0.034195	 TSS200	
cg11108991	 3	 178984910	 KCNMB3	 0.570648	 0.677315	 0.106668	 0.014777	 0.034199	 TSS200	
cg05126514	 3	 49697458	 BSN	 0.394914	 0.520379	 0.125465	 0.015634	 0.034566	 Body	
cg10666341	 3	 119348585	 PLA1A	 0.856089	 0.660493	 -0.1956	 0.021421	 0.039487	 3'UTR	
cg20187719	 3	 13691967	 LOC285375	 0.143143	 0.366947	 0.223804	 0.02786	 0.042902	 TSS1500	
cg19726630	 3	 32400704	 CMTM8	 0.166092	 0.050292	 -0.1158	 0.043851	 0.048598	 Body	
cg25377865	 4	 72669944	 	 0.647265	 0.749341	 0.102076	 0.001077	 0.017112	 	
cg01406776	 4	 8386748	 ACOX3	 0.656012	 0.868224	 0.212212	 0.001633	 0.018181	 Body	
cg03271827	 4	 726053	 PCGF3	 0.437336	 0.628997	 0.191662	 0.006236	 0.026666	 5'UTR	
cg01503299	 4	 2963264	 NOP14	 0.588444	 0.692817	 0.104373	 0.01625	 0.035256	 Body	
cg03640465	 4	 10042842	 SLC2A9	 0.438843	 0.688466	 0.249623	 0.028802	 0.043203	 TSS1500	
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cg24794857	 4	 187113578	 CYP4V2	 0.228094	 0.33663	 0.108536	 0.03058	 0.044754	 Body	
cg16301894	 4	 129389744	 	 0.584892	 0.703459	 0.118567	 0.031364	 0.044833	 	
cg27251155	 4	 8155589	 ABLIM2	 0.820801	 0.922974	 0.102173	 0.034918	 0.046044	 Body	
cg04118610	 4	 62707027	 LPHN3	 0.561343	 0.67866	 0.117316	 0.041099	 0.047479	 Body	
cg04277055	 4	 185749877	 	 0.806784	 0.940016	 0.133232	 0.042915	 0.048096	 	
cg11553311	 5	 66541588	 	 0.387355	 0.551136	 0.163781	 0.000411	 0.015791	 	
cg11791078	 5	 36273196	 RANBP3L	 0.516162	 0.749421	 0.233259	 0.006939	 0.027047	 Body	
cg09819502	 5	 36242508	 C5orf33	 0.076951	 0.33556	 0.258609	 0.007012	 0.027047	 TSS1500	
cg00268547	 5	 2179563	 	 0.643432	 0.748968	 0.105536	 0.011371	 0.03144	 	
cg01231141	 5	 178692691	 ADAMTS2	 0.453387	 0.557818	 0.104431	 0.01223	 0.03144	 Body	
cg09146088	 5	 145305089	 	 0.536783	 0.792077	 0.255295	 0.012237	 0.03144	 	
cg24844518	 5	 156811669	 CYFIP2	 0.822607	 0.55309	 -0.26952	 0.018005	 0.037033	 Body	
cg07601741	 5	 153160425	 GRIA1	 0.570811	 0.680244	 0.109433	 0.018329	 0.037033	 Body	
cg06422277	 5	 63458646	 	 0.699619	 0.841201	 0.141582	 0.020188	 0.038994	 	
cg18236584	 5	 151476553	 	 0.627348	 0.760146	 0.132798	 0.021834	 0.039487	 	
cg25673075	 5	 111963982	 	 0.46002	 0.664048	 0.204028	 0.021997	 0.039487	 	
cg13653328	 5	 148520669	 ABLIM3	 0.72607	 0.494983	 -0.23109	 0.022751	 0.040062	 TSS1500	
cg17534070	 5	 168195355	 SLIT3;MIR218-2	 0.652943	 0.779386	 0.126443	 0.024362	 0.041424	 Body;TSS200	
cg04480106	 5	 72934606	 RGNEF	 0.701768	 0.81463	 0.112861	 0.024889	 0.041424	 5'UTR	
cg00546757	 5	 170845058	 	 0.547751	 0.742788	 0.195037	 0.027243	 0.042902	 	
cg18803147	 5	 2743124	 	 0.617812	 0.505722	 -0.11209	 0.028445	 0.043009	 	
cg12562822	 5	 1219873	 SLC6A19	 0.244169	 0.40093	 0.156761	 0.034624	 0.046044	 Body	
cg09434603	 5	 499552	 SLC9A3	 0.708705	 0.819674	 0.110969	 0.039592	 0.047225	 Body	
cg13913990	 5	 172970	 PLEKHG4B	 0.774701	 0.577771	 -0.19693	 0.043999	 0.048598	 Body	
cg24805360	 5	 77930038	 LHFPL2	 0.38465	 0.546793	 0.162143	 0.048235	 0.049457	 5'UTR	
cg17666981	 6	 28878192	 TRIM27	 0.80185	 0.918272	 0.116422	 0.000132	 0.012583	 Body	
cg24867279	 6	 28853021	 	 0.440899	 0.559996	 0.119097	 0.00119	 0.017112	 	
cg13872627	 6	 31238036	 HLA-C	 0.467414	 0.619214	 0.1518	 0.003559	 0.022817	 Body	
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cg03115532	 6	 28185726	 LOC222699	 0.653625	 0.822196	 0.168571	 0.009168	 0.028934	 Body	
cg23069046	 6	 6543402	 LOC285780	 0.684474	 0.789554	 0.10508	 0.009168	 0.028934	 Body	
cg25716013	 6	 75954053	 COX7A2	 0.603378	 0.707249	 0.103871	 0.009335	 0.029081	 TSS1500	
cg13185413	 6	 30039202	 RNF39	 0.406628	 0.277418	 -0.12921	 0.011261	 0.03144	 Body	
cg13604933	 6	 40145993	 	 0.850344	 0.651854	 -0.19849	 0.01739	 0.036478	 	
cg20866694	 6	 27181670	 	 0.414254	 0.292546	 -0.12171	 0.017875	 0.037033	 	
cg24969496	 6	 32606845	 HLA-DQA1	 0.522875	 0.738345	 0.21547	 0.02038	 0.038994	 Body	
cg06249604	 6	 30039206	 RNF39	 0.266341	 0.160964	 -0.10538	 0.026962	 0.042877	 Body	
cg00947782	 6	 30039142	 RNF39	 0.255623	 0.148406	 -0.10722	 0.030244	 0.044541	 Body	
cg10930308	 6	 30039476	 RNF39	 0.373728	 0.263968	 -0.10976	 0.032706	 0.04594	 Body	
cg14782559	 6	 33131893	 COL11A2	 0.587449	 0.758851	 0.171401	 0.034454	 0.046044	 Body	
cg14926196	 6	 37616482	 MDGA1	 0.374123	 0.502335	 0.128212	 0.03798	 0.047033	 Body	
cg03343571	 6	 30039175	 RNF39	 0.37883	 0.277639	 -0.10119	 0.038325	 0.047033	 Body	
cg15383120	 6	 291909	 DUSP22	 0.355595	 0.485997	 0.130402	 0.038696	 0.047033	 TSS200	
cg12633154	 6	 30039435	 RNF39	 0.550688	 0.435403	 -0.11529	 0.041129	 0.047479	 Body	
cg15820961	 6	 32558459	 HLA-DRB1	 0.741706	 0.863241	 0.121535	 0.04313	 0.048096	 TSS1500	
cg11235426	 6	 292522	 DUSP22	 0.323171	 0.432058	 0.108887	 0.044658	 0.048663	 1stExon;5'UTR	
cg02379549	 6	 36887307	 C6orf89	 0.896679	 0.777463	 -0.11922	 0.045231	 0.049067	 Body	
cg07365741	 6	 170478434	 	 0.613454	 0.456203	 -0.15725	 0.04713	 0.049385	 	
cg13401893	 6	 30039432	 RNF39	 0.577691	 0.469281	 -0.10841	 0.047292	 0.049385	 Body	
cg08491487	 6	 30039130	 RNF39	 0.225518	 0.124175	 -0.10134	 0.047621	 0.049385	 Body	
cg18110333	 6	 292329	 DUSP22	 0.336236	 0.480119	 0.143883	 0.047942	 0.049385	 1stExon;5'UTR	
cg15744124	 6	 32306089	 C6orf10	 0.695888	 0.828451	 0.132563	 0.049399	 0.049693	 Body	
cg21901928	 7	 55139847	 EGFR	 0.664807	 0.801655	 0.136848	 0.000164	 0.012583	 Body	
cg14170201	 7	 155191709	 	 0.658967	 0.891026	 0.23206	 0.000847	 0.015791	 	
cg09756125	 7	 158250978	 PTPRN2	 0.741593	 0.514513	 -0.22708	 0.001714	 0.018181	 Body	
cg18850127	 7	 39170497	 POU6F2	 0.679178	 0.501934	 -0.17724	 0.003236	 0.022817	 Body	
cg20302533	 7	 39170763	 POU6F2	 0.684205	 0.531256	 -0.15295	 0.004059	 0.022817	 Body	
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cg00859877	 7	 158246263	 PTPRN2	 0.592679	 0.85617	 0.263491	 0.006854	 0.027047	 Body	
cg15212455	 7	 39170539	 POU6F2	 0.778134	 0.66443	 -0.1137	 0.008333	 0.028434	 Body	
cg19195077	 7	 47778880	 	 0.456591	 0.620059	 0.163468	 0.017125	 0.036478	 	
cg05541356	 7	 150903922	 	 0.326318	 0.479816	 0.153498	 0.020339	 0.038994	 	
cg23549902	 7	 5184155	 	 0.37424	 0.478793	 0.104553	 0.024727	 0.041424	 	
cg22109827	 7	 30727326	 	 0.735974	 0.466243	 -0.26973	 0.027936	 0.042902	 	
cg25709790	 7	 24742552	 DFNA5	 0.599622	 0.780914	 0.181292	 0.030771	 0.044754	 Body	
cg09281805	 7	 4751840	 FOXK1	 0.533396	 0.751872	 0.218476	 0.031125	 0.044754	 Body	
cg00867835	 7	 149484985	 SSPO	 0.653832	 0.533157	 -0.12067	 0.035159	 0.046044	 Body	
cg19389973	 7	 36692197	 AOAH	 0.482959	 0.690356	 0.207397	 0.037756	 0.047033	 Body	
cg16618979	 7	 143108841	 	 0.917679	 0.724636	 -0.19304	 0.038731	 0.047033	 	
cg16576544	 7	 129410227	 MIR182	 0.757646	 0.85802	 0.100374	 0.038778	 0.047033	 Body	
cg09546755	 7	 132424008	 	 0.648499	 0.762903	 0.114404	 0.039678	 0.047225	 	
cg20026367	 7	 130875551	 MKLN1	 0.762934	 0.872693	 0.109759	 0.040034	 0.047225	 Body	
cg10900271	 7	 156157852	 	 0.819961	 0.56028	 -0.25968	 0.044336	 0.048663	 	
cg22535849	 7	 4118583	 SDK1	 0.792579	 0.609142	 -0.18344	 0.045817	 0.049368	 Body	
cg01760090	 8	 1365659	 	 0.45751	 0.586951	 0.129442	 0.004064	 0.022817	 	
cg04123498	 8	 142283564	 	 0.8625	 0.545042	 -0.31746	 0.004106	 0.022817	 	
cg13070650	 8	 99490901	 STK3	 0.85201	 0.749864	 -0.10215	 0.007584	 0.027175	 Body	
cg19128026	 8	 1792615	 ARHGEF10	 0.752932	 0.855117	 0.102184	 0.012027	 0.03144	 Body	
cg02490460	 8	 1365502	 	 0.593412	 0.702811	 0.109399	 0.014333	 0.034147	 	
cg19787013	 8	 145737513	 RECQL4	 0.456545	 0.692351	 0.235805	 0.021576	 0.039487	 Body	
cg21512324	 8	 89718417	 	 0.675024	 0.794211	 0.119187	 0.024498	 0.041424	 	
cg09019154	 8	 19616280	 	 0.507047	 0.310656	 -0.19639	 0.037667	 0.047033	 	
cg26077133	 8	 10049871	 MSRA	 0.644693	 0.430444	 -0.21425	 0.043147	 0.048096	 Body	
cg17531142	 8	 128940078	 PVT1	 0.646113	 0.768895	 0.122782	 0.049693	 0.049693	 Body	
cg13876960	 9	 9998791	 PTPRD	 0.488714	 0.603157	 0.114443	 0.002375	 0.019901	 5'UTR	
cg13890969	 9	 113804367	 	 0.616747	 0.732108	 0.115361	 0.01384	 0.03397	 	
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cg14451627	 9	 115987035	 SLC31A1	 0.813929	 0.923608	 0.109678	 0.024693	 0.041424	 5'UTR	
cg21177183	 9	 129281647	 	 0.759673	 0.882018	 0.122345	 0.043091	 0.048096	 	
cg14117219	 9	 94476689	 	 0.073225	 0.182177	 0.108952	 0.049571	 0.049693	 	
cg08751451	 10	 53287690	 PRKG1	 0.585886	 0.706745	 0.120859	 0.005619	 0.026257	 Body	
cg15393936	 10	 15354631	 FAM171A1	 0.689283	 0.843025	 0.153742	 0.006213	 0.026666	 Body	
cg13754569	 10	 134956778	 	 0.718748	 0.908916	 0.190168	 0.007598	 0.027175	 	
cg24668570	 10	 134973778	 KNDC1	 0.292176	 0.109391	 -0.18278	 0.00889	 0.028934	 TSS200	
cg14609104	 10	 111989324	 MXI1	 0.73054	 0.911835	 0.181295	 0.008992	 0.028934	 Body	
cg19301501	 10	 22768167	 	 0.770547	 0.87322	 0.102673	 0.012372	 0.03144	 	
cg11005552	 10	 105648138	 OBFC1	 0.340865	 0.442656	 0.101791	 0.012421	 0.03144	 Body	
cg23479191	 10	 54338992	 	 0.594593	 0.701234	 0.10664	 0.013518	 0.03352	 	
cg20245361	 10	 71725755	 	 0.725305	 0.860217	 0.134912	 0.028072	 0.042902	 	
cg01512466	 10	 125624685	 CPXM2	 0.724984	 0.855813	 0.130829	 0.028496	 0.043009	 Body	
cg14964115	 10	 116634877	 FAM160B1	 0.451246	 0.602083	 0.150837	 0.032999	 0.046044	 Body	
cg23698271	 10	 121346762	 TIAL1	 0.599016	 0.783631	 0.184615	 0.033739	 0.046044	 Body	
cg18621672	 10	 82112873	 DYDC1	 0.278917	 0.45743	 0.178513	 0.037615	 0.047033	 5'UTR	
cg00817464	 10	 111662876	 XPNPEP1	 0.516173	 0.726959	 0.210786	 0.039688	 0.047225	 Body	
cg24051234	 10	 111912029	 	 0.71876	 0.865647	 0.146887	 0.041227	 0.047479	 	
cg27057480	 10	 49659559	 ARHGAP22	 0.228219	 0.358829	 0.13061	 0.047562	 0.049385	 Body	
cg04913265	 11	 133939627	 JAM3	 0.515099	 0.645977	 0.130878	 0.00015	 0.012583	 Body	
cg05792312	 11	 61781116	 	 0.301228	 0.624272	 0.323044	 0.000822	 0.015791	 	
cg06394820	 11	 60608291	 CCDC86	 0.565686	 0.776733	 0.211047	 0.006273	 0.026666	 TSS1500	
cg08912652	 11	 130779479	 SNX19	 0.701171	 0.87019	 0.169019	 0.022262	 0.039487	 Body	
cg10662047	 11	 123472546	 GRAMD1B	 0.527266	 0.791022	 0.263756	 0.025832	 0.042413	 Body	
cg14512156	 11	 660597	 DEAF1	 0.712934	 0.859028	 0.146094	 0.031615	 0.044927	 Body	
cg26864826	 11	 33760479	 	 0.491878	 0.245368	 -0.24651	 0.03384	 0.046044	 	
cg19680693	 11	 94111807	 GPR83	 0.495187	 0.320769	 -0.17442	 0.038505	 0.047033	 3'UTR	
cg19471911	 11	 102079985	 YAP1	 0.396051	 0.613639	 0.217588	 0.039951	 0.047225	 Body	
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cg17187785	 11	 132107476	 NTM	 0.914946	 0.743543	 -0.1714	 0.047884	 0.049385	 Body	
cg10578777	 12	 7781093	 	 0.728872	 0.905711	 0.17684	 0.003724	 0.022817	 	
cg11748730	 12	 99815844	 ANKS1B	 0.384339	 0.484957	 0.100618	 0.006528	 0.026887	 Body	
cg14906510	 12	 7781169	 	 0.805048	 0.910312	 0.105263	 0.007351	 0.027175	 	
cg25828445	 12	 7781288	 	 0.75044	 0.892315	 0.141876	 0.010161	 0.030863	 	
cg05565442	 12	 58011856	 	 0.300373	 0.556137	 0.255764	 0.011112	 0.03144	 	
cg08762603	 12	 2031417	 	 0.651426	 0.755396	 0.103971	 0.011647	 0.03144	 	
cg25198316	 12	 48598048	 OR10AD1	 0.753209	 0.91442	 0.161211	 0.015647	 0.034566	 TSS1500	
cg08693745	 12	 132286231	 	 0.576389	 0.719436	 0.143047	 0.029051	 0.043309	 	
cg14912045	 12	 117184799	 RNFT2	 0.734524	 0.841404	 0.106879	 0.038098	 0.047033	 Body	
cg18446441	 13	 32480222	 EEF1DP3	 0.760913	 0.874419	 0.113506	 0.026134	 0.042515	 Body	
cg24702069	 13	 109352806	 MYO16	 0.150338	 0.270571	 0.120233	 0.046485	 0.049385	 Body	
cg26813483	 13	 111980537	 C13orf16	 0.181445	 0.314982	 0.133537	 0.047721	 0.049385	 Body	
cg23881368	 13	 47472343	 HTR2A	 0.681471	 0.560657	 -0.12081	 0.047759	 0.049385	 TSS1500	
cg24320398	 13	 47472158	 HTR2A	 0.786896	 0.627135	 -0.15976	 0.049284	 0.049693	 TSS1500	
cg16706502	 14	 31927974	 C14orf126	 0.10314	 0.485653	 0.382514	 0.000633	 0.015791	 TSS1500	
cg05122082	 14	 20710905	 OR11H4	 0.724618	 0.840612	 0.115994	 0.002072	 0.01938	 TSS200	
cg22824376	 14	 77648248	 TMEM63C	 0.240042	 0.119732	 -0.12031	 0.003903	 0.022817	 5'UTR	
cg14293999	 14	 101840368	 	 0.461624	 0.77028	 0.308656	 0.004815	 0.0252	 	
cg16147201	 14	 105041159	 	 0.534088	 0.750436	 0.216347	 0.00841	 0.028434	 	
cg13528570	 14	 105708343	 BRF1	 0.698573	 0.878507	 0.179933	 0.008912	 0.028934	 Body;5'UTR	
cg11186706	 14	 54815745	 	 0.67984	 0.86824	 0.1884	 0.013491	 0.03352	 	
cg24976563	 14	 24587638	 DCAF11	 0.704412	 0.934959	 0.230547	 0.01495	 0.034273	 Body	
cg14218851	 14	 103018726	 	 0.610948	 0.460758	 -0.15019	 0.0209	 0.039487	 	
cg21193926	 14	 76443578	 TGFB3	 0.195675	 0.418231	 0.222556	 0.02204	 0.039487	 Body	
cg23022053	 14	 52733243	 PTGDR	 0.893364	 0.699746	 -0.19362	 0.041012	 0.047479	 TSS1500	
cg04579183	 15	 88119834	 NCRNA00052	 0.469611	 0.811179	 0.341567	 0.000207	 0.012583	 TSS1500	
cg21557108	 15	 50410962	 ATP8B4	 0.237793	 0.35237	 0.114577	 0.018359	 0.037033	 5'UTR	
146 
  
 
cg23009094	 15	 101862689	 PCSK6	 0.768406	 0.892074	 0.123668	 0.022203	 0.039487	 Body	
cg21829038	 15	 101593831	 LRRK1	 0.742025	 0.925927	 0.183902	 0.033253	 0.046044	 Body	
cg27018984	 15	 90796557	 TTLL13	 0.755236	 0.896252	 0.141017	 0.034676	 0.046044	 Body	
cg03478313	 15	 93655850	 	 0.744629	 0.893277	 0.148648	 0.035854	 0.046343	 	
cg27634195	 16	 1440421	 	 0.637084	 0.509941	 -0.12714	 0.004754	 0.0252	 	
cg06394109	 16	 1152511	 	 0.550503	 0.774634	 0.224131	 0.009752	 0.029997	 	
cg04004158	 16	 1152474	 	 0.724891	 0.826409	 0.101518	 0.012162	 0.03144	 	
cg05185784	 16	 90016020	 DEF8	 0.572342	 0.688635	 0.116293	 0.012321	 0.03144	 5'UTR;Body	
cg07869343	 16	 1797050	 MAPK8IP3	 0.793063	 0.91519	 0.122128	 0.038904	 0.047033	 Body	
cg00645020	 16	 84693148	 KLHL36	 0.666618	 0.535202	 -0.13142	 0.047963	 0.049385	 Body	
cg01401135	 17	 76522783	 DNAH17	 0.83475	 0.954378	 0.119628	 0.014011	 0.034046	 Body	
cg07973125	 17	 54858770	 	 0.928315	 0.6821	 -0.24622	 0.017413	 0.036478	 	
cg02159489	 17	 79459563	 	 0.678078	 0.85289	 0.174812	 0.018593	 0.037033	 	
cg14957731	 17	 39165697	 KRTAP3-1	 0.614446	 0.732681	 0.118235	 0.019068	 0.03767	 TSS1500	
cg20663042	 17	 6734940	 TEKT1	 0.144001	 0.247326	 0.103325	 0.02454	 0.041424	 5'UTR	
cg00901687	 17	 48585270	 MYCBPAP	 0.621566	 0.741851	 0.120286	 0.025301	 0.041824	 TSS1500	
cg25988106	 17	 7258481	 TMEM95	 0.499592	 0.722502	 0.222911	 0.026996	 0.042877	 TSS200	
cg08102564	 17	 19620263	 SLC47A2	 0.563148	 0.446589	 -0.11656	 0.035135	 0.046044	 TSS1500	
cg23633026	 17	 34067305	 RASL10B	 0.594436	 0.735079	 0.140643	 0.042865	 0.048096	 Body	
cg13590055	 18	 77917647	 LOC100130522;PARD6G	 0.273641	 0.377314	 0.103673	 0.011909	 0.03144	 Body;3'UTR	
cg20094343	 18	 34917603	 BRUNOL4	 0.263903	 0.438243	 0.17434	 0.011962	 0.03144	 Body	
cg19815565	 18	 77917615	 LOC100130522;PARD6G	 0.250322	 0.353988	 0.103665	 0.014232	 0.034147	 Body;3'UTR	
cg07258983	 18	 42255459	 	 0.69047	 0.848518	 0.158048	 0.030974	 0.044754	 	
cg05900567	 19	 37466940	 	 0.442992	 0.676886	 0.233893	 0.005067	 0.025265	 	
cg10771931	 19	 34972145	 WTIP	 0.718033	 0.89071	 0.172677	 0.008425	 0.028434	 TSS1500	
cg16253115	 19	 33781998	 	 0.831872	 0.941227	 0.109354	 0.011671	 0.03144	 	
cg18437039	 19	 1444202	 	 0.458154	 0.582318	 0.124164	 0.015896	 0.034799	 	
cg08835041	 19	 37461278	 	 0.755358	 0.876124	 0.120767	 0.016656	 0.035818	 	
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cg26562263	 19	 21863715	 	 0.229641	 0.345673	 0.116031	 0.034378	 0.046044	 	
cg04515524	 19	 17489148	 PLVAP	 0.048071	 0.178275	 0.130204	 0.044595	 0.048663	 TSS1500	
cg11495604	 20	 62053198	 KCNQ2	 0.79919	 0.98268	 0.18349	 0.002278	 0.019771	 Body	
cg17811452	 20	 44007674	 TP53TG5;SYS1-DBNDD2	 0.52683	 0.294003	 -0.23283	 0.004131	 0.022817	 TSS1500;Body	
cg12099423	 20	 61590751	 SLC17A9	 0.259185	 0.375558	 0.116373	 0.005095	 0.025265	 Body	
cg17221813	 20	 61590823	 SLC17A9	 0.388501	 0.524941	 0.136441	 0.005229	 0.025412	 Body	
cg09595245	 20	 44649233	 SLC12A5	 0.830374	 0.930548	 0.100174	 0.005821	 0.026666	 TSS1500	
cg19223824	 20	 44682963	 SLC12A5	 0.635471	 0.871532	 0.236061	 0.006051	 0.026666	 Body	
cg19142181	 20	 61591066	 SLC17A9	 0.366628	 0.538726	 0.172098	 0.006707	 0.027047	 Body	
cg12751644	 20	 60527061	 	 0.64485	 0.529829	 -0.11502	 0.014635	 0.034195	 	
cg00704664	 20	 60500578	 CDH4	 0.268554	 0.483874	 0.215321	 0.032512	 0.045933	 Body	
cg18819889	 20	 60119597	 CDH4	 0.728146	 0.874762	 0.146617	 0.048598	 0.049619	 Body	
cg04985582	 21	 15645988	 ABCC13	 0.437947	 0.555831	 0.117885	 0.020097	 0.038994	 TSS200	
cg00607912	 21	 43240355	 PRDM15	 0.846525	 0.965583	 0.119058	 0.026566	 0.042751	 Body	
cg10543947	 22	 36635882	 APOL2	 0.209491	 0.074167	 -0.13532	 0.000684	 0.015791	 TSS200;1stExon;5'UTR	
cg16121206	 22	 36636055	 APOL2	 0.518891	 0.394903	 -0.12399	 0.000745	 0.015791	 TSS200;TSS1500	
cg02018040	 22	 27152963	 	 0.761077	 0.547243	 -0.21383	 0.018497	 0.037033	 	
cg01234546	 22	 50723473	 PLXNB2	 0.806808	 0.565704	 -0.2411	 0.022203	 0.039487	 Body	
cg19470385	 22	 46446562	 C22orf26	 0.753671	 0.856455	 0.102784	 0.037526	 0.047033	 3'UTR	
cg09219182	 22	 37255542	 NCF4	 0.535842	 0.754528	 0.218686	 0.037891	 0.047033	 TSS1500	
cg23887839	 NA	 NA	 NA	 0.655725	 0.360589	 -0.29514	 0.001886	 0.019093	 NA	
cg24139837	 X	 3730151	 	 0.261992	 0.080879	 -0.18111	 0.015309	 0.034445	 	
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Table	A3.5:	SPMS	DMRs	within	the	MHC	
Probe	ID	 Chr	 Position	 Gene	 Median	
(case)	
Median	
(control)	
Δmeth	 Adj.	p	value	 P	FDR	 Feature	
cg13185413	 6	 30039202	 RNF39	 0.40662837	 0.2774177	 -0.12921067	 0.011260733	 0.031440175	 Body	
cg06249604	 6	 30039206	 RNF39	 0.266340697	 0.160964176	 -0.105376521	 0.026962202	 0.042876543	 Body	
cg00947782	 6	 30039142	 RNF39	 0.255622964	 0.148405783	 -0.107217181	 0.030243898	 0.044541014	 Body	
cg10930308	 6	 30039476	 RNF39	 0.373728199	 0.263967562	 -0.109760637	 0.03270644	 0.045940259	 Body	
cg03343571	 6	 30039175	 RNF39	 0.378829882	 0.277638722	 -0.10119116	 0.038325094	 0.047033022	 Body	
cg12633154	 6	 30039435	 RNF39	 0.550688103	 0.435403086	 -0.115285017	 0.041129289	 0.047479204	 Body	
cg13401893	 6	 30039432	 RNF39	 0.577691457	 0.469281157	 -0.1084103	 0.047291604	 0.049385389	 Body	
cg08491487	 6	 30039130	 RNF39	 0.225517557	 0.124174938	 -0.101342619	 0.04762052	 0.049385389	 Body	
cg15383120	 6	 291909	 DUSP22	 0.35559474	 0.485996596	 0.130401856	 0.038696026	 0.047033022	 TSS200	
cg11235426	 6	 292522	 DUSP22	 0.323171335	 0.432058198	 0.108886863	 0.044657615	 0.048662783	 1stExon;5'UTR	
cg18110333	 6	 292329	 DUSP22	 0.336235687	 0.480119023	 0.143883336	 0.047941744	 0.049385389	 1stExon;5'UTR	
cg18850127	 7	 39170497	 POU6F2	 0.679178294	 0.501934444	 -0.17724385	 0.003236295	 0.022816897	 Body	
cg20302533	 7	 39170763	 POU6F2	 0.684204571	 0.531256436	 -0.152948135	 0.004058751	 0.022816897	 Body	
cg15212455	 7	 39170539	 POU6F2	 0.778133703	 0.664430196	 -0.113703507	 0.008332628	 0.028433856	 Body	
cg23881368	 13	 47472343	 HTR2A	 0.681470902	 0.560657426	 -0.120813476	 0.047759105	 0.049385389	 TSS1500	
cg24320398	 13	 47472158	 HTR2A	 0.786896069	 0.627134741	 -0.159761328	 0.049283649	 0.049692891	 TSS1500	
cg13590055	 18	 77917647	 LOC100130522;PAR
D6G	
0.273640951	 0.377314174	 0.103673223	 0.011909407	 0.031440175	 Body;3'UTR	
cg19815565	 18	 77917615	 LOC100130522;PAR
D6G	
0.250322353	 0.353987748	 0.103665395	 0.014231871	 0.034147073	 Body;3'UTR	
cg12099423	 20	 61590751	 SLC17A9	 0.259185276	 0.37555796	 0.116372684	 0.005094544	 0.025264782	 Body	
cg17221813	 20	 61590823	 SLC17A9	 0.388500876	 0.524941381	 0.136440505	 0.005228754	 0.025411747	 Body	
cg19142181	 20	 61591066	 SLC17A9	 0.366627625	 0.538725837	 0.172098212	 0.006707346	 0.027047422	 Body	
cg10543947	 22	 36635882	 APOL2	 0.209491257	 0.074166907	 -0.13532435	 0.000684484	 0.015791453	 TSS200;1stExon;5'UTR	
cg16121206	 22	 36636055	 APOL2	 0.5188908	 0.394902851	 -0.123987949	 0.000745084	 0.015791453	 TSS200;TSS1500	
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APPENDIX FOUR 
  
C-MYC is DROSHA’s transcription factor, and we therefore performed RT-qPCR to 
determine whether it is a contributing factor in the down-regulation of DROSHA that 
we reported. Figure A4.1 demonstrates that there was no significant difference in 
expression of C-MYC between MS patients and their respective HCs. 
 
 
Figure A4.1 Tukey boxplot of expression relative to GAPDH of C-MYC in (A) HC 
(blue) and RRMS (pink), and (B) HC (green) and SPMS (grey). Whiskers represent 
data within 1.5 interquartile range (IQR) of the upper and lower quartile. Data points 
outside of the 1.5 IQR are represented by black dots.   
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APPENDIX FIVE 
 
Luxol Fast Blue - Periodic Acid-Schiff staining and Pathology Criteria	
	
Equipment  
Plate at 58°C 
Oven at 60°C 
Cover slips 
 
 
 
 
 
 
 
 
 
 
Reagents 
Acetic acid (10%) 
Acid alcohol 
Scott blue solution 
dH2O 
DPX (mounting fluid) 
EtOH (70, 95 and 100%) 
Haematoxylin 
Lithium carbonate 
Luxol fast blue 
Periodic acid 
Schiff’s reagent 
Xylene 
Preparation of stains  
1% Periodic Acid – Store at 4°C 
Periodic acid (Sigma P7578-25G) 1g 
dH2O      100ml 
 
0.1% Luxol Fast Blue – Store at room temperature for 12 months (re-usable) 
Luxol Fast Blue    0.1g 
95% EtOH     100ml 
10% Acetic acid    0.5ml 
 
Saturated Lithium Carbonate 
Lithium carbonate    1g 
dH2O      100ml 
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Protocol 
Provided	by	Brain	and	Mind	Research	Institute,	Sydney	
Approximate	time	to	complete	–	5	hours	
	
1. Bring	Schiff’s	reagent	to	room	temperature.	
2. De-wax	sections	at	58°C	for	20	min.	
3. Deparaffinise	sections:	
a. 2x	Xylene	5	min	
b. 2x	100%	EtOH	5	min	
c. 95%	EtoH	5	min	
d. 70%	EtOH	5	min	
e. 2x	dH2O	5	min	
4. Place	sections	in	1%	periodic	acid	solution	for	10	min.	
5. Wash	sections	in:		
a. Running	tap	water	for	4	min	
b. dH2O	for	1	min	
6. Pipette	Schiff’s	reagent	onto	sections	and	sit	for	30	min.	
7. Wash	sections	in	running	tap	water	for	10	min.	
8. Set	oven	to	60°C.	
9. Wash	sections	in:	
a. 70%	EtOH	for	1	min	
b. 95%	EtOH	for	1	min	
10. Stain	sections	with	0.1%	LFB	at	60°C	for	2	hours.	
11. Cool	slides	in	tap	water	for	5	min.	
12. Differentiate	sections	in	lithium	carbonate	(1/3	tap	water	and	2/3	saturated	solution	
of	lithium	carbonate)	(2-3	dips).	
13. Place	sections	in	tap	water	for	5	min.	
14. Counter	stain	with	Haematoxylin:	
a. Place	slides	in	haematoxylin	for	30	secs	
b. Wash	in	running	tap	water	for	1	min	
c. Dip	2	times	in	acid	alcohol	
d. Wash	in	running	tap	water	for	1	min	
e. Scott	blue	solution	2	min	
	
15. Dehydrate	sections:	
a. 70%	EtOH	3	min	
b. 95%	EtOH	3	min	
c. 2x	100%	EtOH	5	min	
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d. Xylene	6	min	
e. Xylene	3	min	
16. Mount	coverslip	(DPX	or	appropriate	substitute)	
	
Criteria for identifying MS related pathology 
Normal	 appearing	 white	 matter:	 Consistent	 myelin	 coverage	 (LFB	 positive)	 with	
oligodendrocytes	exhibiting	normal	pathology,	parallel	to	the	axons.	
Active	 Lesion:	 LFB	 positive	 material	 (i.e.	 phagocytosed	 myelin)	 seen	 clustered	 within	
macrophages.		
Recently	active	lesion:	Presence	of	macrophages	containing	PAS	positive	material.	Indicative	
of	myelin	phagocytosed	a	while	ago;	 the	macrophages	are	no	 longer	actively	attacking	 the	
myelin.	
Chronic	lesion:	Absence	of	LFB	positive	material.	Astrocytes	can	be	clearly	seen.	
Remyelinated	 lesion:	 Patchy	 areas	 of	 myelin	 and	 few	 oligodendrocytes.	 No	 evidence	 of	
macrophage	activity.	
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